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Summary  
The rapid growth of ketamine and amphetamine misuse worldwide has led to the 
development of methods for the detection and analysis of ketamine and 
amphetamines in biological specimens. Most methods previously developed in 
forensic toxicology for the detection of ketamine and amphetamines used GC-
MS. The present work developed alternative methods based on LC-MS/MS. 
Ketamine was chosen as the drug of interest because there are no data currently 
available on the extent of ketamine abuse in Malaysia even though a large 
amount of ketamine has been seized by the Malaysian Royal Police, while 
amphetamines are the most widely abused synthetic drugs in South East Asia 
including Malaysia.   
 
The study addressed some of the challenges facing the forensic toxicologist, such 
as the need to use new technology (LC-MS/MS) and improve sensitivity and 
selectivity in forensic toxicology analysis through efficient sample preparation 
techniques. The general requirements of method validation, including as the 
parameters linearity, limit of detection (LOD) and Lower Limit of Quantification 
(LLOQ), recovery, precision and matrix effects were observed. Three main 
techniques were used in the study: enzyme-linked immunosorbent assay (ELISA), 
liquid chromatography tandem mass spectrometry (LC-MS/MS) and molecularly 
imprinted polymer solid phase extraction (MISPE). MISPE is a new extraction 
technique in forensic toxicology applied to biological samples. 
 
Initially work was carried out on the optimization, development and validation 
of the Neogen® ELISA for screening ketamine and norketamine in urine. The 
Neogen® ketamine ELISA kit was found to be adequately sensitive and precise for 
ketamine screening at a cut-off concentration of 25 ng/mL.  The ELISA test was 
shown to be highly specific to ketamine and demonstrated minimal (2.1%) cross-
reactivity to its main metabolite norketamine compared to ketamine.  
 
Subsequently, an LC–MS/MS confirmation method for ketamine and norketamine 
in urine samples was developed and validated with application of the method to 
urine samples from chronic ketamine users in Malaysia. The method 
demonstrated good linearity, LOD, LOQ, accuracy and precision and had 
acceptable matrix effects.  
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The efficiency of ELISA as a screening method at cut-off of 25 ng/ml and LC-
MS/MS as a confirmation method at 2 ng/ml was evaluated.  These methods 
complemented each other and both ELISA and LC-MS methods were 100% 
sensitive and specific with no false positive results for ketamine and 
norketamine in urine samples. The results demonstrated that a combination of 
these two methods can be reliably used for routine screening and confirmation 
of ketamine and norketamine in urine specimens. Preliminary data from this 
study provided information on the concentrations of ketamine and norketamine 
typically found in urine samples collected from individuals frequenting pubs in 
Malaysia. 
 
The main work in this thesis involved molecularly imprinted polymer materials 
which were used as sorbents in solid phase extraction (MISPE). Ketamine was 
used as a model substance for novel in-house synthesised MIPs as no anti-
ketamine MIP have previously been reported and because the ketamine structure 
is suitable for the synthesis of molecularly imprinted polymers. The study was 
intended to improve the selectivity and sensitivity of the extraction method 
(MISPE) prior to LC-MS/MS analysis. Evaluation of polymer imprinting was carried 
out using HPLC-UV.  
 
MIP extraction and LC-MS/MS analysis were applied to the determination of 
ketamine and norketamine in hair samples and compared with a conventional 
SPE-based method. MISPE extraction was selective and sensitive with fewer 
matrix effects than the conventional SPE method and could also be applied to 
norketamine, the principal metabolite of ketamine, due to the group-selective 
binding nature of the MIP, but not to structurally dissimilar analytes such as PCP 
and tiletamine. MISPE was superior to conventional SPE for trace detection of 
ketamine and norketamine in hair, in terms of improved sensitivity, lower limits 
of detection and reduced matrix effects. 
 
In addition, the commercial product Amphetamine SupelMIPTM was evaluated for 
identification of amphetamines in post mortem blood coupled with LC-MS/MS 
analysis. This work assessed whether the MIP, sold by the manufacturer for the 
extraction of amphetamines in urine, could also be used for whole blood. The 
results demonstrated that the MIP can be used successfully for the 
determination of amphetamines in post mortem blood. The recoveries of five 
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amphetamines were lower than with a comparable GC-MS method but the LODs 
and LLOQs of the LC-MS/MS method were better and suitable for detection of 
low levels amphetamines in post mortem blood. Further optimisation is needed 
to develop an improved protein precipitation method prior to MISPE. 
 
Liquid Chromatography Electro-Spray Ionization Mass Spectrometry (LC–ESI-MS) 
was used with the MISPE and SPE methods for detection and quantification of 
ketamine, norketamine and amphetamines in urine, whole blood and hair 
samples. LC-ESI-MS was found to be easy to use and could detect lower 
concentrations of drugs and gave reproducible results for all the methods 
developed in this thesis.  
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1 GENERAL INTRODUCTION 
1.1 Forensic Toxicology 
A poison is defined as a substance which, taken by any route, can cause a 
noxious action on the body [1]. Toxicology, or the science of poisons, is often 
considered to have been founded by Paracelsus, the “father of toxicology”, in 
the 16th century. Toxicology is about the harmful effects of poisons on living 
organisms subsequent to the chemical and physical properties of the poisons. 
These include the symptoms, methods of treatment and identification of the 
poisons.  
Forensic toxicology is a subspecialty in toxicology concerned with medico-legal 
aspects of the harmful effects of poisons [2]. Arguably, the most important 
aspects of forensic toxicology are the identification of poisons by chemical 
analysis and subsequent interpretation of the test results and, as a result, the 
technology and techniques for obtaining and interpreting the results are the 
main concerns in this field [3].  
The criminal justice system increasingly relies on the output of forensic 
toxicology laboratories to provide evidence relevant to forensic cases, including 
homicides, sexual assaults and impaired driving, especially when linked to 
fatalities. Therefore, the identification and quantification of substances of 
toxicological relevance have become more demanding and challenging.    
Forensic toxicology has been developed considerably from its inception to 
include branches such as post-mortem toxicology, driving under the influence of 
drugs (DUID), workplace testing, drug abuse, drug facilitated assault, doping in 
sport and analysis of natural products [4]. 
1.2 Challenges in Forensic Toxicology 
Today new drugs or new derivatives of drugs continue to emerge, especially 
synthetic drugs such as those in the amphetamines group, and toxicologists have 
to develop new methods and techniques for their identification. Sensitivity and 
selectivity are critical in forensic toxicology testing, in which an analytical 
Norlida Harun - 2010                                                                                                             Page 2 
technique should be able to detect trace levels of drugs even in the presence of 
large concentrations of other drugs.  
Forensic toxicologists have been able to respond to the challenge of detecting 
new drugs and metabolites. Toxicologists from all over the world have developed 
analytical methods for these new drugs. A few recent examples of these were  
methods developed and validated by researchers for identification in post-
mortem blood of 25 opioid  drugs [5], 13 amphetamines and derivatives [6], 
cocaine and its metabolites [7] and 20 anti-depressants [8]. 
It is impossible to use one extraction procedure to isolate all types of drugs from 
a sample. In fact, in real casework it is possible to miss four or five drugs that 
are actually present in a sample. This error is often caused because current 
methods cannot detect and identify all foreign substances present, or else the 
concentrations of certain drugs are so low that they are below the detection 
limits of many techniques. However, in response to this challenge, methods have 
been published for screening common drugs of abuse using chromatographic 
techniques [9,10, 11].  
There are also challenges in the use of different types of alternative specimens 
such as oral fluid, hair and vitreous humour in situations when the usual samples 
such as blood and urine are not available. This gives the toxicologist wider scope 
for obtaining information and providing evidence but he or she is still limited by 
the acceptance of the techniques in a court of law, where issues of good 
laboratory practice and method validation arise because of the lack of 
internationally-accepted guidelines, as discussed by Cone [12], and lack of 
accredited  laboratories, as found in a survey carried out by the Society of Hair 
Testing [13] . Recently, a few guidelines have been published that include 
alternative specimens, for example those produced by the Society of Hair 
Testing (SOHT) [14] and the Society of Forensic Toxicologists (SOFT) [15].   
Recently, legal systems in many countries have recognised more and more the 
impact of forensic science, including forensic toxicology, in the medico-legal 
process. One consequence of this growth in prominence is that scientific 
evidence in general and toxicology results in particular are subject to greater 
scrutiny than ever before. This situation has triggered further challenges to 
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toxicologists and has both given opportunities but also demands for them to 
refine and update toxicology testing in the future.  
1.3 Possible Solutions to Current Problems in Forensic 
Toxicology 
One possible solution for the problem of strengthening forensic toxicology 
testing is by improving the techniques of sample preparation. Sample 
preparation techniques such as solid phase extraction (SPE) and liquid-liquid 
extraction (LLE) have been used routinely in forensic laboratories for many 
years. Solid phase extraction has emerged dramatically to fulfil the need for 
sample preparation techniques to enhance selectivity and sensitivity.  
SPE began in the mid 20th century using adsorbents such as Amberlyte XAD-2 
resin, a polystyrene material. Then in the 1980’s, substituted silica-based 
materials used as SPE sorbents began originally through the work of Professor 
Michael Burke of Arizona University and were put into the market place by the 
first commercial supplier, Analytichem.  
Ten years later mixed-mode sorbents such as Certify™ were introduced and were 
shown to improve extraction of basic drugs and minimize the number of co-
extracted interferences. These were followed a few years later by polymeric 
sorbents such as Strata™ X which have the advantage of having no residual 
surface silanol groups, unlike the substituted silica sorbents. Later in 2008, the 
first molecular imprinted polymer (MIP) based SPE sorbent was introduced [16 ].   
Solid phase micro extraction (SPME) is a miniaturized and solvent-free sample 
preparation technique that has also been introduced to analytical toxicology. 
SPME uses a coated silica needle for extraction but is only used routinely in 
optimised methods for specific analytes in forensic toxicology laboratories [17]. 
To overcome the issue of sensitivity and selectivity, new products for sample 
preparation have been introduced commercially or have been synthesised in the 
toxicologist’s own laboratory, such as molecularly imprinted polymers (MIPs) 
which demonstrate superior selectivity and sensitivity and can minimise matrix 
effects. 
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They are in the form of sorbent in cartridges and can be used for typical solid 
phase extraction (SPE) methods for isolation of analytes from biological 
matrices. These new products provide the analyst with alternatives to SPE and 
liquid-liquid extraction (LLE) which for a long time have been used routinely.   
Molecularly imprinted solid phase extraction (MISPE) was investigated in the 
work for this thesis. 
Chromatography plays a central role in the forensic identification of substances 
in biological fluids. This has traditionally used gas chromatography with a range 
of detectors including the flame ionisation detector (GC/FID), the nitrogen-
phosphorus detector (GC/NPD) and the mass spectrometer (GC-MS) and/or high 
performance liquid chromatography with UV detection (HPLC/UV), to detect all 
the toxicologically-relevant substances present in a subject. However, the 
change that has been occurring in many forensic laboratories across the world is 
the implementation of liquid chromatography-tandem mass spectrometry (LC-
MS/MS) [18], as demonstrated by the exponential increase in the number of 
publications per year which was almost double the GC-MS publications even back 
in 2003.  
 
Recently, the advances in LC-MS/MS systems, especially for detection and 
quantification of more polar, thermo-labile or low-dose drugs, may have 
provided the basis for analysis techniques in the future. This equipment is both a 
good supplement and a good complement to GC-MS for multi-analyte procedures 
for screening and quantification of drugs in clinical and forensic toxicology as 
discussed by Maurer [19]. LC-MS/MS may potentially replace immunoassay due to 
the ease of development of new methods. In areas where immunoassay products 
are not available and high sensitivity is needed, GC-MS has been used as a 
screening technique. However, many of the compounds of interest require 
derivatization to be detectable at appropriate levels.  
 
Compared to GC-MS, LC-MS/MS excels at detecting a wide range of analytes 
without derivatization. However LC-MS/MS also has disadvantages, such as 
irreproducibility of fragmentation patterns and reduction of ionization due to 
matrix effects, as experienced by the present work. The use of LC-MS/MS for 
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identification and quantification has, together with an enzyme-linked 
immunosorbent assay (ELISA), been investigated in this thesis. 
 
Urine, whole blood and hair were used for identification of ketamine and its 
metabolites and drugs in the amphetamines group in the work for this thesis. 
Urine is used because the method of collection is non-invasive, a large volume of 
sample can usually be obtained, sample pre-treatment and analysis are simple, 
there is often a wide drug detection window and parent drug and metabolites 
are often present in high concentrations compared to other matrices. 
Furthermore, analytes of interest have been found to be stable in urine for a 
longer time if the samples were frozen [20,21]. However, the analyst must be 
aware that urine samples can be adulterated by substances such as detergent, 
vinegar and table salt to give false negative results [22].  
 
Blood samples are used because most toxic substances can be detected in a 
blood sample and they have been found very useful in forensic toxicology as 
their concentrations may be interpreted, within limits, in terms of the effects on 
the subject.  Hair samples are a good way to test for substance abuse that has 
occurred over the long term as well as being non-invasive and not easily 
adulterated.   
  
1.4 Method Validation 
For the results of toxicology testing to be scientifically valid in terms of 
accuracy, reliability and adequate for intended purposes such as to be 
presentable in court of law, the methods and procedures used for analyzing 
specimens must be validated. Method validation procedures used in the work for 
this thesis were dependent on whether the method concerned was qualitative, 
for example, immunoassay (ELISA) or quantitative, for example LC-MS/MS. Not 
all validation parameters are appropriate for each type of method and these are 
discussed below. 
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1.4.1 Method Validation for Immunoassay  
Three important parameters for validation of immunoassay are selectivity/ 
cross-reactivity, limit of detection (LOD) and precision [23].  
Selectivity/cross-reactivity is tested by analysing samples under specified test 
conditions which have been spiked with metabolites of the target analyte, drugs 
in the same group and other classes of drugs/subtances  commonly found in the 
matrix in which the drugs is analysed. The assay should also be tested with 
samples known to be positive or negative. A very selective immunoassay would 
have no significant cross-reactivity with other drugs or substances.   
The LOD is obtained by measuring the absorbance of 10 blank samples which 
have been spiked with different concentrations of the target analyte to 
determine the minimum concentration which can reliably be detected. The 
other way to obtain the LOD for an immunoassay kit is by measuring the 
absorbance of 10 blank specimens and calculating values for the mean and 
standard deviation of these readings. The concentration corresponding to the 
mean absorbance value of the blanks minus 3 standard deviations is obtained 
from the immunoassay calibration curve and this approximates to the LOD. The 
LOD value should be substantially lower than the cut-off concentration to 
discriminate between negative and positive samples. 
The intra-day precision was determined by analysing 10 blank samples spiked 
with the analyte of interest at a concentration equal to the cut-off value on the 
same plate and on the same day. For inter-day precision the tests are carried 
out on five different days with different batches of reagent kits. The RSD values 
for both should be better than ±20%.   
Immunoassay validation may also include characterisation of the calibration 
model (the dose-response curve) which is the ability of the test method to 
produce test results which are proportional to the concentration of the analyte 
in the sample within the expected concentration range. A range of concentration 
levels of analyte of interest is spiked into blank samples and a graph of the dose 
response curve is plotted. A cut-off value of the assay is selected from the linear 
part of the response [24]. 
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1.4.2 Method Validation for LC-MS/MS  
The components of method validation tested for LC-MS/MS in the present work 
were linearity, limit of detection (LOD), lower limit of quantification (LLOQ), 
intra-day and inter-day precision, accuracy, recovery and matrix effects. The 
procedures for the method validation were conducted based on guidelines from 
United Nations Office on Drugs and Crime (UNODC) on the Implementation of a 
Quality Management System in Drug Testing Laboratories [25]  and from the book 
by Bliesner on the validation of chromatographic methods [26].      
 
1.4.2.1  Linearity 
Linearity is the ability of a test method to produce test results which are 
proportional to the concentration of the analyte in the sample within the 
expected concentration range. The expected concentration should depend on 
the concentrations of target analytes found in the body. Linearity is evaluated 
using a minimum 6 point standard calibration curve within a concentration span 
of 80 % - 120 % of the expected range and should be established by visual 
inspection of the analytical response [27,28].   
In this study, the linear response relationship between the peak area ratio of an 
analytes and its internal standard and concentration has been evaluated 
statistically from the calculation of the regression line by the method of least 
squares, which gives the slope of the line, the intercept on the y axis and the 
correlation coefficient (R2). The good linearity means there is no significant 
deviation from linearity over the concentration range, which means a correlation 
coefficient of 0.99 or better is required for a good method of analysis [15,25]. 
1.4.2.2 Limit of Detection (LOD) and Lower Limit of Quantification (LLOQ) 
The limit of detection (LOD) of an analytical procedure is the lowest 
concentration of an analyte in a sample that can be detected by a method but 
not necessarily quantified as an exact value. The lower limit of quantification 
(LLOQ) is defined as the lowest concentration in the sample that can 
quantitatively determined with acceptable precision and accuracy. 
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There is more than one procedure to obtain the LOD and LLOQ values. In the 
most used method the LOD and LLOQ are determined by the value of the signal 
to noise (S/N) ratios of 3 and 10 of the analyte peak to matrix background noise 
[28]. The LLOQ also can be defined as the lowest calibration standard that can be 
measured with acceptable precision and accuracy [15,28].  
In the work of this study, the LOD and LLOQ were calculated statistically from 
the regression line of the calibration curve. LOD was calculated using 3 times the 
standard error of the regression line and the LLOQ using 10 times the standard 
error of the regression line. This type of calculation was found to be easier and 
fit for the purpose of method validation in this study and has been used in 
method validation previously [29,30].   
1.4.2.3 Recovery  
Recovery is a measure of the efficiency of a method in isolating analytes from 
their matrix and is reported as the percentage of the known analytes of interest 
which are obtained from a complete method, including the extraction and 
analysis. Recovery can be determined by comparing the response of an extracted 
standard with that of the neat, unextracted solution which is assumed to give 
100 % recovery. The corresponding internal standard is added after the 
extraction to allow direct comparison with the unextracted standards. The 
experiment was carried out using at least five replicates of low, medium and 
high concentration levels in the expected range. The acceptable recoveries in an 
analytical method are usually more than 50 % [28]. 
1.4.2.4 Selectivity (Specificity) 
Specificity refers to the ability of a method to produce a response of single 
analytes only while selectivity refers to the ability of the method to distinguish 
the response of a single analyte from other analytes in the complex mixture.  
Selectivity is the most important component in the validation of a 
chromatographic method. Selectivity is obtained by optimising separation and 
detection of standard mixtures and also by observing the selectivity of the 
method in the analysis of real samples. 
It is suggested that selectivity and specificity are investigated by analysing six 
different sources of blank specimens. However, in the work of this study an LC-
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MS/MS was used and it is sufficient to include a blank (negative sample) from the 
same matrix in every batch analysis of case sample to assess the presence of 
possible interfering analytes that will affect the selectivity of the target 
analytes [28].    
1.4.2.5 Precision and Accuracy 
Precision is the closeness of agreement (degree of scatter) between a series of 
measurements obtained under a set of prescribed conditions. Precision is 
expressed as percentage of the coefficient of variation (CV %) or percentage of 
relative standard deviation (RSD %).       
In the work of this study, repeatability or intra-day precision was measured by 
analysing five replicates of the specimen on the same day, using the same 
method at low, medium and high concentrations.  Reproducibility or inter-day 
precision was measured in the same manner over five different days. The 
method should show a good consistency for all replicates and a  % RSD of 20 % or 
less is considered to be acceptable for a valid method [15]. 
Normally, accuracy or the degree of closeness to the determined value was 
assessed together with the precision study. The experiment was carried out 
using five replicate blank samples spiked at low, medium and high 
concentrations in the expected calibration range. A calibration curve was 
plotted and the accuracy was determined by comparing the mean calculated 
concentration of the spiked urine samples with the target concentration. The 
acceptable limit was the same as for precision with an  % RSD of 20 % or less 
considered to be acceptable [15]. 
1.4.2.6 Matrix Effects Assessment   
Matrix effects can be defined as the change in response observed for a given 
concentration of target analyte in the presence of other sample components. 
The presence of matrix components in biological fluids can cause suppression 
(under-estimation) or enhancement (over-estimation) of the target analyte 
response. As demand for assay sensitivity requirements increases, the need for 
improved sample preparation methods becomes critical in order to limit matrix 
effects. 
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Electrospray ionization (ESI), which was used in this study, can be affected by 
factors other than target analyte concentration more than atmospheric pressure 
chemical ionization (APCI) [31] – and this can compromise or invalidate data. 
Therefore matrix effect assessment becomes compulsory and was included in 
this study.  Matrix effects could  be reduced (clean up) or magnified (pre-
concentrate) by sample preparation steps such as extraction, as demonstrated 
by previous studies using different types of sample preparation [31,32].  
 
The matrix effect assessment in this study was determined following the method 
of Matuszewski et. al [33]. Replicate blank samples from different individuals 
were collected to obtain accurate data on the size of matrix effects between 
individuals and to evaluate the robustness of the matrix effect analysis. 
The blank samples were spiked at low, medium and high concentrations and 
compared with other replicates which were spiked with the same concentrations 
in the loading solvent (neat solutions). Internal standard was added after the 
extraction. The percentage matrix effect was the peak area ratio of the analyte 
to internal standard in human matrix (urine, blood, hair extract) over the peak 
area ratio of the analyte to internal standard in the neat solution, respectively.   
1.5 Conclusion 
In conclusion, the toxicologist must be up-to-date with respect to technology 
and techniques for obtaining and interpreting analytical results, with more 
attention being given to sensitivity and selectivity in the validation of methods 
in the laboratory. Adequate training must be provided on new equipment and 
techniques, on proper method validation and laboratory accreditation as well as 
professional training in serving as an expert witness in court.  
 
Toxicologists also must be able to use all sorts of opportunities such as the 
availability of different sample matrices and the advance in new equipment such 
as LC-MS/MS for improvement of the investigation methods in the laboratory. 
Furthermore, validation of methods and techniques provides more confidence 
for their application to routine and research work. 
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In response to the challenges in the field, the work in this thesis investigated the 
use in forensic toxicology of one of the latest techniques in sample preparation, 
molecularly imprinted polymer solid phase extraction (MISPE) together with LC-
MS/MS for detection and quantification of drugs. It was hoped that data 
collected from this work will be useful and provide some information on the 
techniques available for forensic toxicology testing.  
  
1.6 Aims of the Study 
This study involved the development and validation of both screening and 
confirmatory detection methods for ketamine and its metabolites in biological 
samples. Various extraction methods were applied prior to analysis and 
identification of these compounds with a mass spectrometry technique. The 
aims of this project could therefore be summarized as follows: 
[1] Development and validation of an ELISA screening method for ketamine and 
its metabolites.  
[2] Development and validation of an LC-ESI-MS/MS method for ketamine and its 
metabolites in urine. 
[3] Investigation of the use of SPE and MISPE extraction techniques for ketamine 
and its metabolites in hair. 
[4] Comparison of MISPE and SPE methods for the detection and quantification of 
ketamine from hair samples by LC-ESI-MS/MS. 
[5] Evaluation and validation of MISPE for amphetamines in whole blood.   
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2 KETAMINE 
2.1 Introduction 
Ketamine is not a new drug but has been used for over 40 years. It is a rapidly 
acting dissociative anaesthetic which was first synthesised in 1962 by Calvin 
Stevens at Parke-Davis laboratories, Michigan [34] .The drug was patented in 1963 
in Belgium and in 1989 in the United States of America (USA). It was first 
marketed in the early 1970s as an alternative to phencyclidine [35], which 
produced side effects such as hallucinations and delirium. A pharmacological 
effect common to both ketamine and PCP is the separation of perception from 
sensation and this is the reason that they are members of the same drug group 
[36].   
Ketamine has been used clinically as an anaesthetic in veterinary medicine and 
to a lesser extent in human medicine, especially for emergency treatment. It has 
three important drug properties: it is a hypnotic (sleep inducing), analgesic (pain 
relieving) and amnesic (short term memory loss).   
In the United Kingdom, ketamine is classified as a Class C drug under the Misuse 
of Drugs Act 1971, which carries up to two years imprisonment and/or an 
unlimited fine for possession and up to fourteen years imprisonment and/or an 
unlimited fine for possession to supply or supplying the drug [37]. Ketamine is in 
the same class as anabolic steroids, benzodiazepines and gamma-
hydroxybutyrate (GHB).  
Recreational use of ketamine was first reported in the United Kingdom and 
European countries in the 1990s. Ketamine has been classified as one of the club 
drugs by the National Institute on Drug Abuse (NIDA) in the USA because it was 
being abused by an increasing number of young people in clubs and was being 
distributed at raves and parties [38]. The trend of ketamine abuse has been 
followed in Asian countries, especially China, Taiwan and Singapore [39].   
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2.2 Chemical and Physical Properties of Ketamine 
Ketamine is an arylcycloamine and in systematic nomenclature it is 2-(2-
chlorophenyl)-2-(methylamino)-cyclohexanone, C13H16ClNO, molecular weight 
237.74. It is a weakly basic, lipid soluble compound which contains a chiral 
centre at C2 of the cyclohexane ring, forming two enantiomers, S-(+)-ketamine 
and R-(-)-ketamine.  The molecular structures of ketamine enantiomers are 
shown in Figure 2-1.  The hydrochloride salt is soluble in water, methanol and 
chloroform and a solution of ketamine. The racemic HCl standard in methanol is 
available commercially as an analytical standard. The melting points of the free 
base and hydrochloride are 92-93oC and 262-263oC respectively.               
 
Figure 2-1 Molecular structures of S-(+)- ketamine (left) and R-(-)- ketamine (right) 
       
Ketamine manufactured by pharmaceutical companies must meet the standards 
of Good Manufacturing Practice (GMP) which means purity and quality are 
guaranteed. The racemic form is used for pharmaceutical purposes as the 
hydrocholoride salt, prepared in aqueous solution and packaged in small glass 
vials, ready for parenteral administration. It is marketed as Ketalar®, Ketolar®, 
Ketaject®, Ketanest®, Ketavet®, Ketavet 100®, Ketalin®, Vetalar®, Kalipsol®, 
Calipsol®, Substania®, Ketamine Panpharma®, Ketamine UVA®, Chlorketam® and 
Imalgene®. 
On the street ketamine is commonly known as K, Ket, Special K, Vitamin K, Kit 
Kat, Keller, Kelly’s Day, Green, Blind Squid, Cat Valium, Purple, Special La Coke, 
Super Acid and Super C [40]. It is available in powder form, tablet and as a 
vaporiser of unknown purity and quality. 
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2.3 Pharmacokinetics 
The reported volume of distribution varied from 1.5 to 3.21 l/kg. The clearance 
was in the range of 12-28 ml (kg.min). Volume of distribution and clearance for 
the S-(+)-ketamine are 9 to 14 % greater than the R-(-)-ketamine, respectively 
[41]. 
2.3.1 Absorption 
In the clinical setting the most common route of administration into the body of 
ketamine in solution is by injecting intramuscularly. It is more rapidly absorbed 
(Tmax 5-15 min) compared to the nasal (Tmax 20 min) and oral (Tmax 30 min) 
routes. The bioavailability decreases from intramuscular to oral or rectal 
administration by 17 % or 25 % respectively, because of the effects of first-pass 
metabolism in the liver and intestine.  It is even lower after nasal administration 
(the bioavailability is less than 50 % of that obtained by intramuscular 
administration)[42]. The reason is unknown but it is assumed to be caused by 
swallowing of a significant amount of the intranasal deposit. 
2.3.2 Distribution 
Ketamine base has a high lipid solubility and low plasma binding (12 %). It readily 
crosses the placenta and rapidly transfers across the blood-brain barrier, having 
immediate effects on the subject, whether human or animal. Studies in animals 
showed it was highly concentrated in lung, body fat and liver while lower 
concentrations were obtained in heart, skeletal muscle and blood plasma.  After 
absorption, ketamine is distributed to highly perfused tissues such as brain (the 
distribution phase half-life after i.v. administration was 24 sec) and achieves 
four to fives times higher concentration than in the plasma. Then, CNS effects 
subside, following redistribution to less well-perfused tissues (re-distribution 
half-life 2.7 min).  
2.3.3 Biotransformation 
Phase I biotransformation of ketamine primarily takes place in the liver. 
Ketamine undergoes extensive hepatic metabolism with only 2 % of the dose 
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recovered unchanged in the urine. 88 % of the dose can be recovered as 
metabolites in the urine over 72 h. Ketamine undergoes N-demethylation by liver 
microsomal cytochrome P450 enzymes CYP3A4, CYP2B6 and CYP2C9 to form its 
primary metabolite, norketamine (metabolite I) [43].  
Norketamine is hydroxylated on the cyclohexanone ring at positions 5 and 6 to 
form metabolite III and IV which can be excreted as conjugates or converted to 
metabolite II (dehydronorketamine) by dehydration. Ketamine itself can undergo 
hydroxylation on the cyclohexanone ring at positions 5 and 6 to form metabolites 
V and VI which can similarly be excreted as conjugates or converted to 
metabolite VII by dehydration.  
Metabolite VII can be transformed to metabolite II (dehydronorketamine) by N-
demethylation. Only 16 % of the dose can be recovered in urine as hydroxylated 
ketamine or norketamine. Phase II involves metabolism of hydroxylated 
metabolites results in formation of O-glucuronides which are water soluble and 
are easily excreted in urine (> 80% of the dose). 
The main metabolites, norketamine and dehydroxynorketamine can be measured 
in the same assay as for ketamine due to their closely related chemical 
structures. The metabolism route of ketamine is depicted in Figure 2-2 [44,45].  
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Figure 2-2  Metabolism of ketamine 
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When taken orally or rectally, the initial plasma concentration of norketamine is 
higher than ketamine but the plasma area under the curve is similar for all 
routes of administration. The bioavailability of ketamine is low when given orally 
or rectally due to extensive first pass metabolism in the liver and intestine which is 
largely responsible for this effect [46]. Norketamine has the analgesic properties of 
ketamine but has only one third of its anaesthetic potency. Dehydronorketamine 
(DHNK) was originally believed to be an analytical artefact caused by the high 
temperature of gas chromatography but recent research findings have shown 
that DHNK is a true metabolite of ketamine [47]. The anaesthetic effect of DHNK 
is unknown. 
2.3.4 Elimination 
The main route of ketamine elimination is by liver metabolism to hydroxy 
metabolites which are conjugated and mainly excreted via the kidney in the 
urine. Ketamine and norketamine can be detected in urine up to 5 and 6 days 
after administration, respectively, while dehydronorketamine can be detected in 
urine for up to 10 days [48]. Renal elimination accounts for 90 % of the total with 
about 4 % of unchanged ketamine, while fecal elimination accounts for up to 
5 %.  Ketamine clearance was susceptible to blood flow-affecting factors due to 
its high extraction (0.9). The elimination half-life for ketamine is in the range of 
2 to 3 hours.   
2.4 Pharmacodynamics   
Ketamine is a dissociative anaesthetic drug. The term “dissociative” refers to a 
psychological state in which the user experiences a feeling of dissociation of the 
mind from the body [49,50]. The pharmacology of ketamine involves the effects of 
the substance on the neurotransmitter systems related to its clinical and 
recreational use (primary pharmacology) and also the effects of this drug on 
various organs in the body (secondary pharmacology). 
2.4.1 Effects on the Central Nervous System (CNS)  
Ketamine appears to exert most or all of its effects in the Central Nervous 
System (CNS). It binds to the PCP-binding site which is located within the cation 
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channel of neurones and a separate site of the N-methyl-D-aspartic acid (NMDA) 
receptor complex. NMDA receptors function as calcium-gated ion channel 
receptors. Binding of ketamine blocks the transmembrane ion flux and ketamine 
acts as a non-competitive NMDA-receptor antagonist.  
The activation of the endogenous NMDA receptors by excitatory amino acids, 
such as glutamic acid, aspartic acid and glycine results in opening of the ion 
channel and depolarisation of the neurone.  They are involved in sensory input 
at the spinal, thalamic, limbic and cortical levels. Ketamine would be expected 
to block sensory input to the higher centres of the CNS (NMDA receptors) and 
disturb the processing of memory, thinking and learning [51] .  
Some effects of ketamine may be caused by its action on the catecholamine 
system which notably enhances dopamine activity [52,53]. Ketamine increases NAc 
dopamine efflux by mobilization of the dopamine storage pool to release sites 
and not by blocking dopamine reuptake, auto receptors or NMDA receptors [54]. 
Repeated ketamine administration diminishes the initial five-fold increase in 
dopamine release in the prefrontal cortex, while enhancing the level of 
extracellular 5-hydroxyindole acetic acid (5-HIAA), a serotonin metabolite. 
Repeated ketamine administration can therefore alter the balance between 
dopamine and serotonin neurotransmission in the prefrontal cortex [55]. This 
suggests that the addictive, euphorigenic and psychotomimetic properties of 
ketamine may be related to the dopaminergic effects.  
S-ketamine has a 3 to 4 fold higher affinity for the PCP site of the NMDA-
receptor than R-ketamine and therefore has more anaesthetic potency. It is also 
known that S-ketamine is the enantiomer that causes the psycotomimetic effects 
of ketamine, although sub-anaesthetic doses of the R-ketamine may induce a 
state of relaxation [41,52].   
Several studies have indicated the relationship between opioid receptors and the 
pharmacological effects of ketamine [56]. Crisp et al. reported that the analgesic 
effects of ketamine can largely be attributed  to the action of these spinal and 
central receptors [57]. A more recent study in rats by Ji et al. indicated that 
ketamine has the ability to suppress morphine withdrawal syndrome in an 
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experimental setting  without motor interference and Nucleas Accumbens is 
mentioned as the site of action [58]. 
The major metabolite norketamine (NK) is pharmacologically active but has a 
shorter duration of action. It has one third of the anaesthetic potency and 
binding affinity to the NMDA-receptor compared to the parent compound.  
Norketamine mainly contributes to the analgesic properties of ketamine [59]  and 
also contributes to the antinociceptive effect of ketamine [60].   
2.4.2 Effects on the Cardiovascular System  
Ketamine appears to stimulate the cardiovascular system and can produce 
changes in heart rate, blood pressure and cardiac output as reported by Haas 
and Harper [61] . The cardiovascular side effects of ketamine use include 
hypertension and sinus tachycardia, hypotension and sinus bradycardia and other 
cardiac arrhythmias. Patients with high blood pressure, ischemic heart disease or 
cerebrovascular accident must avoid the use of ketamine but its use is not a 
problem to a healthy individual. Following recreational use, physical 
examination showed that most of the patients brought into the emergency and 
trauma department of a hospital were diagnosed with the symptom of 
tachycardia [62]. 
2.4.3 Effects on the Respiratory System  
Following high doses of ketamine, respiratory depression and apnea can occur. 
Respiratory depression was reported in some cases after rapid intravenous 
injection and also after routine paediatric use of ketamine administered 
intramuscularly  [63,64]. Laryngospasm and other forms of airway obstruction may 
occur in rare cases. This does not happen after administration of low doses of 
ketamine because it is known as a mild respiratory depressant. There have been 
no cases of respiratory depression reported as a result of recreational use of 
ketamine. High doses of ketamine cause a shift of the CO2 dose-response curve 
to the right but do not change the slope. Therefore, the respiratory drive in 
response to CO2 is depressed by 15 to 22 %. Other effects of ketamine include 
increases in blood glucose, plasma cortisol, prolactin and muscle tone [65]. 
Ketamine also decreases intraocular pressure [63]. 
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2.4.4 Common Effects of Ketamine –Non fatal Intoxications 
The effects of ketamine use are dose dependent and are affected by the route 
of administration, body weight and the user’s health, thus the duration and 
severity of effects varies from one person to another. The onset of effects is 
rapid and occurs a few minutes after administration.  
The general effects of ketamine on recreational users include symptoms such as 
numbness, loss of coordination, sense of vulnerability, muscle rigidity, violent 
behaviour, slurred or blocked speech, exaggerated sense of strength, blank 
stare, amnesia, agitation, memory loss, unconsciousness, nausea and delerium. 
The predominant symptom on physical examination for cases brought to 
emergency department was tachycardia followed by rhabdomyolysis [62]. 
The main effects include neuro-behavioural, anxiety (especially for first-time 
users), agitation, change of perception (loss of notion of danger, visual 
disturbances), disorientation and impairment of motor function, such as ataxia, 
dystonic reaction. To some extent, users also cannot feel pain and this can lead 
to self injury [
66-68] .  
A team from the University College London who carried out a range of memory 
and psychological tests on 120 frequent ketamine users found that ketamine 
harms memory. This fact was supported by poor performance on skills such as 
recalling names, conversations and patterns [69]. The relationships between the 
route of ketamine administration, the dosage, the onset, the effects and 
duration of action are shown in Table 2-1.   
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Table 2-1  Common effects of ketamine 
Administration Dosage Onset Effects Duration  
Intramuscular 
injection 
10-40 mg 
 
60+ mg 
     3-4 minutes 
after 
injection 
 
 
Mild hallucinations 
 
Out of body, near death 
hallucinations; terrors 
 
     45-90 
minutes 
 
 
 
Intranasal 
ingestion 
 
 
10-60 mg 
 
100+  mg 
     5-15 minutes 
after 
ingestion 
Mild hallucinations 
 
Out of body, near death 
hallucinations; terrors 
 
      10-30 
minutes 
Oral ingestion 40-75 mg 
 
200+ mg 
    5-20 minutes 
after 
ingestion 
Mild hallucinations 
 
Out of body, near death 
hallucinations; terrors 
 
    Up to 90 
minutes 
 
2.5 Toxicological Data 
The non-human single acute dose toxicity (LD50) of ketamine is 140 mg/kg intra-
peritoneal in the neonatal rat and 616 mg/kg body weight orally in the mouse [70] 
while the LD50 values in adult mice and rats are 224 mg/kg and 229 mg/kg, 
respectively.  In the human it was estimated that intravenous doses of more 
than 11.3 mg/kg can be fatal, which is equivalent to a dose above 680 mg for a 
60 kg human. A summary of fatal cases involving ketamine is shown in Table 2.2. 
In most of these cases ketamine was taken in combination with other drugs such 
as benzodiazepines, cocaine, opiates, alcohol and other anaesthetics.  
4 out of the all cases in the table identified ketamine as the only source of the 
fatal intoxication, while the other cases involved mixed drug fatalities or a 
minor role for ketamine. The ketamine concentrations in these cases were in the 
anaesthetic range or above, 4-17 times the recommended dose for anaesthesia; 
or 1.3-2.5 times the recommended intramuscular dose for anaesthesia (based on 
a body weight of 60 kg) [71]. 
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Table 2-2 Fatalities involving ketamine 
Drug concentration Case 
number 
Country Sex Age Drugs involved 
Blood 
µg/ml 
Urine 
µg/ml 
Other µg/g 
1 Italy M 18 Ketamine 
Norketamine 
27.4 
present, 
not 
quantified 
8.51 bile=15.2 
brain=3.2 
liver=6.6 
kidney=3.4 
2 USA F 31 Ketamine 
Norketamine 
- 
present, 
not 
quantified 
- 
- 
liver=6.3 
kidney=3.2 
lung=1.6 
heart=2.4 
3 USA M 46 Ketamine 
Norketamine 
3 
 not 
present 
 
- 
- 
liver=0.8 
kidney=0.6 
spleen=0.8 
brain=4.0 
lung=2.2 
heart=3.5 
4 Italy M 34 Ketamine 
Norketamine 
- 
- 
 
- 
- 
liver=12.2         
brain=3.7             
lung=16.4 
kidney=15.5 
spleen=14.1  
liver=0.15 
brain=4.0 
lung=0.17 
kidney=0.7 
spleen=0.12 
5 USA M 45 Ketamine 
Tiletamine 
Zolazepam 
0.037 
0.295 
1.71 
0.031 
0.682 
1.33 
- 
liver=0.196  
liver=15.5 
6 USA M 32 Ketamine 
 
Ethanol 
Nalbuphine 
1.8 
 
170 
<0.020 
2 
 
- 
- 
Brain=4.3 
spleen=6.1 
liver=4.9 
kidney=3.6 
 France M - Ketamine           
Norketamine  
chloroform  
cocaine  
benzoylecgonine 
methylecgonine 
ester  
anhydroecgonine 
ester          
codeine       
 6-MAM      
 thiopental   
pentobarbital  
diazepam   
nordiazepam  
oxazepam            
1.4     
- 
30.7   
0.576   
- 
0.78    
0.12   
0.013   
0.420   
1.97     
2.64   
0.070     
0.2 
- 
present 
 present  
present 
 present  
present 
present 
present  
present 
present 
- 
- 
- 
- 
 present 
hair =11.3 
hair=1.0 
- 
hair=5.5 
hair=1.5 
hair=1.0 
- 
- 
hair=4.4 
hair=3.4 
hair=5.3 
hair=10.0 
hair=1.2 
hair=0.1 
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Lalonde and Wallage [72] reported 2 fatality cases which were attributed to 
ketamine use in Canada. The concentration of ketamine in heart blood in these 
cases was 6.9 and 1.6 mg/L, respectively, while the concentration of ketamine 
in femoral blood was 1.8 and 0.6 concentrations mg/L, respectively. The first 
case strongly pointed to ketamine as the sole factor of the fatal poisoning, and 
the other case involved asthma as a co-morbidity factor in the death.  
In Taiwan Lin et al. reported 59 fatalities involving methylenedioxy-
methamphetamine (MDMA) use in the years 2001 to 2008. Of these, 37 were 
attributed to drug intoxication and 22 to trauma, with drugs being an incidental 
finding. Within the group attributed to drug intoxication, 16 fatalities were 
caused by MDMA alone, with concentrations from 0.48 µg/mL  to 16.53 µg/mL in 
post-mortem blood. Another 15 fatalities in this group involved concurrent use 
of MDMA with ketamine and other drugs, including lidocaine, chlorpheniramine, 
morphine, flurazepam, phenytoin and ethanol. The other 6 fatalities were  
intoxications involving MDMA and multiple drugs other than ketamine [73]. Earlier 
in 2000, an article by Gill and Stajic in New York City reported 87 ketamine-
positive deaths over a 2 year period (1997-1999) reviewed by the New York City 
Chief Medical Examiner. 1 out of 15 non-hospital deaths was a fatal intoxication 
exclusively involving ketamine, 12 were caused by acute multi-drug intoxications 
with opiates, amphetamines and cocaine, 1 involved ethanol and 1 had an 
unknown cause [74].   
2.6 Medicinal Use of Ketamine  
Ketamine is used in humans as an anaesthetic in combination or alone, for short 
term paediatric and adult surgical procedures, especially in emergency and 
trauma care. The major drawback after awakening from ketamine anaesthesia is 
the occurrence of emergence reactions such as hallucinations, vivid dreams, 
floating sensations and delirium. These emergence phenomena appear to occur 
more frequently in adults (30-50 %) than in children (5-15 %) [51,64] . For this 
reason, it is usually used concurrently with benzodiazepines to put the patients 
in a low stimulus environment.  
For clinical analgesic purposes, it is administered intramuscularly, intravenously, 
orally, rectally and intrathecally. An intravenous dose equivalent to 2 mg of 
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ketamine per kg body weight (ranging from 1.4 - 4.5 mg/kg) given in 60 seconds 
produces surgical anaesthesia lasting 5 to 10 minutes while an intramuscular 
dose equivalent to 10 mg per kg body weight (ranging from 6.5 - 13 mg/kg) 
produces anaesthesia within 3 to 4 minutes and lasting for 12 to 25 minutes. The 
i.v. and intramuscular doses for children are 0.5 - 2.0 mg/kg and   3 - 7 mg/kg, 
respectively. 
Analgesic effects are produced by a dose of 0.2-0.75 mg/kg intravenously and 
0.5 mg/kg intramuscularly or orally.  In the liver, ketamine is transformed to 
norketamine, the major metabolite. The analgesic effect was similar through 
different routes of administration due to the strong analgesic properties of 
norketamine which is also an NMDA receptor inhibitor and has a half maximal 
inhibitory concentration (IC50) about 10 times higher than that of ketamine 
[75,76]. 
Psychotropic effects of ketamine are produced with a dose ranging from 25 - 200 
mg/kg intramuscularly and 0.1 - 1.0 mg/kg intravenously.   
2.7 Misuse of Ketamine 
Ketamine is available illicitly in liquid, powder and pill forms. It can be taken 
orally, smoked, snorted, drunk or injected. It is believed that legitimate 
ketamine is obtained in bulk from pharmaceutical companies in the USA and 
United Kingdom and then distributed worldwide for black market purposes.  It is 
known that the synthesis of ketamine is too difficult for a clandestine chemist 
and because of that they use legitimate sources and mix the ketamine with 
other drugs such as amphetamines and benzodiazepines.  
Ketamine misuse was first spotted at the West Coast of USA in the early 1970s 
[77]. Recently, a survey in the USA reported that ketamine is commonly injected 
intramuscularly among the youth, involving multiple injections, shared bottles of 
ketamine and used syringes from secondary sources. These practices increase 
the risk of transmitting infectious diseases such as HIV and Hepatitis C and are 
different from those used with other drugs such as heroin, cocaine or 
methamphetamine, which are injected intravenously and or once or twice in a 
session by users alone or in small groups [78]. 
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There have been several reports on the recreational use of ketamine  in UK in 
the early 1990s [79,66].  In 2005, the DrugScope Street Drug Trends Survey first 
highlighted the emergence of ketamine use as a recreational drug. The finding 
indicated that the drug had become a major street drug in eight of the 15 UK 
towns and cities surveyed, in which nine of the 20 areas surveyed in the 2008 
research reported an increase in ketamine use [80]. Furthermore, recreational use 
of ketamine has also been reported in EU countries [67] as reported by the 
EMCDDA inquiry, 2002.  
 
Lifetime use of ketamine was reported by 1 % of Australians aged 14 years or 
older, with 0.3 % reporting recent use. Prevalence of ketamine use was highest 
amongst those aged 20–29 years who were also more likely to report the recent 
use of a wide range of other drugs [81].  
 
The recreational use of ketamine at raves, parties and nightclubs has grown, 
thus increasing public concerns about the potential hazards of this drug [82]. A 
recent Taiwanese study reported that ketamine was detected in 47 % of the 
urine samples obtained from a study of those attending rave parties but only in 2 
% of the urine samples of police detainees [34]. A recently conducted review of 
drug use in China mentions that drugs such as amphetamines and ketamine have 
been abused in the country since 1997, quoting a 2002 survey of poly drug use 
among heroin addicts in which 16.2% reported ketamine use, and concluded that 
club drug use was a serious concern in some regions of the country [83]. Ketamine 
abuse has also been reported in Singapore [39] and most recently has been found 
in urine samples from suspected drug users in Malaysia [84]. 
Apart from mainstream recreational use, several smaller groups have been 
identified in which ketamine is abused, such as in a subset of gay men for sexual 
pleasure purposes [85], also by homeless and runaway youths which increased 
rate of risks with regards to sexual use and injecting behaviour of this drug in 
the USA [78,86]. 
 
The extent of crime involved in trafficking, distribution and illicit production of 
ketamine is not well known and global seizures of ketamine are still low 
compared to other regularly abused drugs such as amphetamine type stimulants. 
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These activities are focused primarily in Asia and in Oceania countries, which 
may be related to the tourism industry in which increasing numbers of European 
and American tourists are able to get the product in these countries. 
In the Annual Reports Questionnaire 2003 submitted by governments to UNDOC, 
Australia, Greece, Hong Kong, Macao, Philippines and Malaysia reported 
ketamine seizures; Malaysia and Hong Kong reported the largest seizures (82.5 
kg and 51 kg respectively). Then, in the Annual Reports Questionnaire 2004, 4 
governments reported seizures of ketamine (Australia, Belgium, Hong Kong and 
Macao) the largest seizure being reported by Hong Kong (46.44 kg). The amount 
of ketamine seized each year by the Royal Police of Malaysia from 1998 to 2007 
is shown in Table 2.3. 
Table 2-3 Ketamine seizures in Malaysia from 1998 to 2007 [87] 
 
Year 
 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 
 
Ketamine 
(kg) 
 
 
0.3 
 
0.8 
 
1.0 
 
7.3 
 
10.0 
 
82.5 
 
11.7 
 
395.9 
 
190.4 
 
177.91 
 
 
2.8 Ketamine and Drug-facilitated Sexual Assault   
Ketamine is known as a drug with dissociative and sedative properties and has 
been used in drug-facilitated sexual assault (DFSA). In this kind of crime, the 
drug is mixed in the victim’s drink without their knowledge and the victim will 
be in a state of unconsciousness. Concerned with the harmful effects of these 
DFSA  drugs, a company has came out with a field test kit for detecting ketamine 
and GHB in beverages called Drink Safe Technology Version 1.2 [88].  
There have been reports in the literature about the association of drugs such as 
flunitrazepam (Rohypnol®), gammahydroxy-butyrate (GHB) and ketamine with 
DFSA crimes [89,90,91]. There are also government web-sites regarding drug-
facilitated sexual assaults, for example, the UK Home Office [92] and West 
Virginia Foundation for Rape Information and Services [93].  
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In the UK, ketamine was found in 3 cases of alleged DFSA over a period of 3 
years (2000 – 2003) in samples analysed by the Forensic Science Service, London 
laboratory. 1 case indicated ketamine as the sole drug in the sample, 1 case 
detected a  combination of ketamine and cocaine and the third  was a mixture 
of cannabis, amphetamine, cocaine and ketamine [94]. 
Strict laws have been enacted with regards to DFSA drugs, for example,  
ketamine has been included in the Drug-Induced Rape Prevention and 
Punishment Act 1996 in the USA and an offender may face up to 20 years 
imprisonment [95].   
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3 METHODS OF KETAMINE ANALYSIS IN 
FORENSIC TOXICOLOGY 
There are a number of analytical procedures for the detection and identification 
of ketamine and its metabolites in biological fluids.  The specific methods 
chosen by a laboratory depend on a number of factors such as workload, cost, 
and availability of instrumentation, turnaround time, sensitivity, specificity and 
reliability. This chapter will present a review of the methods based on the 
available literature and the possibility of these methods being used for the work 
of the present study. The scope of the review includes screening and 
confirmatory methods. 
3.1 Screening Methods  
Most screening methods involve immunoassay techniques. Immunoassays are 
based on the principle of competition between labelled and unlabelled antigen 
(drug) for binding sites on specific antibody. There are many types of 
immunoassay employed for analysis of drugs in body fluids such as enzyme 
immunoassay (EIA), fluorescence polarization immunoassay (FPIA) and 
radioimmunoassay (RIA). Nowadays, cloned enzyme donor immunoassay (CEDIA) 
and enzyme linked immunosorbent assay (ELISA) are increasingly popular for 
drug screening.  
The major differences between these immunoassays are in the type of end point 
indicator used and the sensitivity required. The exquisite sensitivity and the 
remarkable specificity of immunoassay led to its early application for the 
detection of drug abuse. The small amount of sample needed for the analysis in 
immunoassay techniques, for example a few microlitres of urine or a blood, 
saliva or semen stain, gives a significant advantage to this technique in forensic 
toxicology applications [96].  
Very few papers have previously been published regarding the use of 
immunoassay techniques for ketamine detection due to the unavailability of 
commercial test kits. In 2003, there was  one paper presented regarding the use 
of ELISA kit for ketamine screening [97]. Later in 2005, 1 article has been 
published involving the use of a commercial ELISA kit to detect ketamine and 
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norketamine in monkey urine [98].  Both studies used the Neogen ELISA kit as the 
screening kit which can easily detect ketamine and norketamine at 25 ng/mL for 
screening purposes.  
In 2007 a paper was published which reported a comparison between Neogen® 
and another commercial kit from International Diagnostic System (IDS®) [99] . The 
comparison is shown in Table 3-1. 
Table 3-1 Comparison of 2 commercial kits for ketamine screening in urine 
Reagent 
Characteristics 
Neogen® International Diagnostic System 
(IDS®) 
Cross-reactivity directed towards 
ketamine 
directed towards ketamine 
metabolites norketamine and 
dehydronorketamine 
 
Linear range  narrower  compared 
to IDS ® 
 
wider linear range than Neogen® 
Detection limit higher concentration  
than IDS ® 
 
lower  concentration than 
Neogen®  
 
Sample analysis negative for 
specimen collected 
at late metabolic 
stage 
positive for specimen collected at 
late metabolic stage 
 
The study used 100 ng/mL concentrations as the cut off point to differentiate 
between positive and negative samples prior to a GC-MS confirmation method. In 
this particular study the authors did not expect a close correlation between 
ELISA and the GC-MS confirmation method (R2 < 0.5). This is because ELISA is 
responsive to compounds structurally related to ketamine while GC-MS is very 
specific to the analyte, ketamine.  
However, until now, no ketamine immunoassay kits for other types of biological 
samples such as blood, hair and saliva were available on the market. ELISA for 
ketamine in these biological samples was evaluated and validated in the work 
for this thesis and the principle of the test will be explained in Chapter 4. 
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3.2 Confirmatory Methods  
Antibodies in the immunoassay kits can react with compounds of related 
structure and so may lack specificity. Therefore, immunoassay techniques need 
to be confirmed with another method such as one involving a chromatographic 
technique to give the definitive results needed in forensic toxicology. Not all 
confirmatory methods were used in the present work and three main methods, 
GC-MS, LC-MS and HPLC, will be discussed in this chapter.    
Detection of ketamine and its metabolites in biological fluids requires sensitive 
and reliable methods due to the use of ketamine as an anaesthetic drug in 
humans and to the possibility of self injury or death caused by misuse of the 
drug. To date, chromatographic techniques are suitable for the analysis of a very 
wide range of organic compounds and are often preferred as the analytical 
methods of detection.  
Chromatography involves both preparative (extraction, purification) and 
analytical (separation, identification, quantification) methods using techniques 
such as HPLC, GC-MS or LC-MS [100]. Chromatographic analysis can provide 
qualitative information in terms of characteristic retention parameters, and can 
give precise quantitative information in terms of peak areas or peak heights, 
especially when coupled to mass spectrometry. 
3.2.1 Gas Chromatography-Mass Spectrometry (GC-MS)  
Gas chromatography (GC) is a separation technique in which the mobile phase is 
a gas. Gas chromatography-mass spectrometry (GC-MS) separates chemical 
mixtures (using the GC component) and identifies the components at a 
molecular level (using the MS component).  
GC works on the principle that a mixture can be separated into its individual 
components on the basis of their partition coefficients between the mobile and 
stationary phases. A sample for analysis is vapourised and carried through a long 
capillary column (metres) holding the stationary phase by an inert gas such as 
helium. The constituent molecules of the sample partition into the stationary 
phase according to their partition coefficients between the stationary and 
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mobile phases. When in the stationary phase they do not travel through the 
column and so substances with a high partition coefficient move more slowly 
through the column than those with a low partition coefficient. Temperature 
plays an important role in influencing the speed of analyte separation on GC 
which is applicable for compound that are stable and can volatilised at 
temperatures up to 350◦C.   
As the separated substances emerge from the column opening, they flow into 
the mass spectrometer or into a detector such as the flame ionisation detector 
(FID) and electron capture detector (ECD). Mass spectrometry identifies 
compounds using the characteristic distribution pattern of the analyte molecule 
and its fragment ions, usually displayed as the mass spectrum. 
GC-MS is normally used to separate volatile organic compounds including drugs 
and pesticides. In forensic toxicology GC-MS is a sensitive and specific method 
for drug determination in biological fluids such as blood, urine and hair due to 
generation of reproducible and repeatable mass spectra which can be matched 
with spectra in the available libraries.  
 
Even though GC-MS has been considered as a gold standard technique in forensic 
toxicology, there are a few limitations reported such as being unsuitable for the 
determination of non-volatile or thermally labile substances and often the 
analytes of interest need to be derivatised using toxic chemical derivatising 
agents.   
 
The rapid growth of ketamine misuse worldwide has led to the development of 
various methods of biological sample analysis, mostly using GC-MS [98, 101,102, 103, 
104,105,106] . A comparison of the methods is shown in Table 3-2. 
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Table 3-2 Comparison of various GC-MS methods for determination of ketamine and its 
metabolites  
 
References 
 
 
98
 
 
101
 
 
 
102 
 
 
103
 
 
104
 
 
105
 
 
106
 
Matrix Monkey urine Human hair Human urine Human  
urine 
Human 
urine 
Human 
urine 
Human 
urine 
Extraction/ 
preparation 
Enzymatic 
Hydrolysis 
SPE (HCX 
Isolute®) 
LLE Acid 
hydrolysis, 
LLE 
LLE SPE, Drug- 
Clean ™ 
LLE SPE, Oasis 
HLB 
Linearity 
(ng/mL) 
0-2000  0.05-100 (K) 
0.005-10(NK) 
0-500 100-5000 50-1000 Not 
mentioned 
30-1000 
 
LOD 
(ng/mL) 
5 pg/mL (K) 
5 pg/mL (NK) 
0.02 for K & 
NK 
1 (K) 
5(NK) 
3-75 for K 
& NK 
25 for K & 
NK 
3-10 1 for 
K,NK, 
DHNK 
 
LOQ 
(ng/mL) 
20 (K) 
50(NK) 
pg/mL 
0.05 for K & 
NK 
5(K) 
10(NK) 
9-100 for K 
& NK 
50 for K & 
NK 
5-50 15(K) 
10(NK) 
20 
(DHNK) 
Precision (%) 
Intra-day 
Inter-day 
Not 
mentioned 
< 8.1 for both 
intra- & inter-
day precision 
<2.1 
<5.1 
< 12.3 for 
real 
samples 
Inter- and 
intra- < 15 
Not 
mentioned 
RSD < 8.1 
Screening 
method 
 
Neogen® 
ELISA 
None None None None None Neogen® 
ELISA 
Identification 
mode 
Chemical 
Ionization 
(CI) mode 
SIM Mode SIM Mode Positive ion  
chemical 
ionization 
(PCI) 
Positive ion  
chemical 
ionization 
(PCI  
Full scan 
SIM mode 
SIM mode 
Accuracy (%) 
 
Not 
mentioned 
80 to 98(K) 
82.5 to 117.5 
(NK) 
93.7-102.5  Not 
mentioned 
78-116 Not 
mentioned 
90-104 
Derivatization 
 
None None None Penta-
flouro-
benzoyl 
chloride 
(PFBC) 
None Comparison 
of 10  
agents 
None 
 
 
  
3.2.2 High Performance Liquid Chromatography (HPLC) 
HPLC is an analytical technique that complements other chromatographic 
procedures such as GC for the quantification of drugs and their metabolites in 
biological fluids.  HPLC is preferred for polar, less volatile and thermally labile 
compounds. Generally, HPLC is a technique for the separation of mixtures by 
using a variety of chemical interactions between the analyte and the column.  
A small volume of dissolved sample is introduced into the stream of mobile 
phase passing through the column by means of a valve injector holding a 
constant or variable volume sample loop that is loaded with a syringe manually 
or from an auto-sampler. The sample components are retained by specific 
chemical or physical interactions with the stationary phase as they traverse the 
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length of the column. The degree of retention depends on the nature of the 
analyte and stationary phase and on the mobile phase composition. 
In HPLC analysis, the mobile phase is either a single solvent or a solvent mixture 
which has been degassed and filtered prior to delivery to the column under 
pressure supplied by a constant flow pump. The function of the pressure is to 
increase the linear velocity which gives the components less time to diffuse 
within the column and improves the resolution of the chromatogram. HPLC 
columns are shorter (centimetres) than GC columns and made of stainless steel 
tubing packed with chemically modified silica, unmodified silica, polymeric 
resins or gels. The time at which a specific analyte emerges from the end of the 
column is called the retention time and is an identifying characteristic of a given 
analyte. 
The analysis can involve either isocratic elution, if the mobile phase composition 
is the same throughout the run time, or gradient elution, if the mobile phase 
composition is changed according to a predetermined programme. Apart from 
the column, the pump is the heart of the equipment and supplies pressure for a 
consistent and reproducible flow rate. The choice of mobile phase, additives and 
gradient depends on the nature of the stationary phase and the analyte(s) of 
interest. Variable-wavelength and diode array ultra-violet (UV) detection are 
commonly used in forensic toxicology. Other types of detector encountered 
include fluorescence and refractive index detectors.     
A number of methods using HPLC have been developed for the quantification of 
ketamine and its metabolites in biological fluids, mostly in human plasma, to 
measure the analyte, the metabolites or their enantiomers after medicinal use 
in patients such as anaesthetic or analgesic. These methods showed excellent 
selectivity, reproducibility, speed and simplicity. Another distinct advantage is 
that only a small sample volume and less pre-treatment of the samples are 
required for the analysis [107 ,108, 109,110,46,111].  The characteristics of each method 
are shown in Table 3-3. 
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Table 3-3 : HPLC method for ketamine and metabolites determination  
 
References 
 
 
107 
 
 
108
  
 
 
109
 
 
110
 
 
46
 
 
111
 
Matrix Human 
plasma 
Human 
plasma 
 
Human 
plasma 
 
Human 
plasma 
Equine 
serum 
Human 
plasma 
Extraction/ 
preparation 
SPE, Oasis HLB LLE LLE SPE using Sep-
Pak light C18 
cartridge 
Micro 
separation with 
a 10 000 mass 
cut-off filter 
LLE 
(cyclohexane) 
HPLC  
Column 
 
Monolithic 
silica  
Reversed-phase 
Ultremax 5 µm 
CN  
Chiralcel OD Chiral  AGP Phenyl 
sphrisorb 
Chiral  AGP  
(Assay I)  
Nucleosil RP  
(Assay II) 
 
Mobile-phase 
 
 
 Monobasic 
sodium 
phosphate: 
Acetonitrile 
(75:25,v/v) 
Methanol: 
acetonitrile: 
orthophosphoric 
acid: 
0.01 M sodium 
dihydrogen-
phosphate 
(200:80:2:718, 
v/v/v/v) 
n-hexane: 
2-propanol 
(98:2,v/v) 
10 mM 
potassium 
dihydrogen 
phosphate buffer 
pH 7: 
methanol 
(84:16,v/v) 
acetonitrile: 
ortho-phosporic 
acid: 
water 
(20:2:78,v/v/v) 
Assay I 
2-propanol: 
0.02 M  
Phosphate 
buffer, pH 7 
(2.5:97.5,v/v) 
Assay II 
Acetonitrile: 
0.03 M  
Phosphate 
buffer, pH 7.5 
(30:70,v/v) 
Linearity 
(ng/mL) 
25-2000(K) 
25-1500(NK) 
15-750(DHNK) 
10-400 (K) 10-500 10-350 50-5000 50-5000 (K) 
50-500(NK) 
LOD 
(ng/mL) 
12.5 (K & NK) 
7.5 (DHNK)  
 
1 (K) 5 =K 
enantiomers 
10=NK 
enantiomers 
2 =K & NK 
enantiomers 
 
K=15 (UV) 
K=5 (PDA) 
40 
LOQ 
(ng/mL) 
25 (K & NK) 
15 (DHNK) 
10 (K) Not 
mentioned 
Not mentioned Not mentioned Not mentioned 
Precision (%) 
Intra-day (ID) 
Inter-day 
(IDa) 
ID =1.3 -7.2 
IDa =1-5-8.7 
ID =<11 
IDa = <13.3 
ID = 2.9 9.8 
IDa =3.4 -
10.7 
IDa =4.8 (S-K) 
IDa =6.0 (R-K) 
IDa =8.5 (S-
NK) 
IDa =4.1(R-NK) 
Not mentioned IDa = < 15  
except for  
43.3 
Identification 
mode 
UV at 220 nm 
 
UV at 215 nm 
 
UV at 215 nm 
 
UV at 220 nm 
 
UV at 215 nm 
(screening) 
Photo-diode 
array (confirm) 
at 200-320 nm) 
UV at 215 nm 
 
Recoveries 
(%) 
 
95.3 (K) 
96.9(NK) 
103.9(DHNK) 
79.9 (K) 86-1 to 91.3 
for K and NK 
enantiomers 
81 (K 
enantiomers) 
87 (NK 
enantiomers) 
106.3 (K) 89.3 - 101.4  
(Assay I) 
74.8-103.9 
(Assay II) 
for K and NK 
enantiomers 
Significance 
 
Application of 
monolithic silica 
column for 
ketamine, 
norketamine and 
dehydro-
norketamine 
detection  
To measure 
ketamine & 
bupivacaine 
simultaneously 
at low analgesic 
doses 
Method to 
determine 
ketamine 
enantiomers 
and 
norketamine 
in human 
plasma 
Method to 
determine 
sub-anaesthetic 
concentration of 
ketamine and 
norketamine 
enantiomers in 
human plasma 
Method to 
determine 
Ketamine and 
dehydro-
norketamine 
in equine serum 
Comparison of  
2 methods 
emphasized on 
reverse-phased 
column to  
determine 
concentration of 
ketamine and 
norketamine 
enantiomers in 
human plasma 
 
 
 
However, HPLC also has some limitation in the identification of some drugs such 
as overlapping of analyte peaks, poor absorption of UV light of some analytes in 
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the analysis using the UV and diode array detector (DAD); and also absorbance of 
some analytes are affected by mobile phase composition such as pH and solvent 
strength.  
3.2.3 Liquid Chromatography Mass Spectrometry (LC-MS) 
Remarkable developments have extended the applicability of HPLC to robust, 
efficient and routinely used LC-MS instruments. The technology solves the 
problem of the inherent lack of sensitivity of the ultra violet detector for a 
number of drugs and metabolites by providing a more universal detector in mass 
spectrometry, for more sensitive detection and quantification.  
LC-MS methods can be used to analyse a significantly larger number of organic 
compounds than GC-MS, including those which are polar, less volatile and 
thermally labile. The most common application of LC-MS is to the identification 
and quantification of specific compounds in mixtures [112]. Currently, it is 
increasingly used for screening purposes in many laboratories as an alternative 
to immunoassay [113,114,115]. LC-MS eliminates the need for time-consuming 
derivatisation step often required in GC-MS. 
LC-MS is an analytical technique that combines the physical separation 
capabilities of liquid chromatography (LC) which provides the chromatographic 
separation of analytes from the matrices with the mass analysis capabilities of 
mass spectrometry (MS) which is used to obtain mass to charge ratios (m/z) or 
resolution of the analytes of interest from the matrices (detection of analytes). 
LC is useful for removing the interferences from the sample that would impact 
on the ionization and mass spectrometric detection offers high sensitivity and a 
high degree of selectivity compared to conventional HPLC detectors.  
The vital part of this combined technique is the interface between the 
chromatograph and the mass spectrometer which involves various ionisation 
techniques such as Atmospheric Pressure Chemical Ionisation (APCI), 
Electrospray Ionization (ESI), Thermospray, Fast Atom Bombardment (FAB) and 
Nanospray Ionization (NSI).  Most LC-MS applications today use atmospheric–
pressure ionization (API) techniques which are of two types - ESI and APCI as the 
interface element to introduce the liquid sample into the ion source. These two 
interface techniques are robust and widely used in forensic toxicology and are 
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described frequently in the literature [116,117,118,10,31]. APCI and ESI convert sample 
molecules to ions at atmospheric pressure and then transfer the ions to the high 
vacuum environment of the mass analyzer. 
ESI is considered a soft ionization technique which produces few ions, usually 
consisting of a protonated molecular ion plus some adduct ions involving 
constituents of the mobile phase. This technique transforms ions in a liquid into 
ions in the gas phase and was used in this study. The theory will be explained in 
Chapter 5 [119]. The major disadvantage of the ESI interface is in fact the lack of 
product ions, as often only a pseudomolecular ion is produced. This causes 
problems in satisfying accepted criteria for the identification of analytes and has 
resulted in the advent of tandem mass spectrometry (MS/MS), which allows the 
molecular ion to be fragmented in secondary reaction processes.  This will also 
be covered in more detail in Chapter 5. 
In the APCI interface, vaporised solvents act as the reagent gas. The sample and 
eluent are nebulised in a hot chamber where reagent ions are formed by the 
interaction of solvent molecules with a corona discharge. Reagent ions interact 
with sample molecules via protonation or change transfer to produce sample 
ions. Sample ions pass through skimmers into a mass analyzer. To vaporize the 
sample, the chamber is heated to 200ºC – 500ºC. Higher temperatures will 
decompose the sample. ESI is softer ionisation technique therefore leads to less 
thermal degradation than APCI. 
As shown in Figure 3-1, the ESI interface is preferred to APCI due to its broader 
range of applications [120]. ESI-MS is sensitive for the detection of high molecular 
weight compounds such as proteins and peptides. The interface is also suitable 
for highly polar compounds or thermolabile molecules such as glucuronide 
conjugates and quaternary amines [121].  
 
The interest in LC-MS applications also led to the development and improvement 
of mass analysers including the quadrupole mass analyser, quadrupole ion trap 
mass analyser and time-of-flight mass analyser. A quadrupole ion trap mass 
analyser was used in this study. 
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Figure 3-1 Molecular weight and polarity versus the choice of interface  
 
There are a few publications on the determination of ketamine, its metabolites 
and their enantiomers by LC-MS in various samples such as urine and human 
plasma which showed very good sensitivity, specificity and recovery with a short 
running time. Cheng et al. [116]  developed a method for ketamine determination 
in urine which was rapid (2.5 min analysis time) and had a good recovery (89 %) 
and  good precision (11 % RSD) at 20 ng/ml. Urine samples were extracted by 
automated SPE using a Gilson XL4 with Alltech cartridges, which obtained a 5 
ng/ml detection limit and could analyse up to 200 samples per day. The samples 
were analysed with LC coupled to a Finnigan LCQDUO ion trap mass 
spectrometer with an electrospray ionization source. 
 Lua et al. [122] developed a rapid screening method with a 1.3 min run time per 
sample which involved LLE in 0.2 ml hexane and analysis by LC-ESI-MS operated 
in full scan mode. The detection limits were 3 ng/ml for ketamine and 15 ng/ml 
for norketamine with within-run precision at 3 levels of 4.0 % to 14.7 %. The 
sensitivity and specificity were 97.1 % and 85.7 % when coupled with a GC-MS 
confirmation method for detection of 168 urine samples from disco-dancing club 
participants.  
A sensitive method of determination of ketamine and norketamine in human 
plasma by micro-liquid chromatography mass-spectrometry has been developed 
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by Legrand et al.as part of a clinical trial in a paediatric population [123]. The 
analytes were extracted using solid phase extraction on Oasis MCX® cartridges 
and separation of analytes was performed on a C-18 micro-column using a 
mobile phase of formic acid 0.1 % and acetonitrile (90:10, v/v) with a run time 
of 10 min. The method linear range was 50 to 500 ng/ml and recoveries were 
from 98.1% to 101.7 %. Mass spectral data were obtained using selected ion 
monitoring (SIM) mode and limits of quantification were 4 ng/ml for both 
ketamine and norketamine.  
A group of researchers in the USA [124] developed a method for determination of 
ketamine and norketamine enantiomers in human plasma for a study of ketamine 
in pain management. Extraction was by solid phase extraction (Oasis HLB®) prior 
to direct injection to a LC-MS system and the method could process up to 60 
patient samples per day. The enantioseparation was performed on a chiral AGP 
column using an isocratic mobile phase of 2-propanol-ammonium acetate buffer 
(10 mM, pH 7.6) with a composition of (6:94,v.v) and a flow rate of 0.5 ml/min. 
Chromatographic identification and quantification were carried out using SIM 
mode. The method had a linearity of 1 - 125 ng/ml and an analysis time of 20 
min, with intra- and inter-day precision < 8.0 %. The authors claimed the 
sensitivity was better than in previously reported methods for determination  of 
ketamine and norketamine enantiomers.  
3.3 Techniques for Sample Preparation  
Biological fluids such as blood, plasma or urine are referred to as complex 
matrices and normally contain a number of endogenous components. These 
matrix components may interfere with and may adversely affect the subsequent 
separation and identification of analyte(s) of interest if they are not removed.  
Therefore, two-thirds of the total analysis time in chromatographic methods is 
typically due to the sample preparation steps and these are often the major 
source of error in the overall analytical process. 
Sample preparation impacts on nearly all the later assay steps and is hence 
critical for unequivocal identification, confirmation and quantification of 
analytes. It includes both the isolation and/or pre-concentration of compounds 
of interest from various matrices as well as making the analytes more suitable 
for separation and detection. Extraction procedures are critical preparation 
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processes in analytical methods and identification and separation of compounds 
cannot be achieved without proper treatment of the samples. 
 A few types of extraction method are used routinely in analytical toxicology 
such as Liquid-liquid Extraction (LLE), Solid Phase Extraction (SPE), Solid-Phase 
Micro-Extraction (SPME), and Molecularly Imprinted Solid Phase Extraction 
(MISPE). Currently, the most convenient method for extraction of drugs in 
biological fluids is SPE due to its simplicity and versatility which leaves LLE, 
which is labor intensive and solvent consuming, far behind in analytical 
methodologies. MISPE is currently a growing field in clean up techniques for the 
analysis of biological samples.  SPE and MISPE were investigated and evaluated in 
this thesis.  
 
3.3.1 Solid Phase Extraction (SPE) 
3.3.1.1 Introduction to SPE 
SPE started in the early 1970s but during the 1980s and 1990s development of 
SPE methods and their use in analytical chemistry greatly increased [125]. 
Nowadays, SPE is well established and widely used in many different fields of 
analytical chemistry including forensic toxicology. SPE is a very common type of 
sample extraction and clean up technique for biological fluids in analytical 
chemistry and a well-accepted sample preparation technique in the analytical 
chemistry community [125].  
It is a rapid sample preparation method used to selectively extract, concentrate 
and purify target analytes prior to further analysis by chromatographic 
techniques. It is a form of solid absorption chromatography ranging from simple 
hydrophobic or hydrophilic partition chromatography to ion-exchange or affinity 
chromatography. SPE is a very simple technique to use, employing inexpensive, 
disposable extraction columns that are available in a multitude of column sizes 
and sorbents. SPE cartridges are available in tube, cartridge and disk formats. 
3.3.1.2 Principles of SPE 
Sample preparation with SPE consists of four basic steps: conditioning, sample 
loading, washing and elution. The aim is to retain the analyte in the sorbent 
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bed, wash away interferences and finally elute the analytes as a clean extract in 
a small volume prior to analysis by suitable method such as LC-MS.  
In principle, a sample is loaded on an SPE column. The sample matrix and 
interferences pass through the column while analytes are retained on the 
sorbent material in the column. Interferences can then be selectively removed 
from the column through the correct choice of wash solvents. Finally, the 
analytes may be selectively recovered from the column by an elution solvent, 
resulting in a highly purified extract. Alternatively, an extraction column may be 
selected which retains the interferences in the sample, but allows the analytes 
to pass through unretained. 
Most SPE columns contain sorbents with an average particle size of 45-65 µm 
base material. Most organic solvents will flow through the columns under 
gravity, but for aqueous and other viscous samples and solvents, liquids must be 
passed through the columns using vacuum applied to the column outlet, pressure 
applied to the column inlet, or centrifugation. A vacuum manifold is the most 
commonly employed method.  
These techniques can be used either off-line or on-line. In the on-line mode, the 
sorbent is packed into a pre-column which is located in a six-port switching valve 
connected to an LC system. In the load position, SPE is performed and, in the 
inject position; the pre-column is connected to the analytical column. This 
allows simultaneous elution and transfer of the retained analytes by the mobile 
phase of the LC separation. The on-line coupling of SPE with an LC system 
provides higher enrichment factors compared to the off-line system, when the 
eluent is evaporated and reconstituted before being injected into the analytical 
column.   
3.3.1.3 SPE Sorbents 
SPE is performed using either silica-based or polymer-based sorbents. The nature 
of the base material and the functional groups both affect the way that the 
sorbents are used. Silica-based sorbents have a number of advantages including 
rigid support particles that do not shrink or swell and the availability of a larger 
selection of phases. Polymer-based sorbents have different advantages including 
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lack of the need for acidic/basic elution modifiers, no pH limitations (stable 
from pH 1-14) and high capacity. 
There are a number of phases to suit different SPE applications [126]. Polar 
(normal phase) sorbents extract polar to moderately polar compounds from non-
polar matrices using organic eluents such as acetone, chlorinated solvents and 
hexane. Aminopropyl (NH2), cyanopropyl (CN), diol, silica (Si), florisil and 
alumina are polar phases for normal phase interaction. Retention of an analyte 
under normal phase conditions is primarily due to interactions between the polar 
functional groups of the analyte and polar groups on the sorbent surface. These 
include hydrogen bonding, ∆-∆ interactions, dipole-dipole interactions and 
dipole-induced dipole interactions, among others. A compound adsorbed by 
these mechanisms is eluted by passing a solvent that disrupts the binding 
mechanism, usually a solvent that has polarity more than the analyte’s original 
matrix. 
Reversed phase SPE sorbents extract moderately polar to non-polar analytes 
from aqueous matrices using a non-polar stationary phase, for example the alkyl- 
or aryl-bonded silicas. Octadecyl (C18), octyl (C8), cyclohexyl (CH), phenyl (PH), 
butyl (C4) ethyl (C2) and methyl (C1) are non-polar phases for reversed phase 
interaction. Retention of organic analytes from polar solutions (e.g. water) on 
these sorbents depends on lipophilic interactions (van der Waals forces, or 
dispersion forces) between the carbon skeleton in the analyte and the functional 
groups on the silica surface. To elute an adsorbed compound from a reversed 
phase SPE cartridge, a non-polar solvent is used to disrupt the forces that bind 
the compound to the packing.  
A few studies have successfully used this type of sorbent to extract ketamine 
and metabolites from biological sample matrices such as CleanScreen®  (C8)
 [104], 
Oasis HLB® which contained an equal hydrophilic-lipophilic reversed phase 
sorbent [106, 107,124], Sep-Pak C18
® [110] and Alltech C18
® [116]. 
Ion exchange sorbents separate analytes based on electrostatic interactions 
between the analyte of interest and the positively charged groups on the 
stationary phase. Both the stationary phase and sample must be at a pH where 
both are ionised.  
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Anion exchange sorbents are derivatized with positively charged functional 
groups, such as amines, that interact and retain negatively charged anions, such 
as acids, while cation exchange sorbents are derivatized with functional groups, 
such as acids, that interact and retain positively charged cations, such as amines 
[127] . Benzenesulfonic acids (SCX), quaternary amine (SAX), aminopropyl (NH2) 
and primary/secondary amine (PSA) are examples of ion exchangers.  
Mixed mode sorbents contain both hydrophobic and ionic functional groups which 
enable the sorbent to provide two types of retention mechanisms. This type of 
sorbent is widely used in forensic toxicology because of its high selectivity and 
ability to provide clean chromatograms. Sorbents functionalised as mixed-mode 
cationic exchangers which have high selectivity for basic compounds have been 
used in few studies to obtain high recoveries of ketamine and its metabolites 
from complex sample matrices such as Isolute HCX® [40] and Oasis MCX® [57]. 
Polymer based SPE involves macroporous polymeric media, offering a higher 
loading capacity compared to conventional functionalized silica SPE media.  
They are compatible with all polar and non-polar, protic and aprotic solvents 
and can be used over a wide pH range, pH 1-14. One example is Strata™ X which 
has the advantage of having no residual surface silanol groups, unlike the 
substituted silica sorbents. The structure of Strata™ X is shown in Figure 3-2. 
N
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Figure 3-2 Structure of Strata™ X 
 
SPE techniques have proved to give a better selectivity and specificity for the 
target compound(s) and to result in higher recoveries and reproducibility due to 
the wide range of sorbents available in the market.  SPE also has higher 
concentration factors and can be automated, and this enables an analyst to 
process multiple samples rapidly.  SPE only requires a small volume for 
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extraction compared to LLE. In conclusion, SPE not only offers more advantages 
over LLE in terms of performance but also in economic and environmental 
benefits. 
3.3.2 Molecularly Imprinted Solid Phase Extraction (MISPE) 
A Molecularly Imprinted Polymer (MIP) is a synthetic polymer bearing on its 
surface the molecular imprint of a specific target molecule (the template). The 
main advantage of molecular imprinting is the possibility of preparing a selective 
sorbent pre-determined for a particular substance or a group of structurally 
related substances. The polymer has a permanent memory of the template and 
is capable of selectively rebinding the template or structurally similar molecules 
such as the metabolites [128]. 
The application of MIPs as sorbents in SPE has been found very useful for 
selective extraction for the reason that MIPs offer higher selectivity than 
conventional SPE. MIPs also reduce the influence of the matrix on the resulting 
chromatogram and high sample enrichment factors are achieved. The work on 
MISPE was started by Sellergen in 1994 who successfully extracted pentamidine, 
a drug use to treat pneumonia for AIDs patients, from human urine using a MIP 
material as the SPE sorbent [129].   
From then, several applications of MISPE have been successfully employed in the 
determination of environmental and pharmaceutical samples such as nicotine in 
chewing gum[130] and atrazine in beef liver [131] , in which MISPE was used to 
clean-up the extract and concentrate the analyte for further analysis. This 
removed the interfering components in the sample and subsequently improved 
the accuracy of HPLC analysis and lowered the detection limit. 
MISPE has not been used in forensic toxicology until recently. Ariffin et al [132] 
developed a method for MISPE prior to analysis using LC-MS for benzodiazepine 
detection and found it to be simpler and cleaner compared to conventional SPE.  
The work of Ariffin et al. opened the door to the application of MISPE in forensic 
toxicology. The work in this thesis applied MISPE methods to ketamine extraction 
and compared them to conventional SPE techniques.  
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In this study, an MIP prepared with (±)-ketamine as a template was used in a 
wholly novel sample preparation method for the analysis of ketamine and 
norketamine in hair based on molecularly imprinted solid-phase extraction 
(MISPE). 
SupelMIP® is the first MIP-based SPE sorbent which offers tailor-made selectivity 
for the extraction of trace analytes in complex matrixes and the first to be 
commercialised in year 2008 by Supelco. Part of the present work investigated 
the potential of Amphetamines SupelMIP® for the determination of 
amphetamines in post-mortem blood.  
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4 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
FOR SCREENING OF KETAMINE AND ITS 
METABOLITES 
4.1 Introduction 
ELISA is the acronym for "enzyme-linked immunosorbent assay." This is a rapid 
immunochemical test that combines the reaction of an enzyme, a protein that 
catalyzes a biochemical reaction, with an antibody/antigen reaction. The test 
also requires an appropriate enzyme label and a matching substrate suitable for 
the detection system being used.  
Generally, ELISA tests show the same high sensitivity and specificity as other 
immunoassay tests such as radioimmunoassay (RIA).  For example, there are 
established ELISA tests for proteins such as α-fetoprotein and hCG, with limits of 
detection as low as 1 ng/ml and with good intra-assay precision, with 
coefficients of variation in the range 8-10 %, which produce performance as good 
as the corresponding RIA tests [96].  ELISA kits are also safer and have longer 
usable time periods compared to RIA. The radioisotope commonly used in RIA is 
iodine-125 [96], which has a short half-life and as a result, a short shelf life, 
usually a maximum of six months.   
An ELISA test may be interpreted in a qualitative or semi-quantitative format. 
Qualitative results provide simple positive or negative results for a sample. The 
cut-off is a value serving as an administrative break point for labeling a sample 
as positive or negative and determined by the manufacturer or the analyst. This 
cut-off value is at least equal to but usually higher than the limit of detection 
otherwise a high number of false positive results may be obtained. The cut-off 
value selected should result in a method sensitivity and specificity of better than 
90 % [133].   
In semi-quantitative ELISA, a serial dilution of the target analyte is prepared and 
the optical density or fluorescence emission of the end product of the substrate-
enzyme reaction is interpolated into a standard curve. The test is called semi-
quantitative since the assay result represents the summative contribution from 
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all drugs from a particular drug class in a sample that can compete for the 
antibody binding sites and does not generally represent a single target analyte. 
ELISA has become popular within the forensic toxicology community because it is 
relatively easy to perform, has good potential for automation, needs only a small 
sample size, does not require radioisotopes and can be used with blood, urine 
and other biological samples such as hair and saliva [134] . Currently, it is the only 
type of commercially available immunoassay test for the screening of ketamine 
and its metabolites. The purpose of this study was to evaluate and validate the 
suitability of the commercially-available Neogen® kit for the screening of 
samples for ketamine in urine before being confirmed by a quantitative method, 
liquid chromatography tandem mass spectrometry (LC-MS/MS).  
4.2 Principles of ELISA  
ELISA is one type of immunoassay test which involves a binding reaction between 
an antibody and its cognate antigen (the analyte). The kinetics of an antibody-
antigen reaction in an immunoassay test can be described by the Law of Mass 
Action as shown in Equation 4-1 and Equation 4-2. 
  
 
 
where, 
 
[Ag] = antigen concentration,  
[Ab] = antibody concentration, 
[Ag-Ab] = antigen-antibody complex,   
ka   = association rate constant,   
kd   = dissociation rate constant. 
Keq = equilibrium constant or affinity constant 
Keq, represents the ratio of bound to unbound analyte and antibody. This ratio 
can be translated into a signal that can be measured spectrometrically at a 
selected wavelength.                                                       
Equation 4.2                      Keq  =           ka   =  [Ag–Ab]  
                                                             kd      [Ag][Ab]  
[Ag] + [Ab]                 [Ag-Ab] 
  ka 
kd 
 Equation 4.1 
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There are several different types of ELISA test, including either a competitive or 
sandwich type. In competitive ELISA, an affinity-purified capture antibody such 
as anti-IgG is pre-coated onto a microplate. A limited concentration of primary 
antibody and enzyme-linked analyte along with the sample are added 
simultaneously. Sample analyte and enzyme-linked analyte compete for the 
limited number of binding sites on the primary antibody, which is bound by the 
immobilized anti-IgG. Substrate is added and hydrolyzed by the enzyme, thereby 
producing a colour product that can be measured. The amount of labelled 
analyte bound is inversely proportional to the amount of unlabeled analyte 
present in the sample (signal decreases as analyte concentration increases, 
Figure 4-1) [135] . This type of assay was used in the present study.  
The sandwich technique is so called because the antigen being assayed is held 
between two different antibodies. An antibody for the target analyte is coated 
to a solid support such as microplate wells, then a sample containing antigen is 
added. The mixture is incubated to allow the Ag-Ab reaction to take place 
before the unbound components are washed away. Thereafter, a known amount 
of antibody for the target analyte which has been labelled with enzyme is 
allowed to react with the bound antigen to form an Ab-Ag-Ab complex. Any 
excess unbound enzyme-linked antibody is washed away after the reaction. The 
substrate is then added and the reaction between the substrate and the enzyme 
produces a colour change. The amount of visual colour change is directly 
proportional to the amount of specific enzyme-conjugate bound antibody, and 
consequently to the concentration of antigen present in the specimen tested 
[136]. 
The Neogen direct competitive ELISA ketamine assay operates on the basis of 
competition between the drug or its metabolite in the sample and the drug-
enzyme conjugate for a limited number of specific binding sites on a surface, 
often a microplate pre-coated with antibodies specific to the target analyte.  
The simple assay procedure includes the addition of samples or controls to the 
well of an antibody-coated microplate. The antibody is fixed to the surface to 
render it immobile. The enzyme-ketamine conjugate is added to the mixture and 
this is followed by an incubation time of selected duration. During incubation, 
ketamine in the sample and ketamine-enzyme conjugate compete for binding 
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sites on the antibody-coated microplate. After the incubation, the microplate is 
washed, so that unbound ketamine is removed and only ketamine-antibody 
complexes remain attached to the well. Subsequently, a substrate for the bound 
enzyme is added followed by another incubation time.  The enzyme converts the 
substrate to elicit a chromogenic signal. After the incubation, a stop solution is 
added to end the reaction and the test is read visually or with a microplate 
reader.  
The extent of colour development is inversely proportional to the amount of 
drug in the sample or control. The absence of the drug in the sample will result 
in a more intense colour, whereas the presence of the drug will result in 
decreased or no colour development [137] . A schematic presentation of the test 
principles of the Neogen ketamine ELISA used in this study is depicted in Figure 
4-1. 
 
Figure 4-1 The test principles of Neogen ketamine ELISA 
 (copyright Neogen Corporation® ) 
 
4.3 Experimental Section  
4.3.1 Chemicals and reagents 
Ketamine ELISA kits (product number: 109419) were purchased from Neogen® 
Corporation (Lexington, USA). The kits contained 96 antibody-coated microplate 
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wells, wash buffer (phosphate buffered saline solution, pH 7, containing a 
surfactant), ketamine-enzyme conjugate labelled with horseradish peroxidase 
(HRP),   3,3’,5,5’-tetramethylbenzidine (TMB) substrate solution with hydrogen 
peroxide (H2O2), a red stop solution containing 0.5 M H2SO4, as well as negative 
(0 ng/mL) and positive (2000 ng/mL) controls prepared in synthetic urine.  
Phosphate buffer saline (PBS) pH 7 was purchased from Immunolysis® Corporation 
(Pomona, CA, USA) which contained bovine serum albumin and non-azide 
preservatives. IM HCl was used as the stop solution instead of 0.5 M H2SO4  
provided by the manufacturer to fit the Tecan Reader available in the 
laboratory.  
Ketamine, norketamine and drugs standards used to test the cross-reactivity of 
the ELISA kit, namely amphetamine, methamphetamine, 3,4-
methylenedioxyamphetamine (MDA), 3,4-methylene-dioxymethylamphetamine 
(MDMA), 3,4-methylenedioxyethylamphetamine (MDEA), cocaine, 
benzoylecgonine, diazepam, nordiazepam, morphine, methadone, 6-
monoacetylmorphine (6-MAM) and phencyclidine (PCP) were obtained from 
Promochem (Teddington, UK). Tiletamine.HCl powder was purchased from 
Sigma-Aldrich (Dorset, UK).  
 
4.3.2 Equipment 
A miniprep 75 automatic pipettor purchased from Tecan (San Jose, CA) was used 
to dilute the samples, controls and calibrators and to pipette them into 
microplate wells. A Sunrise Remote EIA Reader from Tecan was used to read the 
microplates at a wavelength of 450 nm. Disposable borosilicate glass culture 
tubes (75 x 12 mm) from VWR International, Poole, UK were used for samples 
and dilutions. Washing was done manually.  
4.3.3 Preparation of solutions [138] 
4.3.3.1 Enzyme conjugate 
The enzyme conjugate supplied with the Neogen® kit was diluted by a factor of 
180 with the EIA buffer (PBS: phosphate buffered saline. pH 7). The volume 
needed was calculated. For example, two eight well strips needed 2880 µl (2.8 
ml) and 25 µl enzyme conjugate stock was added to 4475 µl of EIA buffer. The 
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solution was mixed by inversion. The enzyme conjugate was freshly prepared 
before use. 
 
4.3.3.2 Wash buffer  
The concentrated wash buffer was diluted 10 fold with deionized water. For 
example, 20 ml of concentrated wash buffer was mixed thoroughly with 180 ml 
deionized water. Diluted wash buffer is stable in room temperature for 5 days or 
7 days at 4 ◦C. 
4.4 Method Development 
In ELISA, several requirements are associated with the enzyme-substrate 
reaction, such as timing and development conditions that need to be optimised 
to get a precise, accurate and reproducible assay. There were a few conditions 
applied in this study to get the lowest percentage of colour activity (B/B0) where 
B is the absorbance reading of the bound calibrator and B0 is the absorbance 
value of the blank calibrator.  
The three most important factors evaluated in the study were the volume of 
sample, volume of enzyme-conjugate and the pre-incubation time. For the 12 
conditions, urine spiked with ketamine at a concentration of 25ng/ml was used 
with n=5.  During method development, specimen volume (20 or 40 µl), enzyme 
conjugate (90 or 180 µl) and pre-incubation time (0, 30 or 60 min) were 
evaluated. The experimental conditions used and the results are tabulated in 
Table 4-1.   
In this study, the parameters which proved to give the best distribution of 
absorbance and concentration values and showing the widest difference in 
absorbance between the blank and the 25 ng/ml were used for the subsequent 
validation study. The data in Table 4-1 show that that pre-incubation time was 
not a very significant factor and 0, 30 and 60 min produced quite similar results.  
The most important factor was the volume of enzyme conjugate used: the higher 
volume (180 µl) was better than the lower volume (90 µl) and gave a decrease of 
approximately 10 % in the B/B0 value. 40 µl of sample gave slightly better results 
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than 20 µl but still in the same B/B0 absorbance range. For forensic toxicology 
purposes, where there is a need to have lower sample volumes and shorter 
analysis times, the parameters chosen as a result of this study were 20 µl 
sample, 180 µl enzyme conjugate solution and no pre-incubation time.   
This finding was similar to a study for the optimization of an ELISA method for 
cocaine in hair carried out by Lachenmeier et al., who tried 20 µl and 50 µl 
sample volume, 50 and 100 µl enzyme conjugate and 15, 30 and 45 minutes pre-
incubation time and found that 20 µl sample, 100 µl enzyme conjugate and no 
pre-incubation time were the parameters that gave the desired target and which 
were used in the remainder of the study [139]. The optimized parameters selected 
in the present work also tallied with the procedures recommended by the 
manufacturer.     
Table 4-1 Experimental conditions for method optimisation   
Experimental conditions 
Urine diluted (1:10) 
Volume of 
sample 
(µL) 
 
Volume of 
enzyme 
conjugate 
(µL) 
Pre-incubation 
Time (min) 
 
 
Average B/B0 
(%) 
 
 
STD DEV 
 
 
 
% RSD * 
 
0  84.16 3.09 3.67 
30  84.38 1.37 1.63 
90  
60  83.95 1.63 1.94 
0 * 74.07 3.09 4.17 
30  74.58 1.73 2.33 
20*  
180*  
60  74.42 0.94 1.26 
0  83.52 3.12 3.74 
30 82.93 1.09 1.31 
90  
60 80.85 1.65 2.04 
0 73.94 2.22 3.00 
30 72.14 3.12 4.32 
40  
180  
60  71.52 1.75 2.45 
* Parameter used for validation   
* % RSD = (SD/ Average B/B0 ) x 100 
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4.5 Method Validation 
Method validation procedures used in this study were based on published papers 
dealing with the validation of ELISA methods for drugs in the forensic toxicology 
field [24,140] and also with reference to validation guidelines for a semi-
quantitative method [141]. The ELISA kit manufacturers determined a plate 
sensitivity of 8 ng/mL ketamine in buffer compared to 10 ng/mL ketamine in 
neat urine (1.25 fold lower sensitivity). Therefore the blank, calibrators and 
quality control samples were prepared in blank urine for this study in order to 
take the urine matrix effect into account.  
To minimize the effect of incubation time, pipetting was automated using a 
Tecan miniprep 75 automatic pipettor to get the enzyme conjugate, substrate 
and stop solution delivered to all of the microplate wells at the same time.   
4.5.1 Sample Treatment 
I ml of each urine sample was added to separate disposable borosilicate glass 
culture tubes (75 x 12mm). The samples were vortex mixed then diluted 1:10 
with Neogen EIA buffer. 9 parts of EIA buffer (900 µl) were added to 1 part (100 
µl) of sample. This procedure was performed to reduce the natural background 
as well as to bring the cut-off concentration within the assay range. A miniprep 
75 automatic pipettor was used to dilute the samples, controls and calibrators 
and to pipette them into a series of clean disposable borosilicate glass culture 
tubes. After that, the diluted samples were again vortex mixed.  
4.5.2 ELISA Method 
The ELISA procedure used in this study was the optimised method with no pre-
incubation time; lower sample volume and acceptable B/B0 (%) values. 20 µl of 
diluted samples, calibrators or controls were added to the microplate wells, 
followed by 180 µl of diluted enzyme conjugate. 
The plate was then left in the dark at room temperature for an incubation time 
of 45 minutes for competitive binding between ketamine in the sample and the 
enzyme labelled conjugate for the antibody binding sites on the wells.   After 
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the incubation, the microplate wells were washed five times with 300 µl diluted 
wash buffer to remove the unbound sample or residual conjugate that may have 
been left in the wells. 3,3’,5,5’-tetramethylbenzidine (TMB) substrate was then 
added to the wells and allowed to incubate again for 30 minutes at room 
temperature in the dark. TMB formed a blue product when allowed to react with 
peroxidase enzymes such as horseradish peroxidase. The reactions were then 
stopped with 50 µl of 1M HCl, when the contents of the wells turned yellow and 
this enabled the chromophore to be detected at 450 nm using the Remote EIA 
Reader from Tecan. A schematic presentation of procedures used in this study is 
shown in Figure 4-2. 
 
Figure 4-2 Optimised ketamine ELISA assay procedure 
 
4.5.3  Dose-Response Curve 
A dose-response curve was generated for 1 ml urine spiked at concentrations of 
0, 0.5, 1, 2, 4, 5, 10, 25, 50, 100, 500, 1000, 2000, 4000 and 8000 ng/ml 
ketamine (Figure 4.3). The test was carried out in duplicate and the average was  
20 µl  sample/calibrator/control loaded into each microplate well  
180 µl diluted enzyme conjugate added to each microplate well  
plate incubated for 45 minutes 
plate washed with 5 x 300 µl diluted wash buffer 
150 µl K-Blue substrate added to each microplate well  
 
50 µl stop solution (1M HCl) added to each microplate well 
plate incubated for 30 minutes 
plate read at 450 nm 
 
Norlida Harun - 2010                                                                                                             Page 53 
plotted. The range of values was selected based on previously published report 
of ketamine analysis in urine case samples [34,102,105,106,142,143].  
The B/B0 (%) values were calculated where B is the absorbance value of the 
bound calibrators and B0 is the absorbance value of the blank calibrator. Both x 
and y axes are converted into log-scales and the results show that a higher 
ketamine concentration in the sample resulted in a lower optical density value 
(B/B0 %) due to the lower amount of enzyme conjugate bound to the antibody 
sites.  
The graph also indicated that the ketamine assay S-shaped binding curve had a 
linear portion between 25 ng/mL to 500 ng/mL ketamine, which levelled off 
after 2000 ng/ml ketamine. The response for the main metabolite, norketamine, 
was not taken into consideration in this dose response curve due to lower cross-
reactivity stated by manufacturer - for 196.4 ng/ml norketamine the cross-
reactivity is only 4.6%.  
In conclusion, the cut off value 25 ng/ml was selected from one of the lower 
values within the linear range (25 ng/ml) and any values ≥2000 ng/ml were read 
as >maximum whereas values below 10 ng/ml would not give very accurate 
quantitative results.        
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Figure 4-3  Ketamine ELISA dose response curve from 0.5 to 8000 ng/ml. 
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4.5.4  Intra-day and Inter-day Precision 
The intra-day precision of B/B0 % values was determined by spiking 10 drug free 
urine samples with 25 ng/ml ketamine. The test was carried out on the same 
plate and on the same day. For inter-day precision the tests were carried out on 
five different days with number of samples n=50 and included different batches 
of reagent kits. The results showed that good precision was obtained from the 
developed method. The intraday precision for 10 samples spiked with ketamine 
at 25 ng/ml was 2.5 % RSD and the inter-day precision for 50 samples spiked at 
the same concentration was 4.8 % RSD.   Both intra and inter-day precisions were 
below 5.0 % and are shown in Table 4-2.  
Table 4-2 Intra and inter-day precisions for ketamine ELISA assay in human urine  
 
Intra-day 
n=10 
 
Inter-day 
n=50 
 
 
Average  
B/B0 (%) 
 
 
RSD (%) 
 
Average 
B/B0 (%) 
 
RSD (%) 
 
50.8 
 
2.5 
 
51.8 
 
4.8 
 
 
4.5.5 Limit of Detection (LOD) 
The LOD was calculated using 10 negative samples and Equation 4-3. Ketamine 
was spiked at concentrations of 0.5, 1, 2, 4, 5, 10, 25 and 50 ng/ml to establish 
a calibration curve.  
Equation 4-3        LOD = A0-3s  
 
A0 is the mean absorbance value and s is the standard deviation of the 
absorbance values of the negative samples. B/B0 % of LOD was calculated using 
Equation 4-3 and converted to concentration of ketamine. This study obtained 
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an LOD of 5.0 ng/ml for ketamine in human urine using the Neogen® ELISA kit, 
better than the LOD of 10 ng/ml indicated by the manufacturer in the product 
insert. However, this LOD was not used as the cut off value in this study to avoid 
the many false positive results which would probably be obtained with real case 
samples.                                                                                    
4.5.6 Cross-reactivity 
According to the Neogen® ketamine ELISA package insert, norketamine is the 
only related drug that cross-reacts with ketamine, with a cross reactivity 
percentage of 4.6 % at a norketamine concentration of 197 ng/mL. However 
since the ELISA kit is a semi-quantitative test, the assay might have some cross-
reactivity to the other metabolite, dehydronorketamine and the conjugates of 
hydroxylated derivatives of ketamine (glucuronides) which present very high 
percentage in urine (>80 %).   
Ketamine was spiked at concentrations of 0, 2, 4, 5, 10, 20 and 50 ng/ml to 
establish a calibration curve and norketamine was spiked at 25, 50, 75,150 and 
200 ng/ml. The cross-reactivity was calculated relative to the ketamine 
calibration curve using Microsoft Excel® and the value was found to be 2.1% 
(Figure 4-4).  
Crossreactivity of norketamine to ketamine
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Figure 4-4 The cross-reactivity of norketamine to ketamine in the Neogen ELISA kit 
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Fourteen commonly abused drugs and an anaesthetic drug (tiletamine) were 
spiked at a concentration of 10,000 ng/ml to test for cross-reactivity and the 
results are shown in Table 4-3. Apart from norketamine at very high 
concentrations, none of the drugs cross-reacted with the ketamine antibody and 
this would be very useful for screening use. 
Table 4-3 Cross-reactivity of norketamine and common drugs tested                                                                 
by the Neogen® ketamine ELISA                                                                                 
Compound Spiked Concentration 
(ng/ml) 
Cross-reactivity found 
(%) 
Norketamine 200 2.1 
AMP 10,000 0 
MAMP 10,000 0 
MDA 10,000 0 
MDMA 10,000 0 
MDEA 10,000 0 
Cocaine 10,000 0 
Benzoylecgonine 10,000 0 
Diazepam 10,000 0 
Morphine 10,000 0 
6-MAM 10,000 0 
Methadone 10,000 0 
PCP 10,000 0 
Tiletamine 10,000 0 
 
 
4.5.7 Sensitivity and Specificity 
The sensitivity and specificity were calculated using Equations 4-4 and 4-5.   
Equation 4-5                                   Sensitivity = (TP x 100)/ (TP+FN)  
Equation 4-6                                   Specificity = (TN x 100)/ (TN+FP) 
A true positive (TP) result produced both positive screening and confirmation 
results while a false positive result (FP) produced a positive in the screening but 
negative in the confirmation test. A true negative result (TN) produced a 
negative result for screening and confirmation test whereas a false negative 
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result (FN) was negative for screening but positive in the confirmation test.  The 
ideal test is the one with 100% sensitivity and specificity for the target 
compound but unfortunately most immunoassay tests are sensitive but lack 
specificity because they can react with compounds of similar structure to the 
target analyte. 
Good sensitivity and specificity of a test can also be translated into a good 
correlation between screening and confirmation test results.  For the ketamine 
ELISA test, all the screened samples were subsequently confirmed using an LC-
MS/MS method which had to be developed and validated in order to calculate 
the sensitivity and specificity of the ELISA test. The data are presented in Table 
5.8 (Chapter 5). 
4.5.8 Case Samples 
44 samples were analyzed using the ketamine ELISA kit, of which 10 samples 
screened negative while 34 samples screened positive at a cut-off of 25 ng/ml. 
They also screened positive at cut-offs of 10 and 5ng/ml. A calibration curve was 
obtained from urine samples spiked at zero concentration (blank, 0 ng/ml), at 
the cut off concentration (25 ng/ml), 2 times the cut off concentration (50 
ng/ml) and 5 times the cut off concentration (125 ng/ml).  Spiked samples with 
concentrations lower than the cut off (5 and 10 ng/ml) and 10 times higher than 
the cut off (250 ng/ml) were also analyzed to decide the appropriate cut off for 
this assay. Negative and positive controls provided by the manufacturer were 
included to verify the performance of the test.  
Negative urine samples were collected from colleagues in Forensic Medicine and 
Science, University of Glasgow whereas the 34 positive urine samples were 
obtained from the Narcotics Department, Royal Malaysian Police, collected from 
people arrested by the police at nightclubs. All positive urine specimens (10 mL 
volume in each container) were freezed-dried  at -54°C by the Drug Laboratory, 
Pathology Department, Kuala Lumpur General Hospital in Malaysia using a Cole 
Palmer 1 L bench top freeze-dry system. The lyophilized samples were sent by 
courier to the forensic toxicology laboratory at the University of Glasgow. Each 
of the samples was reconstituted with 10 mL deionised water prior to analysis by 
ELISA. These samples have been previously screened positive using a qualitative 
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GC-MS method with a ketamine cut-off of 350 ng/mL at the Drug Laboratory, 
Pathology Department, Malaysia.  
The results of the samples tested by ELISA are shown in Table 4-4.  All negative 
and positive screening results by this ELISA method were subsequently confirmed 
by an LC-MS method which was developed and validated as part of the present 
study.   
Table 4-4 Neogen® Ketamine Microplate ELISA Positive Screened Results. 
Sample number Concentration (ng/ml) 
 
Positive/Negative 
1 >125 Positive 
2 >125 Positive  
3 >125 Positive  
4 >125 Positive  
5 >125 Positive  
6 >125 Positive  
7 >125 Positive 
8 >125 Positive  
9 >125 Positive  
10 >125 Positive  
11 >125 Positive  
12 32 Positive  
13 >125 Positive 
14 37.4 Positive 
15 25.8 Positive  
16 29.6 Positive  
17 >125 Positive  
18 >125 Positive  
19 >125 Positive  
20 >125 Positive 
21 >125 Positive  
22 >125 Positive  
23 >125 Positive  
24 >125 Positive 
25 >125 Positive  
26 >125 Positive  
27 >125 Positive  
28 >125 Positive  
29 >125 Positive  
30 >125 Positive 
31 >125 Positive  
32 >125 Positive  
33 >125 Positive  
34 >125 Positive  
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4.6 Discussion  
The increase in ketamine misuse in many countries, as noted earlier in Section 2-
1 and Section 2-7, has led to a growing number of clinical and forensic ketamine 
analyses, using methods which include commercial detection kits available in the 
market. Pharmacokinetically, ketamine has relatively short distribution and 
elimination half-lives: the α-elimination phase lasts only few minutes and β-
elimination half-life is 2-3 hours. It follows that a rapid, sensitive and reliable 
method is required to determine ketamine in body fluids [117].  
Previously, many analytical methods developed in-house have been performed 
for the determination of ketamine, such as GC-MS, LC-MS, HPLC-UV and capillary 
electrophoresis, but there were no commercially available rapid test kits for 
screening. Only recently, in 2006, the Neogen Corporation produced an ELISA kit 
for ketamine detection in forensic toxicology. 
Immunoassays for drugs of abuse testing need to be rapid and efficient, and to 
provide high sensitivity and specificity. In this study, the ELISA ketamine test 
procedures were shown to be rapid and efficient test taking less than 3 hours for 
analysis of a 96 well microplate, with intra and inter-day precisions of less than 
5.0 % RSD.  
The optimised test protocol required a minimal sample volume of diluted urine 
(20 µl) with no pre-incubation time included and could be automated. The 
manufacturer should has to provide a bigger volume of concentrated wash 
solution to automate the steps for better performance of the test.  
In this study, a chromogenic substrate, 3,3’,5,5’-tetramethylbenzidine (TMB),  
was used and the colour change could be read on a spectrophotometer at a very 
broad dynamic range (a wavelength of 370 or 655 nm). However in this study, 
the test was optimised such that the enzyme reaction mixture was acidified with 
IM HCl to stop the reaction. TMB turned yellow with an absorbance maximum at 
450 nm, and the absorbance was read at this, which was within the range of the 
Tecan Sunrise Remote EIA Reader available in the laboratory.  This increased the 
sensitivity of the test 2-3 fold compared to the stop solution provided by the 
manufacturer which yielded blue end product that can be read at 650 nm [144]. 
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Procedures in this study took into account the effects of the matrix and 
incubation time as found in the study of Huang et al. [99] .  Matrix effects were 
controlled by using the same matrix (urine) for the calibrators, controls and case 
samples and the effect of the incubation time was solved by using automated 
procedures.  
According to the manufacturer’s product insert, tests performed using buffer as 
matrix produced about 20% higher sensitivity than those performed in urine. In 
this study the comparison was tested using spiked ketamine at 25 ng/mL in 
buffer (n=3) and urine (n=3); with a blank buffer and a blank urine included and 
the results were found to be similar to the manufacturer’s findings.  This was in 
agreement with another study which found that, when using the Neogen® kit for 
urine samples, the lower concentration ketamine standards generated higher 
B/B0 (%) values compared to the same standard concentration prepared in 
buffer. Conversely, the authors of this study also observed that for higher 
concentration ketamine standards, the B/B0(%) was lower than for same 
standard concentration prepared in buffer [99]. 
They also noticed that the results from calibration standards placed at the end 
of the microplate wells (shorter incubation time) apparently gave higher 
ketamine concentration than calibration standards placed at the beginning of 
the microplate wells, indicating that the shorter incubation time resulted in 
higher ketamine concentration readings [99] .  
The ELISA test was also very specific to ketamine and showed a very low cross-
reactivity with norketamine (2.1%) and no cross-reactivity at all to fourteen 
other commonly abused drugs tested in this study. The study of the Huang group 
from Taiwan found that the kit showed some cross-reactivity to the ketamine 
metabolite, dehydronorketamine (DHNK). The percent cross-reactivity decreased 
as the concentration of DHNK increased and was measured as 0.30, 0.18, 0.12, 
007 and 0.05% at concentrations of 200, 500, 1000, 2000 and 4000 ng/ml, 
respectively [99]. However, this metabolite was not available in this study to 
confirm or refute these findings. 
It was also claimed by the manufacturer that the kit has very low cross-
reactivity (<0.01 %) to more than 70 drugs tested by them.  Ketamine is a basic 
drug (PKa = 7.5) and can be metabolized into conjugates during phase II of drug 
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metabolism before being excreted in the urine. Due to low cross-reactivity to 
the metabolites, false negatives might be obtained with some case samples with 
higher concentrations of the main metabolite norketamine, dehydronorketamine 
or their conjugates, which are often present at higher concentrations than 
ketamine itself.  
The ketamine ELISA was quite a sensitive test as shown by the low LOD obtained, 
5 ng/ml. This finding was in agreement with the manufacturer who claimed that 
the kit is intended for use in the determination of trace quantities of ketamine 
in human urine, blood or oral fluid and suitable for forensic use.  It was 
concluded that, if the test gave good correlation with the LC-MS/MS 
confirmation analyses, it would be reliable for use as a routine preliminary test 
for ketamine screening in a forensic laboratory.  
The test had a wide linear range from 25 to 500 ng/ml which was good for 
capturing a range of concentrations in real case samples in forensic toxicology 
testing. At the cut off (25 ng/ml), 34 samples from the Malaysian Royal Police 
tested positive, showing that the kit can detect ketamine concentrations in 
abuse situations. 10 negative control samples from colleagues tested negative, 
showing that the kit can differentiate samples with no ketamine present. 
However the results could not be definitely accepted until tested by the 
confirmatory method. 
4.7 Conclusions 
A simple, rapid and efficient ELISA test for ketamine has been optimised and 
validated for the analysis of ketamine in urine samples. The Neogen® ELISA kit is 
adequately sensitive and specific for ketamine screening at a cut-off 
concentration of 25 ng/mL.  The ELISA test has been shown to be highly specific 
to ketamine and demonstrated minimal (2.1%) cross-reactivity to its main 
metabolite norketamine. The kit demonstrated excellent precision for ketamine.  
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5 VALIDATION OF A METHOD FOR QUANTIFICATION 
OF KETAMINE AND NORKETAMINE IN URINE BY 
LIQUID CHROMATOGRAPHY TANDEM MASS 
SPECTROMETRY  
 
5.1 Introduction 
The aim of this study was to develop and validate an LC-ESI-MS-MS method for 
the quantification of ketamine and its major metabolite, norketamine, in urine. 
The other main metabolite dehydronorketamine was not included in this study 
due to no standard being commercially available at the time the study was 
conducted. General principles of HPLC and LC-MS have been described in 
Sections 3.21 and 3.22. 
The method would then be applied to confirmatory analysis of thirty-four urine 
case samples from the Narcotics Department, Royal Malaysian Police that had 
been previously screened using the Neogen ketamine ELISA kits and qualitatively 
screened by GC-MS with a cut-off 350ng/mL at the Drug and Research 
Laboratory, Pathology Department, Kuala Lumpur General Hospital.  The study 
would determine if the LC-ESI-MS/MS method showed good agreement with the 
ELISA method and if it could be used in future for routine analysis. 
 
5.2 Operational Principle of LC-MS 
 
A Thermo Finnigan LCQ™ Deca XP Plus was used for identification and 
quantification of analytes of interest in this thesis. The instrument has three 
main components: the HPLC system, electrospray interface (ESI) ionisation 
source and a mass spectrometer (the ion trap mass analyser) as shown in Figure 
5-1.  
Norlida Harun - 2010                                                                                                             Page 63 
 
Figure 5-1 A block diagram of Thermo Finnigan LCQ™ Deca XP Plus System [119] 
 
 
5.2.1   Electrospray Ionization (ESI) Interface 
The ESI source consists of a needle and a series of skimmers (Figure 5.2). A 
skimmer produces a beam in which all the ions travel with exactly the same 
velocity so that their energies are proportional to their masses.   
The LC eluent is introduced into an atmospheric-pressure ion source region 
through a fused-silica inner capillary which is inserted through the sample inlet 
and ESI needle.  A sample solution is sprayed through the fine capillary needle 
into the spray chamber in front of the skimmer to form droplets.  
The needle is supplied and held at a very high negative or positive voltage   (3-5 
RV) which causes charge transfer to the liquid. The droplets carry charge when 
they exit the capillary and, as the solvent evaporates, they decreases in size,   
ions come closer together and repel each other.  The droplets split into 
microdroplets during the series of coulombic explosions which occurs when the 
repulsion overcomes the cohesive forces of the surface tension, leaving highly 
charged analyte molecules in the gas phase.  
The charged molecules are transferred into the gas phase of the API stack 
(Figure 5.3) through an ion transfer capillary. Sheath gas and auxiliary gas 
consisting of nitrogen are also directed at the droplets to assist in nebulising the 
sample, stabilize the ion signal and help lower the humidity in the ion source 
during the analysis. The charged molecules travelling from the ion transfer 
Norlida Harun - 2010                                                                                                             Page 64 
capillary will then enter the tube lens to be focused towards the opening of the 
skimmer. From the skimmer cone, the ions are directed into the ion optic 
assembly which separates the ions according to their mass to charge ratios 
(m/z), before entering the ion trap mass analyser.  
 
 
Figure 5-2 Schematic Process of ESI [119] 
 
The equipment requires tuning for several MS detector parameters such as 
electrospray voltage, ion transfer capillary temperature, and tube lens offset 
voltage, capillary voltage, sheath and auxiliary gas flow for each analyte to 
achieve the optimise sensitivity of the analysis. 
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Figure 5-3  Cross-sectional view of an API stack [119] 
 
In electrospray processes, the ions observed may be ions created by the addition 
of a proton (a hydrogen ion) and denoted [M + H]+, or the addition of another 
cation such as sodium ion, [M + Na] +, or the removal of a proton, [M-H]- . 
Multiply-charged ions such as [M + 2H]2+ may also be observed, especially with 
large molecules such as proteins. The schematic process of ESI ionization is 
shown in Figure 5-2 and the ionization mode and the ion type are presented in 
Table 5-1. 
Table 5-1 Typical ions produced by ESI ionisation 
Ionization mode: Type of ions 
Positive mode: [M+H]+ protonated molecule 
[M+Na] +, [M+K] + … adducts 
[M+CH3CN+H]+ protonated molecule + solvent adduct  
Negative mode: [M-H] - deprotonated molecule 
[M+HCOO -] -, … adducts 
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5.2.2 The Ion Optics 
In the ion optic assembly, the ions will be separated according to their mass to 
charge (m/z) ratios [119]. The Deca XP ion optic consists of a quadrupole and 
octapole which are separated by the inter-octapole lens. The quadrupole and 
octapole are arrays of rods that act as ion transmission devices. An RF and DC 
offset voltage are applied to the rods to give rise to electric fields that guide the 
ion along the axis of quadrupole/octapole and allow only ions of a certain m/z 
ratio to pass into the mass analyzer. 
 
Figure 5-4 Cross sectional view of the LCQ Deca Plus ion optics [119]  
 
5.2.3 The Ion Trap Mass Analyser  
The ion-trap mass analyzer consists of three electrodes (one ring electrode and 
two end-cap electrodes) to trap ions in a small volume (Figure 5.5).  The end-
caps are separated either side of the ring electrode to form a hyperbolic cavity 
area which it is possible to trap (store) and analyse ions. The end-caps have 
small holes in the centre to permit the passage of ions into and out of the 
cavity. Ions which travel into the cavity will be trapped until a radiofrequency 
(RF) voltage is supplied to the ring electrode. The mass spectrum is obtained 
when the trajectories of ions of particular m/z values then become unstable and 
the ions are ejected through the exit lens to the detector.  
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Figure 5-5 The ion trap mass analyser [119] 
 
5.2.4 The Electron Multiplier Ion Detector 
Electron multiplier tubes are similar in design to photomultiplier tubes. Their 
function is to multiply the ion current and they can be used in analog or digital 
mode. The electron multiplier consists of a series of biased dynodes that eject 
secondary electrons when they are struck by an ion. The secondary electrons are 
focused by the shape (curved surface) of the conversion dynode and are 
accelerated into the electron multiplier. If sufficient energy is provided by the 
electron multiplier cathode, the electrons will be ejected. In the detector, the 
ions will strike the surface of a conversion dynode to produce one or more 
secondary particles [119]. 
The secondary particles are focused by the curved surface of the conversion 
dynode and are accelerated into the electron multiplier. If the secondary 
particles have sufficient energy, the electron multiplier cathode will eject 
electrons and these electrons will strike the inner surface of the cathode to 
produce more electrons. Thus, a cascade of electrons is created, resulting in a 
measurable current. The current is converted to a voltage by an electrometer 
circuit and recorded by the MS data system. 
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Figure 5-6 Cross sectional view of the ion detection system [119] 
 
5.2.5 Tandem Mass Spectrometry 
An instrument is called MS/MS or Tandem MS when the MSn scan corresponds to 
two or more stages of mass analysis (n = 2 or more scan power). In an MSn scan, 
parent ions are fragmented into product ions in one or more stages. Tandem 
mass spectrometry (MS/MS) is a more powerful technique to quantitate low 
levels of target compounds in the presence of a high sample matrix background 
compared to LC/MS. 
Scan types include: 
-  full scan, which provides a full mass spectrum of each analyte or parent ion; 
- Total Ion Current (TIC), in which each MS scan plotted as an intensity point; 
- Selected Ion Monitoring (SIM), in which the MS is set to scan over a very small 
mass range, typically one mass unit, and only compounds with the selected 
mass are detected and plotted;  
- Selected Reaction Monitoring (SRM),  a two-stage (n = 2 scan power) technique 
in which parent ion and product ion pairs are monitored. In the first stage of 
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mass analysis, the ions formed in the ion source are stored in the mass 
analyzer. Ions of one mass-to-charge ratio (the parent ions) are selected and 
all other ions are ejected from the mass analyzer. Then the parent ions are 
excited so that they collide with background gas that is present in the mass 
analyzer. The collisions of the parent ions cause them to fragment to produce 
one or more product ions. In the second stage of mass analysis, the product 
ions are stored in the mass analyzer. Ions of one or more mass-to-charge ratios 
are selected and all other ions are ejected from the mass analyzer. Then, the 
selected ions are sequentially scanned out of the mass analyzer to produce an 
SRM product ion mass spectrum.  
 
The main advantage of ion trap MS method, in addition to its compact size, is its 
ability to perform multiple stages of isolation and fragmentation of ions (MSn), 
easily enabling the identification of unknowns. However, ion trap analysers 
cannot provide precursor scan and neutral loss modes of data acquisition. For 
quantification, ion trap analysers have been reported to be 10 times less 
sensitive when compared with the tandem quadrupole (triple quad) system 
operated in multiple reactions monitoring mode [145]. 
 
5.3 Experimental Section 
5.3.1   Instrumentation 
LC-MS-MS analysis of ketamine was carried out using a Thermo Finnigan LCQ 
Deca XP instrument (Thermo Finnigan, San Jose CA, USA) equipped with a 
Surveyor autosampler (AS 3000) and two pumps. The instrument was also 
attached to a computer system running Xcalibur 1.3 for data acquisition and 
processing.  
Chromatographic separation was performed using a Synergi Hydro RP column 
(150 mm x 2.0 mm ID, 4 µm particle size) together with a 4.0 mm x 2.0 mm, 4 
µm particle size guard column with the same packing material as the column 
(Phenomenex, Torrance CA, USA). The guard column holder was from 
Phenomenex, Macclesfield, UK. World Wide Clean Screen® SPE columns (ZSDAU 
020) were purchased from United Chemical Technologies, Inc. (Pennsylvania, 
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USA). Gas-tight autosampler vials and caps were obtained from Kinesis Ltd, 
(Greensbury Farm Bolnhurst, UK). 
 
5.3.2 Drug Standards and Chemicals 
Ketamine, norketamine, ketamine-d4 and norketamine–d4 were obtained from 
Promochem (Teddington, UK). Ammonium acetate and ammonium formate were 
purchased from Fluka (Buchs, Switzerland). Formic acid, methanol and 
acetonitrile were HPLC grade, from BDH (Poole, UK). Ammonium formate was 
purchased from Sigma-Aldrich (Dorset, UK).  
 
5.3.3 Stock and Calibration Standards 
Working solutions with concentrations of 1 µg/mL and 0.1 µg/mL were prepared 
and used to prepare spiked samples for method validation, including seven point 
calibration curves at concentrations of 0, 50, 100, 200, 400, 800 and 1200 
ng/mL. Stock and working solutions had a nominal shelf life of 6 months and 
were kept refrigerated (4 °C) when not in use and replaced on an as-needed 
basis.  
5.3.4 Preparation of Solutions 
5.3.4.1 Mobile Phase 
An acidic mobile phase consisting of 3 mM ammonium formate and 0.001% formic 
acid in water was prepared by adding 0.189 g ammonium formate and 10 µl of 
concentrated formic acid to a 1000 mL volumetric flask and making up to 1000 
mL with deionised water. 
5.3.4.2 Phosphate Buffer (0.1 M, pH 5.0) 
1.70 g of sodium hydrogen phosphate and 12.14 g of sodium dihydrogen 
phosphate were weighed out and transferred to a 1 L volumetric flask. 800 mL 
distilled water was added to the flask. The contents were dissolved by stirring 
and the pH was adjusted to pH 5.0 using orthophosphoric acid. The volume was 
made up to 1 L with deionised water.  The buffer was kept in the refrigerator  
(4º C). 
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5.3.4.3 Sodium Acetate Buffer (1 M, pH 5.0) 
42.9 g of sodium acetate trihydrate was weighed out and 10.4 mL concentrated 
glacial acetic acid (17 M) was measured and both were added to a 500 mL 
volumetric flask. 400 mL distilled water was added to the flask. The contents 
were dissolved by stirring and the pH was adjusted to pH 5.0 using 1 M acetic 
acid. The solution of was made up to volume with deionised water then kept in 
the refrigerator (4 ºC). 
5.3.4.4 Methanol with 2% Aqueous Ammonium Hydroxide  
98 mL methanol was measured using a volumetric cylinder and 2 mL ammonium 
hydroxide was added to make up the volume to 100 mL.  The solution was 
transferred into a bottle and was kept at room temperature for 2 months.   
5.3.5  Urine Samples 
Thirty-four urine samples which had previously screened positive using GC-MS 
were obtained from the Narcotics Department, Malaysian Royal Police collected 
from people arrested by the police at nightclubs and ten negative samples were 
obtained from volunteers in the laboratory.  The positive samples were freeze 
dried and were kept in the freezer prior to analysis. All samples were screened 
by an optimised and validated ELISA method as described in Chapter 4.0. 
5.3.6  Hydrolysis Method 
All samples were hydrolysed enzymatically using β-glucuronidase crude solution 
(Helix Pomatia). 1 mL urine or diluted urine sample was put into a tube. Dilution 
was done by adding 900 µl 0.1 M phosphate buffer pH 5.0 to 100 µl urine samples 
and was applied for those samples that were screened > 125 ng/mL by the ELISA 
method.  1 mL 1.0 M acetate buffer pH 5.0 was added into each tube followed 
by 40 µl β-glucuronidase. All tubes were centrifuged and capped. The tubes 
were placed in an oven for 3 hours at 60º C. After cooling, 3 mL 0.1 M phosphate 
buffer pH 5.0 was added to each tube and was vortex mixed. The pH was 
adjusted to pH 5.0 with 1 M potassium hydroxide. The tubes were centrifuged at 
2500 rpm for ten minutes. After centrifuging, the samples were ready for loading 
in the extraction method.  
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5.3.7  Extraction Method 
Solid phase extraction (SPE) was used for method development and World Wide 
Monitoring Clean Screen® columns (ZSDAU 020) were selected for use in this 
study.  The column size was 10 ml, with 200 mg sorbent. The columns were 
conditioned sequentially with 3 mL of methanol, 3 mL of distilled water and 1 
mL 0.1 M phosphate buffer, pH 5.0.   
The columns were loaded with urine samples which were allowed to drip through 
without any vacuum. Upon completion of sample loading, 3 ml of 0.1 M 
phosphate buffer pH 5.0 followed by 1 mL of 1.0 M acetic acid were applied to 
the columns to wash out interfering substances.  The columns were then dried 
for 5 min under full vacuum.  The analytes of interest were eluted into 
collection tubes using 2 mL of methanol containing 2 % aqueous ammonium 
hydroxide. The tubes containing the elution solvent were placed in drying blocks 
at 40 ± 0.5°C and the elution solvent was evaporated to dryness under a stream 
of nitrogen.  The extracts were reconstituted in 150 µL of mobile phase in its 
initial composition and were vortex mixed.  20 µL of the reconstituted extract 
was injected for analysis.   
 
5.3.8  LC-MS-MS Conditions 
LC analysis was carried out using a mobile phase containing 3 mM ammonium 
formate + 0.001% formic acid and acetonitrile at a flow rate of 0.25 mL min-1.  
The elution program consisted of a linear gradient over 13 minutes of 3 mM 
ammonium formate (95-5%).  The percentage of ammonium formate was then 
decreased to 74 % between 13 to 22 minutes.  It was held at 20 % between 22 to 
29 minutes before being increased to the initial condition (95 %) between 30 to 
36 minutes. 20 µl samples were injected on the Synergi Hydro column. 
All mass spectral data were acquired in electrospray positive ion mode.  The 
capillary temperature, sheath and auxiliary gas flow rates and collision energies 
were optimized for each analyte (Table 5.2 in the Results, Section 5.4).  The 
probe voltage used was 4.5 kV.  Internal standard data was collected in selected 
ion monitoring (SIM) mode and analytes were identified on the basis of their 
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retention time and full MS-MS spectra.  The product ion ratios were monitored to 
gain further qualitative identification data.   
5.3.9  Method Validation 
5.3.9.1 Method Validation  
Parameters investigated for method validation were limit of detection (LOD), 
lower limit of quantification (LLOQ), linearity, recovery, intra- and inter-day 
precision, accuracy and matrix effects. Validation procedures were mostly based 
on a paper published by Peters et al. [28]. 
5.3.9.2 Linearity, LODs and LLOQs 
Urine calibration standards were prepared by spiking the appropriate amount of 
ketamine and norketamine stock solutions (1.0 µg/mL) into test tubes containing 
drug-free urine to provide final concentrations of ketamine and norketamine 
ranging from 0-1200 ng/mL. These were extracted using the SPE procedure 
describe earlier and analysed by LC-MS-MS. Calibration curves were constructed 
by plotting the peak area ratios of standards/internal standards against the 
spiked analyte concentrations and were subjected to linear regression analysis. 
Two replicate analyses were performed for each concentration to evaluate 
linearity for statistical purposes. LODs were calculated using Equations 5-1 and 
5-2 where YB is the intercept, SB is the standard error of the regression line and 
m is the gradient. 
 YLOD=YB + 3SB   Equation 5-1  
 LOD=(YLOD-YB)/m   Equation 5-2 
 
LOQs were calculated using the same method but using 10 times the standard 
error of the regression line. 
 YLOQ=YB + 10SB   Equation 5-3 
 LOQ=(YLOQ-YB)/m   Equation 5-4  
                    
Norlida Harun - 2010                                                                                                             Page 74 
5.3.9.3 Precision and Accuracy  
The intra- and inter-day precisions were determined by analysing extracts of 
human urine spiked with analytes at concentrations of 50, 500 and 1000 ng/mL 
five times in the same day (intra-day precision) and once a day during 5 
successive days (inter-day precision). No commercially-available control 
standards were available and accuracy was determined by comparing the mean 
calculated concentration of the spiked urine samples with the target 
concentration. 
5.3.9.4 Matrix Effect Assessment 
This study was conducted to assess the interference caused by urine matrix 
components during LC-MS-MS analysis. Six replicates of 1.0 ml blank urine were 
spiked with 50 ng/mL, 500 ng/mL and 1000 ng/mL of ketamine and norketamine 
and compared with another six replicates which were spiked with the same 
concentration of ketamine and norketamine in 2 ml of loading buffer. All of the 
samples were vortex mixed, centrifuged and extracted using the described SPE 
procedure. 100 ng/mL of internal standard was added after the extraction. The 
percentage matrix effect was calculated according to Equation 5-5, where ‘a’ 
and ‘b’ are the peak area ratios of the analyte to internal standard in neat 
solution and human urine, respectively. 
 
 Percentage matrix effect = b/a x 100%    - Equation 5-5 
 
A value of <100 % indicates signal suppression whereas >100 % indicates signal 
enhancement due to matrix interference. 
5.3.9.5 Recovery Studies 
Ketamine and norketamine were spiked in 1.0 ml aliquots of drug free urine at 
concentrations of 50, 500 and 1000 ng/ml (n=5) and extracted using the SPE 
procedure. Two unextracted standards were also prepared at each concentration 
without internal standards and were kept in the fridge throughout the 
extraction. Internal standards ketamine-d4 and norketamine-d4 (100 ng of each) 
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were added to each tube before blowing down the samples under nitrogen. The 
extracted and unextracted standards were analysed by LC-MS-MS. Recoveries 
were determined by comparing peak area ratios of extracted standards/internal 
standards with those of unextracted standards, expressed as a percentage.  
5.4 Results  
5.4.1.1 Mass Spectral Characteristics 
In this study LC-tandem mass spectrometry (LC-MS/MS) was used to provide 
selectivity, sensitivity and reliable results. Identification of ketamine and 
norketamine was based on retention time and full MS/MS spectra. Selected 
reaction monitoring (SRM) was used for data collection where one parent ion and 
two daughter ions were selected for each analyte and this fulfilled the 
requirements of the European Union for identification and confirmation of illicit 
drugs[146]. The major product ions with 100% relative abundance were used as 
quantification ions and the ratios of the other product ions provided 
qualification data. Parent ions were present at 10 % of the intensity of the 
quantification ions.  
The mass spectral data acquired for both analytes and their deuterated internal 
standards were based on electrospray (ESI) positive ion mode which produced 
protonated molecular ions, [M + H]+. The precursor ion for ketamine was at m/z 
238 and the daughter ions were at m/z 220, 207 and 179, while the norketamine 
precursor ion was at m/z 224 and the daughter ions were at m/z 207, 206 and 
179. Precursor ions for ketamine-d4 and norketamine-d4 were at m/z 242 and 
228 respectively and their daughter ions were at m/z 224, 211 and 183 for 
ketamine-d4 and m/z 211, 183 and 129 for norketamine-d4.  
Specimen SRM chromatograms from collision-induced dissociation of parent ions 
at m/z 238 for ketamine and m/z 224 for norketamine and MS-MS spectra are 
shown in Figure 5-7(blank), Figure 5.8 (5ng extracted ketamine and 
norketamine) and Figure 5.9 (positive sample). 
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Figure 5-7 SRM chromatograms  from collision-induced dissociation of parent ions at m/z 238 
for ketamine and m/z 224 for norketamine and MS-MS spectra showing the quantitation ions  
of 220 for ketamine and 207 for norketamine in a blank sample 
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Figure 5-8 SRM chromatograms  from collision-induced dissociation of parent ions at m/z 238 
for ketamine and m/z 224 for norketamine and MS-MS spectra showing the quantitation ions  
of 220 for ketamine and 207 for norketamine in a 5 ng/mL ketamine and norketamine 
standard extracted from urine  
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Figure 5-9 SRM chromatograms  from collision-induced dissociation of parent ions at m/z 238 
for ketamine and m/z 224 for norketamine and MS-MS spectra showing the quantitative ions  
of 220 for ketamine and 207 for norketamine in (a positive sample for ketamine ( 17260 
ng/mL) and norketamine (1040 ng/mL) 
  
Subsequent validation procedures and analysis of real case samples were carried 
out using the above parent and daughter ions. The optimum collision energy, 
precursor and product quantitation and qualifier ions are shown in Table 5-2. 
Table 5-2  MS-MS parameters for Ketamine, Norketamine, Ketamine-d4 and                
Norketamine-d4 in the ESI positive mode  
Compound Precursor 
Ion (m/z) 
Product Ions 
(m/z) 
Collision Energy 
(%) 
Ketamine 238 220*, 207, 179 26 
Norketamine 224 207*, 206, 179 25 
Ketamine-d4 242 224*, 211, 183 26 
Norketamine-d4 228 211*, 183, 129 25 
* Quantitation ions (100% relative abundance) 
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5.4.1.2 Linearity, LOD and LLOQ 
The linearity of the LC–ESI-MS-MS method was evaluated within the range 2–1200 
ng/mL. Linear correlation coefficients (R2) of the calibration curves were 0.9995 
and 0.9979 for ketamine and norketamine, respectively (n=3), as shown in Figure 
5.10.  
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Figure 5-10  Calibration curves for ketamine and norketamine in urine over the 
concentration range 0– 1200 ng/mL. 
 
The linearity measurement provided the necessary information to estimate the 
limit of detection based on linear regression analysis. The LODs for ketamine and 
norketamine were 0.56 and 0.63 ng/mL respectively and LOQs were 1.9 and 2.1 
ng/mL respectively. The linearity, the linear equation, limit of detection and 
limits of quantification are summarised in Table 5-3. 
Table 5-3 Analytical characteristics of LC–ESI-MS-MS method for ketamine and norketamine 
in urine  
Compound  
 
Linear 
range 
(ng mL−1)  
 
Linear equation  
 
Correlation 
coefficient 
(R2)  
 
Detection 
limit (ng /mL)  
 
Quantitation 
limit (ng/ mL)  
 
Ketamine 0-1200 Y = 0082x + 0.08 0.9995 0.6 1.9 
Norketamine 0–1200 Y = 0.0004x + 0003 0.9979 0.6 2.1 
 
5.4.1.3 Intra- and Inter-day Precision and Accuracy 
The intra-day precision and accuracy were evaluated by performing five 
replicate analyses of three different concentration spiked QC samples in the 
same day. The precision of the method was calculated as the relative standard 
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deviation (RSD) of the results. Inter-day precision and accuracy were determined 
by analysing similar spiked QC samples over a period of 5 days, with fresh 
calibration curves being prepared in duplicate analyses each day. Intra- and 
inter-day precisions are shown in Table 5-4.  
Accuracies were determined by comparing the mean calculated concentration of 
the spiked urine samples with the target concentration. The intra- and inter-day 
accuracies for all the samples were from 96.6 % to 105.2%. The results indicated 
the repeatability of the assay was acceptable and demonstrated high accuracies.  
Table 5-4 Intra- and inter-day precision and accuracy of the QC samples of ketamine and 
norketamine in urine  
Intra-day  
(n=5) 
 
Inter-day 
(n=5) x 5 different days 
Analyte 
Spiked 
concentration 
(ng mL−1) 
Mean ± S.D.  
 
Accuracy 
(%) 
 
R.S.D. 
(%) 
 
Mean ± S.D.  
 
Accuracy 
(%) 
 
R.S.D. 
(%) 
 
50.0 49.0 ± 0.8 98.0 1.7 49.8 ± 2.5 99.6 5.0 
500.0 499 ± 6.2 99.8 1.3 498± 3.9 99.6 0.8 Ketamine 
1000.0 997 ± 7.4 99.7 0.7 996 ± 5.0 99.6 2.2 
 
50.0 47.4 ± 3.3 94.80 7.0 48.0 ± 1.7 95.9 3.6 
500.0 497 ± 4.5 99.47 0.9 498 ± 2.6 99.6 0.5 Norketamine 
1000.0 997 ± 0.5 99.70 0.5 995 ± 2.7 99.5 0.3 
 
5.4.1.4 Assessment of Matrix Effects  
When a sample contains high concentrations of salts or an excess of another 
analyte that can ionise under the operating conditions, there might be a 
competition effect in the ionisation. This is called a matrix effect. Most 
researchers include the assessment of matrix effects in their LC-MS method 
development to ensure that the chromatographic separations developed using 
different matrices were not affected or showed minimal or acceptable matrix 
effects, at least when performing quantitative analysis [32].  
The results show that matrix effects caused by co-extracted interferences in the 
urine were small and were acceptable for both ketamine and the metabolite 
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norketamine. Matrix effect analysis for ketamine showed ion suppression of <10 
% while norketamine showed ion enhancement of <20 % at three concentration 
levels. A summary of the observed matrix effects is given in Table 5-5. 
Table 5-5 Matrix effects during LC-MS-MS analysis of ketamine and norketamine in urine 
(n=3) 
Analyte Spiked concentration (ng mL−1) 
 
Matrix Effect 
(%) [% RSD] 
                   n=6 
50 -8.6 [2.3] 
500 -4.7 [10.4] Ketamine 
1000 -4.0 [5.1] 
 
50 +19.7 [13.2] 
500 + 6.3 [11.9] Norketamine 
1000 +12.9 [10.7] 
 
5.4.1.5 Recovery Studies 
Recoveries of ketamine and norketamine from human urine samples at low (50 
ng/ml), medium (500 ng/ml) and high (1000 ng/ml) concentrations are 
presented in Table 5-6. The method produced high recoveries ranging from 97.9 
to 113.4 % with RSDs of less than 10%.  
Table 5-6   Recoveries of ketamine and norketamine from human urine samples 
Analyte 
Spiked 
concentration 
(ng mL−1) 
 
Recovery 
(%)  
      (  n=5 )    
  
SD 
 
RSD (%) 
50 113.4 0.1 1.1 
500 107.6 0.6 3.6 Ketamine 
1000 98.3 1.8 7.1 
50 102.1 0.1 1.1 
500 104.3 0.5 5.6 Norketamine 
1000 97.9 0.3 3.8 
Norlida Harun - 2010                                                                                                             Page 81 
5.4.1.6 Application to Urine Samples 
The results for blank samples included in each analysis indicated no ketamine 
and norketamine present. A set of 34 specimens was analysed using the 
optimised and validated method along with calibration standards with 
concentrations ranging from 0 to 1200 ng/ml of ketamine and norketamine.  
Three quality control samples at 50 ng/ml, 500 ng/ml and 1000 ng/ml were 
included to check the performance of the analysis. Samples were diluted 10 
times with phosphate buffer pH 5.0 and reanalysed if the ketamine and 
norketamine values did not fall within the set calibration concentration range. 
Samples which still contained very high ketamine and norketamine concentration 
after the second analysis were subject to further dilution (100 times).  
 
For the LC–MS–MS analysis in this study, a concentration equal to or more than 
the high control (1000 ng/mL) is defined as a high concentration. All of the 34 
samples were confirmed positive by LC–MS/MS with most of them containing high 
concentrations of ketamine and norketamine. The data showed no consistent 
ratio of norketamine to ketamine but in most samples the concentration of 
norketamine appeared to be higher than that of ketamine. The average ratio 
was 14.2 and the ratio median was 4.3. The ratio of norketamine to ketamine 
ranged from 0.001 to 82.2 with norketamine being higher than ketamine in 27 
out of 34 samples.  The LC-MS/MS results demonstrated approximately the same 
results as ELISA for the parent drug ketamine as presented in Table 5-7. 
In this study, referring to the field of toxicology, a urine specimen was 
considered positive by the LC–MS/MS method if either the ketamine or 
norketamine concentration was higher than its LLOQ. The results also 
highlighted that there is a ketamine abuse problem in Malaysia as all 34 samples 
were confirmed positive and showed ketamine and norketamine present in high 
concentrations.  
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Table 5-7 Results of analysis of case urine samples by GC-MS, ELISA and LC-MS-MS.  
Sample 
Number 
 
GC-MS  
qualitative 
screening at 
cut off of 350 
ng/mL 
ELISA 
Concentration  
LC-MS/MS 
Ketamine 
LC-MS/MS 
Norketamine 
Ratio of 
Norketamine: 
Ketamine 
 
 (ng/mL) (ng/mL) (ng/mL)  
1 Positive >125 *2830 *6960 2.5 
2 Positive >125 880 *3970 4.5 
3 Positive >125 *2670 *6800 2.5 
4 Positive >125 *1200 *1230 1.0 
5 Positive >125 *5340 *4070 0.8 
6 Positive >125 *1210 *6960 5.7 
7 Positive >125 *4570 420 0.1 
8 Positive >125 920 *6400 6.9 
9 Positive >125 150 1830 12.1 
10 Positive >125 200 *10990 56.0 
11 Positive >125 790 *5250 6.6 
12 Positive 32 30 690 22.2 
13 Positive >125 *11070 *8810 0.8 
14 Positive 37.4 40 *1540 42.9 
15 Positive 25.8 20 *1080 49.2 
16 Positive 29.6 30 *1250 46.4 
17 Positive >125 *8460 220 0.03 
18 Positive >125 130 *8980 71.3 
19 Positive >125 *1150 *10320 8.9 
20 Positive >125 560 *8650 15.4 
21 Positive >125 130 *10680 82.2 
22 Positive >125 790 *3270 4.1 
23 Positive >125 30 740 22.5 
24 Positive >125 120 *1020 8.3 
25 Positive >125 130 250 1.9 
26 Positive >125 190 200 1.1 
27 Positive >125 *17,260 *1040 0.06 
28 Positive >125 *2610 *3254 1.2 
29 Positive >125 *1810 *2200 1.2 
30 Positive >125 *2360 *3800 1.6 
31 Positive >125 *8150 *1000 0.1 
32 Positive >125 218 *1000 4.6 
33 Positive >125 *31670 25 0.001 
34 Positive >125 *4560 *5620 1.2 
* High concentration equal to or more than the highest quality control sample, 1000 ng/mL  
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5.5 Discussion  
Human urine samples used in this study were collected by the Royal Malaysian 
Police from persons in bars in the southern part of Peninsular Malaysia. Urine is 
one of the preferred matrices for control of drug abuse and the only legally 
recognised matrix for workplace testing in many countries. Urine is considered 
advantageous because of the presence of compounds and their metabolites as 
well as because the volume of sample available is higher than with other 
matrices, while the collection is non-invasive.  
 
According to Wieber et al. [147], only very small percentages of unchanged 
ketamine (2.3 %), norketamine (1.6 %) and dehydronorketamine (16.2 %) are 
eliminated in urine compared to 80% of dose which is present as conjugates of 
hydroxylated metabolites of ketamine. This study was aimed at the detection of 
total ketamine and norketamine in urine samples, though LC-MS-MS allows 
detection of conjugates, including glucuronides [148]. This was because no 
standards of ketamine metabolite glucuronides were commercially available 
during this study.  
 
The LC-MS/MS method was intended to be used for confirmation purposes and 
applied an enzymatic hydrolysis step to cleave glucuronide conjugates of 
hydroxylated metabolites. In this study it was thought that the hydrolysis would 
not make any difference to the total ketamine and norketamine concentrations, 
since neither ketamine nor norketamine has a hydroxyl group and they could 
only form glucuronides on the amine nitrogen atom (N-glucuronides), on the 
oxygen atom of the ketone in its enol form or on a carbon atom, which would be 
very unusual. However, there are no published reports of N-glucuronidation of 
ketamine and norketamine and it is possible that the hydrolysis step could be 
omitted. The hydrolysis step would improve the sensitivity of the method (i.e. 
percentage of true positives detected) if the hydroxylated metabolites were 
targeted, but this was not possible since standards were not available. 
Nevertheless, the LODs and LLOQs obtained for ketamine and norketamine were 
very low, 0.6 ng/mL and LLOQ 1.9 and 2.1 respectively, which are suitable for 
determination of trace concentrations of ketamine in urine in forensic 
toxicology.  
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This is supported by previous studies, for example, Kronstrand et al. [148] in their 
analysis of buprenorphine, norbuprenorphine and their glucuronides by LC-MS/MS 
concluded that direct LC-MS/MS analysis without hydrolysis and pre 
concentration is suitable only for screening but the method with SPE increased 
the sensitivity for both analytes from 20 µg/L to 1 µg/L. Another study by Al 
Asmari et al. [149] confirmed that a hydrolysis procedure was effective in cleaving 
glucuronide conjugates in the range of concentrations encountered in urine 
cases in his study which indicated buprenorphine abuse.  This finding indicates 
that the hydrolysis method used in this study could be effective in indicating 
ketamine abuse when the case samples are analysed. However, the direct 
method without hydrolysis would be considered in future work because of the 
routine heavy workload in the author’s laboratory in Malaysia. 
 
 This study applied solid phase extraction for the extraction of ketamine and 
norketamine. World Wide Monitoring Clean Screen® columns have been used in 
many studies for detection of drugs and have shown good recoveries [150, 151].  
The solid-phase extraction method used operated by a mixed-mode cationic 
exchange mechanism based on the sorbent composition of C8 chains and 
benzenesulfonic acid residues. As a result, ketamine and its metabolites can be 
retained on the column via both hydrophobic and ionic interactions and high 
recoveries of more than 97 % have been obtained for ketamine and norketamine 
at concentrations of 50 ng/ml, 500 ng/ml and 1000 ng/ml.  The SPE step also 
helped in obtaining low limits of detection and in reducing the matrix effects 
during LC-MS-MS analysis [151]. 
 
For the urine sample analysis, ketamine and norketamine were both detected by 
LC–MS/MS in all 34 of the urine specimens. However, the concentrations of 
ketamine and norketamine in each sample varied widely, 22-31670 ng/mL for 
ketamine and 25-10990 ng/mL for norketamine.  This could be caused by a 
number of factors such as dose and route of administration of ketamine, the 
time interval between administration and collection of the urine sample, the 
subject’s rate of metabolism, weight and health. The duration of the drug in the 
body and severity of effects varies from one person to another [95].  Most results 
for ketamine were in the range 51–10,000 ng/mL with a median of 903 and most 
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norketamine results were in the range 1001-10,000 ng/mL with a median of 
2720, as shown in Figure 5-9. 
 
 
 
 
 
       
 
 
 
Figure 5-11 LC-MS/MS results for urine samples 
 
Wieber and co-workers reported that the t½ of ketamine in urine was 
3.37 ± 0.14 h, the t½ of NK was 4.21 ± 0.35 h, with both analytes being 
undetectable after 22 h, and the t½ of DHNK was 7.21 ± 1.39 h, which was 
undetectable after 60 h. It seems that those samples which had ketamine 
concentrations greater than those of norketamine in this study were probably 
collected soon after use of the drug. The high concentrations of ketamine and 
norketamine in most samples may suggest regular intake of ketamine in those 
abusers. The high concentrations of ketamine and norketamine in real samples 
collected from participants in bars show the same pattern of abuse in Malaysia 
and Taiwan [99] and alarmed the governments that ketamine was emerging as a 
new drug of abuse in those countries. 
As part of the present study, a comparison was made of the LC–MS/MS and ELISA 
methods for urine specimens. The linear range of the Neogen® ELISA kit for 
ketamine was evaluated as 25–500 ng/mL. A previously published paper 
comparing ketamine ELISA with GC-MS [99], using 100 ng/mL as the ELISA cut- off, 
as well as a GC-MS cut-off of ≤ 2.6 ng/ml demonstrated a poor correlation 
between methods (less than 30%) in 43 samples. In another study [106], 90.9 % 
sensitivity and 98.9% specificity and 1.1% false positive results were found when 
using 10 ng/mL of ketamine as the ELISA screening cut-off and 15 ng/mL of 
ketamine as the GC–MS confirmation cut-off.  
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Based on the previous studies above and the results for ELISA method evaluation, 
25 ng/mL an intermediate value between 10 ng/mL[99]  and 100 ng/mL[106] was 
chosen as the ELISA cut-off for screening and the LLOQs of ketamine and 
norketamine (2 ng/ml) as the LC-MS/MS cut-offs. Comparison of the two 
methods yielded 100% sensitivity and specificity with no false positive or false 
negative results, as presented in Table 5-8.  
The method also found that there was no ketamine or norketamine in the blank 
samples. The test performance of the two methods indicated that the cutoff 
value determined for this assay, 25 ng/mL, was shown to be fit for purpose and 
had no norketamine cross-reactivity issues at the levels that were detected for 
these particular samples. Therefore the combination of the ELISA screening test 
and an LC–MS/MS confirmation analysis produced an acceptable, highly sensitive, 
specific and efficient system for the determination of ketamine and norketamine 
in urine samples. 
Table 5-8 ELISA and LC-MS-MS test performance 
Test results 
 
 
Test Performance 
 
Screening 
ELISA at 
cut –off   25 ng/mL 
 
Confirmation 
LC–MS/MS  
 
Efficiency 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
FP rate 
(%) 
FN rate 
(%) 
Positive 
 
Negative Positive Negative 
34 
 
10 34 10 
 
100 
 
100 
 
100 
 
0 
 
0 
 
Efficiency = (TP + TN) × 100/Total. 
Sensitivity = TP × 100/(TP + FN). 
Specificity = TN × 100/(TN + FP). 
False-positive rate = FP × 100/(FP + TN). 
False-negative rate = FN × 100/(TP + FN).  
 
5.6  Conclusions 
A liquid chromatography-tandem mass spectrometric method for the 
confirmation and quantitation of ketamine and norketamine in human urine has 
been developed and validated. The method demonstrated good linearity, LOD, 
LOQ, accuracy and precision and had acceptable matrix effects. The efficiency 
of ELISA as a screening method has been evaluated using the LC-MS/MS method.  
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Thirty four urine specimens collected from suspected drug users were used and 
the results were well correlated with those obtained using the validated LC–
MS/MS method as the confirmation procedure.  These methods complemented 
each other and showed that both ELISA and LC-MS/MS methods are sensitive and 
specific for determination of ketamine abuse based on analysis of urine samples. 
The data demonstrated no false positives or negatives at a cut-off 25 ng/ml for 
ELISA and at the LOQ values of ketamine and norketamine for LC-MS/MS 
confirmation. 
   
A combination of ELISA and LC–MS/MS methods can be reliably used as routine 
tests in a dual approach test strategy (screening and confirmation) for the 
determination of ketamine in urine specimens and could in principle be applied 
to other biological samples. This study also found that ketamine and 
norketamine were present in all specimens, with more than 90 % of the samples 
having high concentrations, and highlighted that there is a ketamine abuse 
problem in Malaysia.  
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6 MOLECULARLY IMPRINTED POLYMERS (MIPS) 
6.1 What are MIPs? 
Molecular imprinting is defined as the ability of one molecule to attach to 
another molecule that has a complementary shape. Molecular imprinting 
produces a polymer that displays molecular recognition for a chosen analyte. 
The polymer is synthesised in the presence of the analyte, which acts as a print 
molecule, template or mould. Polymerisation occurs in the presence of 
functional monomers, excess cross-linking agent, a non-aqueous solvent and an 
initiator.  
After the synthesis, the template is removed by an extraction process, leaving 
behind imprinted binding sites (cavities) within the polymer network that are 
tailored in size, shape and chemical functionality to the template. A schematic 
diagram of the polymerisation is shown in Figure 6-1. Under appropriate 
conditions, these cavities are able to rebind with the template molecule or 
structurally related compounds in a strong and selective manner when they are 
reintroduced to the polymer.  
      
Figure 6-1 Polymerisation steps in the synthesis of a molecularly imprinted polymer 
 
MIPs are highly cross-linked polymers that have pre-determined selectivity for a 
single analyte or a group of structurally related analytes. The materials are 
physically stable, resistant to mechanical stress, high pressure and elevated 
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temperatures. Furthermore, MIPs possess an imprint memory of more than 100 
times without loss of memory. These characteristics make a MIP an ideal 
analytical material [131, 152, 153].   
The synthesis of MIPs usually involves a parallel process involving synthesis of a 
non-imprinted polymer (NIP) under conditions identical to those of the MIP 
except that the template is absent. In principle, the NIP is entirely analogous to 
the MIP except that any binding sites within its porous structure are non-
selective. The NIP can therefore be used as a benchmark for assessing the 
selectivity of the MIP such as recovery and breakthrough as reported in published 
papers [154,155]. 
6.2 History of Molecular Imprinting 
Today the technology of molecular imprinting is a growing area in many fields 
with broadened approaches and applications. MIP technology has been intensely 
explored as shown by the number of publications on MIP over 70 years from 1930 
to 2003 in Figure 6-2. There was a dramatic increase in the number of 
publications over recent years from 1995 onwards, with more than 2000 
scientific papers. The research done so far included the characteristics, the 
design and the applications of molecular imprinting polymers in separations 
sciences, biosensors, synthetic antibodies, catalysts and nanotechnology.  
  
 
Figure 6-2 The number of publications of MIP per annum from 1931-2003 
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Molecular imprinting was first reported in 1931 by a Soviet chemist, Polyakov 
and co-workers from Kiev. They imprinted various additives such as benzene, 
toluene and xylene (templates) in a silica matrix formed from sodium silicate, 
water and ammonium carbonate as the gelating agent during the drying process. 
The results showed that the imprinted additives had selectivity effects for use in 
chromatography [156].  
 
In the 1940's Linus Pauling hypothesized that a process similar to molecular 
imprinting could be responsible for the selectivity of antibodies to their 
respective antigens [157]. Later in 1949, the theory was supported by experiments 
done by his graduate student, Frank Dickey, who demonstrated imprinting and 
specific adsorption of several different dyes in silica using methyl orange as the 
template. The approach done was slightly different from Polyakov because the 
template was present from the beginning and some organic acids were used as 
acidifying agent. The method demonstrated selectivity for the dye. His 
technique has contributed to the present MIP development methodology [158].  
 
Imprinting in silica gained some popularity over the next 15 years, but did not 
really catch on due to the instability of the silica matrix, high variability in the 
absorption capacities of the matrices between batches and limitations in the 
diversity of compatible template molecules [159].  
 
With the decline of silica imprinting, molecular imprinting in organic polymers 
was introduced. The concept of molecular imprinting was revived in the 1970's 
when Wulff and Klotz discovered that highly crosslinked organic polymers could 
be used to make molecular imprints with high specificity. They successfully 
prepared a molecularly imprinted synthetic organic polymer capable of 
discriminating between the enantiomers of glyceric acid  using covalent 
approaches [160]. In covalent imprinting the monomer and the template are 
bound by a covalent linkage, then the covalent conjugate is polymerised under 
conditions where the covalent linkage is intact, the template is removed by 
cleaving of the covalent linkage and the analyte rebinding is also formed under 
the same covalent linkage.  
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Ten years later in the early 1980s, Mosbach and co-workers introduced a non-
covalent approach which has been widely applied in modern imprinting work 
[161]. In non-covalent imprinting the monomer and the template are connected by 
non-covalent interactions; after polymerisation the template is removed by 
certain solvents and rebinding of analytes occurs through the same non-covalent 
interactions. 
In 1995, Whitcombe et al. reported an intermediate approach that appeared to 
combine the advantages of both approaches; the polymer was prepared by 
covalent linkage but the analyte rebinding was formed by the non-covalent 
interactions[162] . Details of covalent, non-covalent and semi-covalent imprinting 
are explained in Section 6.4. Imprinted polymers have now been used to capture 
a wide range of compounds, such as drugs and steroids and today some research 
procedures enable the capture of large and fragile proteins [163,164]. 
 
6.3 Principles of Molecular Imprinting 
The success of the imprinting experiment relies on the careful choice of the 
template molecule, the functional monomers, the cross-linking agent, the 
polymerization solvent, called the porogen, and the radical initiator. MIP is 
usually synthesised for an intended analytical use, for example, as a sorbent in 
an SPE column, that implies the choice of a given template molecule.  
The structure and the functionalities of this molecule define the subsequent 
properties of the binding sites. Even though molecular imprinting synthesis is 
simple and easy to perform, it depends on criteria such as cost, availability of a 
template and the interactions sites.  
Normally, expensive or difficult-to-synthesize templates can be substituted by a 
structural analogue to decrease the cost of the material. Some researchers use a 
structural analogue [165,166,167] or an isotope (atoms of the same chemical element 
which have a different number of neutrons) [168,169] as an alternative imprint 
molecule, which is known as "dummy imprinting" as shown in Figure 6-3 for 
sildenafil [170]. This process should give rise to imprints that have the ability to 
bind the target analyte. In this case template leaching from the polymer will not 
lead to erroneous results in the analysis of the target analyte. 
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Figure 6-3 Examples of analogues of sildenafil used as templates in MIP synthesis 
 
6.4 Approaches to MIP Synthesis  
There are two basic approaches to molecular imprinting. The first one is the pre-
organised approach developed by Wulff and co-workers [171] in which reversible 
covalent bonds maintain the aggregates in solution prior to polymerisation. The 
other is the self-assembly approach developed by the Mosbach group [172] in 
which the pre-arrangement between the print molecule and the functional 
monomers is formed by non-covalent or metal coordination interactions (Figure 
6-4).  
Both imprinting procedures make use of a high percentage of crosslinker 
resulting in rigid and insoluble polymers. These approaches used template-
assisted assembly and thus can be performed in a very direct way, leading to an 
artificial recognition matrix. Covalent, non-covalent and semi-covalent linkage 
methods of synthesising MIPs are based on these two basic approaches. 
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Figure 6-4 Molecular imprinting technology 
 
In covalent imprinting, templates and monomers are bound to each other by 
covalent linkages. Polymerisation occurs under conditions where the covalent 
linkage is intact. After polymerization, the templates are removed by cleaving 
the bonds and the functionality in the cavities is able to rebind with target 
molecules by the same covalent interactions. The main advantages of this 
technique are that the monomer/template complexes are stable and 
stoichiometric and that a wide variety of polymerization conditions can be 
employed. Slow release and binding of templates and less economical synthesis 
of monomer/template complexes limit its application. 
In non-covalent imprinting, the complex of template and functional monomer is 
formed in situ by non-covalent interactions, such as hydrogen bonding, 
electrostatic forces, van der Waals forces, or hydrophobic interactions. 
Templates are removed by disrupting the interactions and extracting the 
template using appropriate solvents. Rebinding of analytes by the polymer also 
occurs through the same non-covalent interactions.  
This technique is advantageous in terms of easy preparation of the 
template/monomer complex, easy removal of the templates from the polymers 
and fast binding of templates to MIPs. Non-covalent imprinting is the most 
widely used for the preparation of MIPs. In this technique, optimisation is 
needed and the polymerization conditions must be carefully chosen to minimize 
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non-specific binding sites in the formation of the labile complex of template and 
monomer. 
Semi-covalent imprinting is a hybrid approach of covalent and non-covalent 
imprinting. Covalent bonds are used in the polymerisation steps and non-
covalent interactions are used for the re-binding steps of analytes of interest.  
Semi-covalent imprinting combines the main advantages of covalent and non-
covalent binding techniques - the stable and stoichiometric complex in covalent 
imprinting and the fast guest binding (rapid kinetic rebinding of the target 
analytes) in non-covalent imprinting. Therefore some workers combined both 
techniques in their research. The types of imprinting linkages are shown in 
Figure 6-5.  
 
Figure 6-5 Types of binding during molecular imprinting [173]. 
 
Covalent and non-covalent molecular imprintings have the advantages and 
disadvantages summarised in Table 6-1. Based on the advantages, non-covalent 
imprinting shows more versatility than covalent imprinting.  
 
 
 
 
 
Norlida Harun - 2010                                                                                                             Page 95 
Table 6-1 Advantages and disadvantages of covalent and non-covalent imprinting [174] 
 
Characteristics 
 
Covalent Imprinting 
 
Non-Covalent Imprinting 
 
Synthesis of monomer-
template conjugate 
necessary unnecessary 
Polymerisation conditions rather free restricted 
Removal of template 
after polymerisation 
difficult easy 
Guest binding and guest 
release 
slow fast 
Structure of guest 
binding site 
clearer Less clear 
   
6.4.1 Templates 
Templates or targets are very important in molecular imprinting. The structure 
and functional groups of a template must be compatible with and able to attach 
to the functional groups of the monomers to define the subsequent properties of 
the binding sites. An ideal template must withstand polymerisation conditions 
which may involve mechanical stress, high pressure and elevated temperatures 
or UV radiation. A template must not be too expensive and must be available in 
the market in powder form. A selected template must produce a polymer that 
has a high affinity and rebinding selectivity to the analytes of interest when used 
in real applications such as for extraction of drugs in forensic toxicology.  
Several of the drawbacks of MIPs can be overcome by the use of 
stoichiometrically associating monomer-template systems, which means that the 
relative amounts of monomer and template are calculated as a balanced 
chemical reaction to produce the percent yield of the imprinted polymer. The 
use of stoichiometric systems has resulted in a range of receptors exhibiting high 
capacity and effective recognition properties in aqueous media [175,176,177].  
6.4.2  Functional Monomers  
In non-covalent imprinting, the role of the monomers is to create the non-
covalent binding interactions within the imprinted binding sites. To enhance this 
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process the monomers are used in excess compared to the templates, such as a 
1:4 molar ratio. The excess of monomers helps in the formation of template- 
monomer complexes and maintains its integrity during the polymerisation [178].   
Today, many monomers are synthesised using vinyl or acrylic groups as 
imprinting matrix and are commercially available. These monomers usually 
contain inhibitors or stabilizers (hydroquinone or phenols) to avoid undesired 
polymerisation during storage and therefore must be distilled before use. Typical 
functional monomers, shown in Figure 6-6, are carboxylic acids (acrylic acid, 
methacrylic acid, vinylbenzoic acid), sulphonic acids (acrylamido-
methylpropanesulphonic acid) and heteroaromatic weak bases (vinylpyridine, 
vinylimidazole). 
 
Figure 6-6 Some monomers used for the synthesis of MIPs. 
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6.4.3 Cross-linking Agents 
In an imprinted polymer the cross-linker fulfils three major functions. First, both 
covalent and non-covalent binding use a high degree of cross-linking. Therefore 
they can control the morphology of the polymer matrix. Second, the role of the 
cross-linkers is to stabilise the imprinted binding site in the desired polymer 
structure. Third, the cross-linkers impart stability to the polymer matrix. 
The reactivity of a cross linker and a monomer used in a polymerisation should 
be similar to avoid them being predominant over each other and 
copolymerisation not taking place sufficiently. The commonly utilised cross-
linkers such as ethylene glycol dimethacrylate (EGDMA) and trimethylolpropane 
trimethacrylate (TRIM) are shown in Figure 6-7. Standard formulations such as 
1:4:20 of template, monomer and crosslinker have been proposed to give a 
simple, fast and rational way of obtaining MIPs with improved molecular 
recognition sites and in which polymers with cross-linker ratios in excess of 80% 
are often the norm [178, 179].  
 
Figure 6-7  Different types of crosslinkers used in the synthesis of MIPs. 
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6.4.4 Porogens/solvents  
An organic solvent has many roles in a polymerization reaction and is responsible 
for the outcome of a molecular imprinting process. One role is to dissolve the 
reagents for the polymerisation. The solvent also facilitates the template-
monomer complex formation and thus enhances the imprinting efficiency.  
The most important role of a solvent is to provide a porous structure in the 
polymer for promoting the rate of rebinding of analytes and removal of 
template.  This is done by controlling the strength of non-covalent interactions 
and allowing the polymer chains to move apart and swell in a solvent. The 
spaces occupied by the solvent in the polymer become pores in the polymer 
after post-reaction treatment. A low surface area and a low macroporosity 
increase the difficulty in accessing the binding sites and may diminish 
recognition. Another role of the solvent is to disperse the heat generated during 
the reaction and therefore avoiding any side reactions occuring in the 
polymerisation [174].  
In non-covalent imprinting the solvent polarity affects the recognition sites in a 
polymer in a proportional manner. Solvents with low dielectric constants (Κ), 
such as toluene and dichloromethane, can promote the strength of template-
monomer binding and a fairly polar solvent such as acetonitrile (Κ = 36) leads to 
more macroporous polymers than chloroform (Κ = 5) [132].  
 
6.4.5  Initiators 
Free radical initiators such as 2,2’-azobisisobutyronitrile (AIBN) and                 
2,2’-azobis(2,4-dimethylvaleronitrile) (ADVN) are commonly used for 
polymerisation reactions. Due to their electrical neutrality, they contain an odd 
number of electrons and are highly reactive and can be used to initiate free 
radical polymerization and other radical reactions. In the polymerisation 
process, radicals formed by decomposition of the initiator (Figure 6-8) attack the 
monomer and produce propagating radicals.  
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Figure 6-8 Decomposition of AIBN to form two 2-cyanoprop-2-yl radicals 
 
One example of the conversion of methyl methacrylate monomer by AIBN in the 
initiation step in a radical polymerisation is illustrated below in Figure 6-9. 
  
Figure 6-9 Conversion of methyl methacrylate monomer into poly (methyl methacrylate) 
using AIBN in free radical polymerisation 
 
The imprinting process can be carried out under a wide range of conditions such 
as using solvents with different polarity and pH and this characteristic allows the 
polymerisation reaction to be optimised. Initiation of free radical polymerisation 
can occur via photolysis (UV) or thermolysis.  
During the polymerisation process, it is important to remove molecular oxygen 
that can trap radicals in the reaction mixtures and retard or stop the 
polymerisation. This can be done by degassing with nitrogen and freeze-thaw 
cycles under reduced pressure.   
 
6.5 MIP Application Areas 
Molecular imprinting is a generic technology and can be used in a variety of 
applications such as chromatography, affinity solid phase extraction, selective 
permeable membranes, drug or fragrance release matrices, sensors and 
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multisensors for environmental and clinical diagnostics and as catalysts in 
chemical processes in industry [174,180]. To date, solid phase extraction using MIPs 
by far dominates the applications and some of the MIP-based separation 
products have been commercialised. 
6.6 Molecularly Imprinted Solid Phase Extraction 
(MISPE)  
MIPs are amongst the most selective phases used in SPE and this technique is 
known as molecularly imprinted solid-phase extraction (MISPE). MISPE is based 
on conventional SPE where the processes of conditioning, loading, clean-up and 
elution are typically applied. The use of MIPs as selective sorbents in SPE was 
first pioneered by Sellergren et al. in 1994, who successfully extracted 
pentamidine, a drug for treatment of AIDS-related pneumonia, from urine 
samples [129]. The continuing development of MISPE indicates its potential value 
in affinity separation studies due to the high separation factors and resolution 
performance obtained [179, 181,182]. 
Previously, most MISPE studies focused on the optimisation of polymer 
preparation and SPE procedures and the characteristics of the MIP materials. 
There are very few papers on the extraction of analytes from real samples. 
According to Feng and his group in their review, there have been about 110 
original papers on MISPE applications to real samples published in the five years 
from 2001 t0 2006[128]. The distribution of the studies can be divided into 
biological samples (33.9 %), environmental samples (36.5 %), drug samples (14.8 
%), food samples (12.2 %) and other samples (2.6 %). Out of these, none of the 
papers involved the field of forensic toxicology as in this thesis. 
6.6.1 MISPE Protocol and Application 
It is important to underline the fact that MIPs are not intrinsically selective. 
Therefore optimisation of the extraction steps is required, especially the 
washing and elution steps, in terms of pH, ionic strength and solvent 
composition. It is the MISPE procedure used (conditions of percolation, washing 
and elution) that confers selectivity on the MIP. Theoretically, the best results 
expected when using MIPSPE correspond to the achievement of a recovery close 
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to 100% on the MIP with no retention on the NIP after percolating real samples 
containing the target analytes.  
Most published studies of MISPE have used an off-line mode mainly, due to its 
simple procedure and instrumentation required, which are similar to off-line SPE 
methods with conventional sorbents. The main advantages of this format are 
that the whole operation is simple and easy, that more solvents and additives 
can be used without regard to their influence on the subsequent 
chromatographic analysis, and that consequently a high enrichment factor and 
selectivity can be obtained.  
Furthermore, in cases where an organic solvent is used as wash solvent, the MIP 
needs to be dried in order to overcome the immiscibility with aqueous systems 
during the loading step. This drying step is difficult to combine with an on-line 
procedure. In this study, a small amount of imprinted polymer (20 mg) was 
packed in SPE cartridges and these were taken through the typical SPE process in 
order to isolate the target compounds from real samples. The off-line mode also 
allowed the use of stronger elution conditions which were sometimes not 
compatible with the analytical instrumentation.  
On the other hand, on-line MISPE involves the automation of MISPE, coupled with 
the analytical system. This mode minimises sample manipulation between the 
pre-concentration and analysis steps, thus reducing the loss of analytes and the 
risk of contamination as well as providing improved accuracy and reproducibility 
[183]. Because it has been automated, on-line MISPE can reduce the time for pre-
treatment of real samples. Additionally, the sample volume needed can be 
smaller because the whole sample extract is transferred to the analytical column 
[184].  
The MIP phase shows maximum selectivity when the experimental conditions are 
chosen that generate the selective interactions that are usually obtained in 
organic solvents (porogens) used for MIP synthesis. This approach allows the MIP 
to be used for trapping analytes from aqueous solution by hydrophobic or ionic 
interactions. Washing with a solvent breaks selective binding of matrix 
components and, finally, washing with an organic solvent disrupts the strong 
bonds between the polymer and target analytes. 
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As most MIPs are synthesized in nonpolar and aprotic solvents, MIPs seem to be 
well adapted to the clean-up of complex matrices. The direct extraction of 
compounds from aqueous matrices on MIPs is more difficult. During the 
percolation of an aqueous sample, retention of trace analytes is mainly ensured 
by non-selective hydrophobic interactions with the polymeric matrix. A careful 
choice of the washing solvent should be made; it should enhance the 
development of selective polar interactions between the analytes and the 
cavities. Thus, the use of a control polymer, a non-imprinted polymer (NIP), in 
parallel is essential to evaluate the real selectivity of the MIP and the 
contribution of non-specific interactions.  
6.6.2 Advantages and Limitations of MISPE 
There are several advantages of the MISPE technique. One of those is that MISPE 
can perform selective extraction to pre-concentrate and separate target 
analytes from complex matrices, which will lead to cleaner extracts and less 
interferences during analysis and subsequently lead to increased sensitivity.   
It is well known that MISPE sorbents are very stable. They can be exposed to a 
broad range of organic solvents, can withstand high temperatures and can be 
used over broad pH ranges without loss of selectivity, which allows them to be 
stored at room temperature for prolonged periods of time. Another unique 
characteristic of MISPE is that it can reduce matrix effects in LC-MS by improving 
selectivity/sample cleanup when compared to conventional SPE. This is due to 
the tailor-made selectivity of the sorbent material created during the design and 
production of the MIP.  
Conversely, there are few disadvantages of MISPE.  Most of the time the 
template can be removed completely but template bleeding may cause false 
positives in the analysis of analytes in real samples. The use of an analogue 
molecule or dummy template which is structurally related to the target analyte 
can overcome this problem. For example a bromide molecule can be used 
instead of chlorinated template molecule. Andersson et al. reported the 
synthesis of an MIP using a template that was a close structural analogue of the 
target analyte, sameridine [185].  
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Some researchers have come out with several techniques of template removal 
including thermal annihilation, microwave-assisted extraction and desorption 
with supercritical fluids in cases where an analogue molecule is not available 
[186].  
The problem of irregular size and shape of particles from monolith 
polymerisation may influence the effectiveness of the extraction. This drawback 
is overcome by several alternative techniques for preparing more homogeneous 
MIP particles such as precipitation, dispersion and suspension polymerisation 
[187,188,189].  
The other disadvantage of MISPE is that each sorbent must be custom made in-
house which may be laborious or costly. Nowadays this problem may be solved 
by using specialist commercial laboratories to prepare MIP materials or by buying 
from commercial suppliers that sell MISPE columns.  
6.7 Aims  
The work in this thesis involved the investigation of the potential of a 
molecularly imprinted polymer material in a MISPE application in tandem with 
LC-MS-MS analysis for drug determinations in forensic toxicology. The aims of the 
study were: 
[1] Synthesis of anti-ketamine MIPs in collaboration with the Polymer Group, 
Pure and Applied Chemistry, University of Strathclyde, Scotland. 
[2] Optimisation of a MISPE technique using the anti-ketamine MIP and 
application to real samples. 
[3] Investigation of the potential of commercial MISPE columns such as the 
Amphetamine SupelMIP from Supelco for extraction of other matrices such as 
blood and urine.  
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7 SYNTHESIS OF MOLECULARLY IMPRINTED 
POLYMERS BASED ON A KETAMINE TEMPLATE 
7.1 Introduction 
There is an on-going challenge for rapid and efficient determination of 
compounds with low cost analytical methods in the environmental, forensic and 
drug development fields.  Methods developed using biological molecular 
recognition such as those using enzymes and antibodies are often time- and cost-
consuming. Molecularly imprinted materials, which involve solid materials 
containing cavities that have shapes and functional groups complementary to the 
imprinted template molecule, can be synthesised and be used as alternatives to 
natural receptors [159]. MIPs as synthetic receptors can be used in many 
applications such as the separation, extraction and detection of drugs and their 
metabolites and therefore can be useful in the field of forensic toxicology. 
From the beginning, MIPs have found their main applications in the fields of 
chromatography and solid phase extraction (SPE) for the separation, pre-
concentration and detection of low molecular weight compounds, including 
drugs and their metabolites, from different matrices such as blood, plasma and 
urine samples [190,191,192,193]. The only problem that must be solved is template 
bleeding, which can interfere with drug detection and must be solved before 
MIPs are used for any analytical purpose.  
Nowadays, with an increasing amount of research in MIP technology focusing on 
the characterization of MIPs and their applications, also with the help of 
computer simulations, there is some hope that the weakness of MIPs can be 
overcome. MIP technology has been commercialised, for example, one company 
focusses on MIP products for solid phase extraction (MIP4SPE®) and separation 
(MIP4LC® for HPLC) [194,195] .  
In the past, there was no attempt to use MIP materials as sorbents for extraction 
of ketamine prior to further analysis or as stationary phases in liquid 
chromatography columns for detection of ketamine and its metabolite in the 
field of forensic toxicology. In this chapter the synthesis of MIP materials for 
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(R/S)-ketamine and the potent enantiomer (S)-ketamine and chromatographic 
evaluation of the MIPs will be described. 
7.2 Aim  
The aim of this study was to synthesise MIPs using free base (R/S)-ketamine and 
the single enantiomer (S)-ketamine as templates and to evaluate the imprinting 
factors using liquid chromatography before applying them to MISPE protocols.  
7.3 Experimental Section 
This study was carried out in collaboration with the Polymer Unit, Department of 
Pure and Applied Chemistry, University of Strathclyde, Scotland.  The study used 
the expertise and facilities of the Polymer Group, University of Strathclyde and 
the MIPs prepared were used in forensic toxicology.   
7.3.1  Chemicals and Materials 
(R/S)–ketamine.HCl and (S)–ketamine.HCl were purchased from Sigma Aldrich 
(Dorset, UK). Methacrylic acid (MAA) and ethylene glycol dimethacrylate 
(EGDMA) were obtained from Aldrich (Steinhem, Germany) and 2,2’-
azobisisobutyronitrile (AIBN) was from Acros Organics (Geel, Belgium). 
Dichloromethane (DCM), sodium bicarbonate and anhydrous magnesium sulphate 
were from Sigma Aldrich (Dorset, UK). HPLC grade acetonitrile, acetone and 
toluene were purchased from BDH (Poole, UK).  
7.3.2 Converting Ketamine.HCl Salts into Free Base Ketamine 
For the synthesis of an anti-ketamine MIP, the template must be present as free 
base ketamine. Most commercial ketamine standards are sold as ketamine 
hydrochloride salt which must be converted to the free base form to serve as a 
template in the polymerization process. The process of obtaining free base 
ketamine was as follows:  
(R/S)-ketamine salt (1.0 g) was partitioned between saturated aqueous sodium 
bicarbonate (20 mL) and DCM (20 mL). The DCM layer was separated from the 
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aqueous layer and then washed twice using sodium bicarbonate (2 x 20 mL) and 
once with deionized water (1 x 20 mL).  The DCM layer was dried over anhydrous 
magnesium sulphate and the drying agent was removed by vacuum filtration. 
The DCM was removed by evaporating in a weighed round bottom flask using a 
rotary evaporator under reduced pressure.  
The product was dried overnight at 40° C in a vacuum oven. The mass of the 
product was 0.87g (95.1%). The procedure was repeated to convert 1 gram of 
(S)-ketamine hydrochloride salt into the corresponding free base. The yield for 
(S)-ketamine free base was 0.85g (97.6 %).   
To ensure the identity of the end products, the melting point was measured and 
found to be 92-93° C, which is the melting point of free base ketamine. The 1H 
1H-NMR spectra were also recorded and were consistent with the structures of 
R/S- and S-ketamine free bases.   
7.3.3   Preparation of Solvents for Synthesis of Ketamine MIPs  
7.3.3.1 Porogen –Toluene 
Analytical grade toluene was sodium dried and ready to use for the synthesis of 
MIPs. 
7.3.3.2 Cross-linker – EGDMA 
EGDMA was washed with 10% aqueous NaOH in brine and then dried over 
anhydrous magnesium sulphate and distilled under reduced pressure prior to use. 
7.3.3.3 Monomer – MAA 
MAA was dried over anhydrous magnesium sulphate and distilled under reduced 
pressure prior to use. 
7.3.3.4 Initiator – AIBN 
AIBN was dissolved in acetone at room temperature and then the solution was 
filtered and kept in the freezer to recystallize prior to use. 
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7.3.4   Synthesis of Ketamine MIPs and NIP  
Ketamine MIPs were prepared using a bulk polymerization procedure following 
the method published by the Vlatakis group [196]. R/S-ketamine or S-ketamine 
(0.2758 g, 1.16 mmol), MAA (0.39 mL, 4.64 mmol) and EGDMA (4.5 mL, 2.32 
mmol) were dissolved in toluene (6.7 mL) in a 25 mL, thick-walled glass kimax 
tube obtained from Sigma Aldrich. AIBN (0.0838 mg, 0.51 mmol) was then added 
and the solution was deoxygenated by bubbling oxygen-free nitrogen through the 
reaction mixture for 5 min while the flask was immersed in an ice bath.  This 
procedure was to remove oxygen, which can retard the free radical reaction.  
The kimax tube was sealed with the screw cap under a flow of nitrogen and 
placed on a Stovall flat-bed roller for 48 hours without introducing any speed or 
rolling (static). The temperature was kept at 60 °C for thermal polymerisation to 
occur. The template was extracted from the product MIPs with methanol/ acetic 
acid (9/1, v/v) for 24 h. A non-imprinted polymer (NIP) was prepared under the 
same conditions as the MIPs but in the absence of template.  
The tubes were then smashed with a hammer and the MIP and NIP monoliths 
were separately crushed, mechanically ground using an automated grinding 
machine and wet-sieved using acetone. The retained particles were collected 
and allowed to sediment twice from acetone in order to separate the desired 
fractions from the finest particles. The end products obtained from the ground 
materials were in multiple sizes and were not all suitable for MISPE and LC 
analysis purposes. Only particulates of 25-38 µm size were collected for the 
purpose of the study. The products were weighed and dried overnight at 40 °C in 
a vacuum oven.  
7.3.5    In-house Column Packing and Off-line Column Washing 
Column Packing: The MIPs and NIP particles were packed into three liquid 
chromatography columns of dimensions 0.46 x 5.00 cm, with a frit size of 0.2 
nm. Approximately 0.5 g polymers were packed in each column. An Altech Model 
1666 Slurry Packer was used to pack the columns following procedures 
recommended by the manufacturer.  Acetone was used as the slurry solvent. The 
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columns were packed at an air pressure of 500 psi over 20 minutes and about 
100 ml acetone passed through the columns.    
Column Washing: The purpose of column washing was to remove any ketamine 
which may bleed from the template.  The columns were washed overnight off-
line using a Gilson Model 303 pump with 95%:5% acetonitrile:acetic acid (v:v) 
with a flow rate of 0.5 mL/min at a pressure of 100 psi. The S-ketamine and R/S 
ketamine columns were washed simultaneously in tandem in the order S-
ketamine column followed by R/S ketamine column to avoid any cross over.  
7.3.6  High Performance Liquid Chromatography (HPLC) Analysis  
In order to demonstrate the recognition properties of the MIP materials before 
being used for further analysis, they were evaluated using an HPLC system 
consisting of a Waters 1535 Binary pump, to which the columns were connected, 
a Waters 717 autosampler and a Waters 2487 dual wavelength absorbance 
detector. The software used was the Waters Breeze System.  
The analysis was done using isocratic conditions. The mobile phase was 100% 
acetonitrile in Pump A with a flow rate of 0.5 ml/min. The sample volume was 
10 µl and the detector wavelength was 220 nm. Sample injections on to the 
columns were carried out in the following order: pure acetone, 10 mM S-
ketamine and 10 mM R/S-ketamine in the mobile phase. An imprinting factor was 
calculated by comparing the retention factors of the imprinted and non-
imprinted columns. The peak areas were also compared. 
The retention factor (k’) was calculated as Equation 7-1 
 
Equation 7-1 k’ =    tr - t 0 /  t 0  
 
Where t0 is the retention time of the void marker (acetone) and  tr  is the 
retention time of the target analyte. 
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The imprinting factor (IF) was calculated using the Equation 7-2: 
Equation 7-2                                        IF = k’MIP / k’ NIP 
 
Where k’ MIP is the retention factor on the MIP column and k’ NIP was the 
retention factor on the NIP column. 
7.3.7  Scanning Electron Microscopy (SEM) 
Scanning electron microscopy (SEM) imaging was carried out at the SEM unit, 
Chemistry Department, University of Glasgow, using a Joel 6400 instrument.  
Very small samples of the polymer powders were sputter-coated with gold prior 
to SEM. SEM was used to image the size and shape and also the porosity of the 
polymer particles but not to measure the degree of polymer imprinting [178].    
7.4 Results and Discussion 
This study used a non-covalent approach for making MIPs where complex 
formation is the result of non-covalent or self assembly coordination interactions 
in the reaction mixture. These methods are more flexible in the range of 
chemical functionalities which can be targeted and thus the range of template 
that can be used [197].  Two MIPs, R/S- and S-ketamine, and a corresponding non-
imprinted polymer (NIP) were made as shown in Table 7-1 using the most 
common method for MIP preparation, bulk polymerization.  
Table 7-1 MIPS and NIP prepared using monolith polymerization  
Polymer Template/   
monomer 
cross-linker 
Template 
(mg) 
Monomer 
MAA  
(mmol) 
Cross-
linker 
EGDMA 
(mmol) 
Porogen 
Toluene 
(mL) 
 
Initiator 
AIBN (mmol) 
 (NIP) 0:4:20 0 4.64 2.32 6.67 0.51 
 S-MIP 1:4:20 0.26 4.64 2.32 6.67 0.51 
R/S-MIP 1:4:20 0.26 4.64 2.32 6.67 0.51 
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The materials were prepared on a 5 gram scale with the ratio of 1:4:20 for the 
template (ketamine), monomer (MAA) and cross-linker (EGDMA) in the presence 
of the porogen, toluene in appropriate volume. The polymerization reactions 
were carried out under thermal conditions at a temperature of 60ºC as shown in 
Fiqure 7-1.  This procedure involves free radical polymerization and oxygen can 
retard the process. To ensure good polymerization occurred, oxygen was 
removed by displacement with an inert gas, nitrogen, for 5 min while immersed 
in an ice bath.   
The ketamine MIPs prepared in this study were based on the most commonly 
used monomer, cross-linker, initiator and porogen with the intention that the 
template ketamine has a high affinity and rebinding selectivity to the polymer. 
Furthermore, the template had to withstand elevated temperature for thermal 
polymerization at 60ºC and this was studied before selecting ketamine as the 
template. The MIP preparations in this study were easy and not cost- and time- 
consuming and the materials obtained were stable and could be stored at room 
temperature, in contrast to natural receptors such as antibodies and enzymes.  
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Figure 7-1 Schematic diagram of the MIP preparation process 
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As known from previous studies, the materials resulting from bulk polymerization 
were irregular with respect to particle size and shape. The MIPs and NIP 
obtained in this study correlated with the previous findings as shown in Figure 7-
2. For the purpose of this study, only 25-38 µm particles were selected because 
particle sizes under 25 µm were not suitable for MISPE due to the difficulty of 
obtaining suitable frits for SPE columns.  
The SEM (x 1000) photograph showed that the particle sizes were in the range 25 
-38 µm as desired and so were suitable for use in the next study.  The irregular 
size and shape of the particles produced by this method may result in poor 
chromatographic performance and can increase column back pressure. However, 
there have been many successful studies using MIP materials produced by bulk 
polymerization.  
For example, Caro et al. successfully determined enrofloxacin and ciprofloxacin, 
which are used to promote animal growth and may endanger human health, 
below the maximum residue limits established by the European Union using two 
SPE steps, including MISPE [198]. Another example was a successful study of the 
synthesis and evaluation of molecularly imprinted polymers for extracting 
hydrolysis products of organophosphate flame retardants by Moller et al. which 
used a structural analogue, ditolyl phosphate, as template, instead of the target 
compound triphenyl phosphate [199].  
 
Figure 7-2 SEM micrograph (x 1000) of an S-ketamine MIP obtained from bulk 
polymerization process).  
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Chromatographic evaluation of ketamine-imprinted polymers was carried out 
using HPLC with a UV detector.  The purpose of this evaluation was not to 
determine the detection limit of ketamine but to measure the imprinting factor 
of the MIPs, both racemic and S-enantiomer. For that reason, the instrument 
conditions were not optimised. 
The detector wavelength was set at 220 nm based on a previous study of 
ketamine detection by HPLC [107]. Measurements were carried out in duplicate 
and the results indicated that the columns were reproducible, as shown in Table 
7-2. 
Table 7-2 Retention Time and Peak Area data of HPLC-UV for NIP, S-MIP and R/S-MIP 
ketamine columns 
Column Injections (10 µl) Retention Time 
(min) 
Peak Area (uV*sec) & 
 Relative Peak Area  
(in bracket) 
Acetone 1.5 5173188 (1.0)) 
10 mM S-ketamine 2.4 12182852 (2.35) 
10 mM R/S ketamine 2.5 12930074 (2.49) 
Acetone 1.57 5177303 (1.0)  
10 mM S-ketamine 2.4 13134462 (2.53) 
NIP 
 
 
10 mM R/S ketamine 2.4 13633078 (2.63) 
Acetone 1.6 5467569 (1.0)  
10 mM S-ketamine 7.3 56548754 (10.34) 
10 mM R/S-ketamine 5.6 54877542 (10.03) 
Acetone 1.6 5567438 (1.01) 
10 mM S-ketamine 7.3 56548754 (10.34) 
S-MIP 
 
 
 
10 mM R/S ketamine 5.7 55098623 (10.07) 
Acetone 1.6 5440285 (1.0) 
10 mM S-ketamine 5.9 56548754 (10.39) 
10 mM R/S ketamine 5.7 53253862 (9.78) 
Acetone 1.6 5503451(1.01) 
10 mM S-ketamine 5.9 56047906 (10.30) 
R/S-MIP 
 
10 mM R/S ketamine 5.7 53256879 (9.79) 
    
 
Acetone was used as the void marker due to its lower affinity towards the 
polymers and therefore it had a shorter retention time than ketamine. Acetone 
as the void marker can be used as indicator to assess the column packing. The 
good, symmetrical peak shape of acetone on the NIP and MIP columns indicated 
that the columns had been well packed.  
HPLC evaluation of the MIP columns was done by comparing the affinity of the 
MIP columns towards the target analytes with the NIP column which was 
similarly synthesised and packed but without the presence of the template. The 
retention factors (k’) and the imprinting factors (IF) for the MIP and NIP columns 
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were calculated according to Equations 7.1 and 7.2 from the raw data in Table 
7.2 using the average of the duplicates and the results were tabulated as shown 
in Table 7-3. The imprinting factor was more than 1.0, indicating that the 
polymers have been imprinted. 
Table 7-3 Retention Factors (k’) and Imprinting Factors (IF) obtained during the 
chromatographic evaluation of the imprinted polymers 
Compound/Column Retention Factor 
(k’) 
Imprinting Factor(IF) 
S ketamine on NIP 0.64 NA 
R/S ketamine on NIP 0.64 NA 
S-ketamine on S-MIP 3.45 5.39 
R/S-ketamine on S-MIP 2.42 3.78 
S-ketamine on R/S-MIP 2.61 4.07 
R/S-ketamine on R/S-MIP 2.45 3.82 
 
The results in Table 7.3 indicated that both racemic ketamine and 
enantiomerically pure S-ketamine (R/S- and S-ketamine) had been imprinted and 
enatioseparated on both R/S and S-ketamine MIP columns as shown by their 
imprinting factors of > 1.0. The results also indicated that the MIP columns (R/S- 
and S-ketamine) could recognise the target analytes (ketamine enantiomers) but 
each column (R/S and S-ketamine MIP) has different affinity and selectivity 
towards the enantiomers as shown by the value of their imprinting factors.  
 
S-ketamine was retained more strongly on the S-MIP column compared to the 
R/S-MIP column, as indicated by the imprinting factors (5.39 > 4.07). From 
Figure 7.3 the S-MIP column can discriminate between the R/S and S-ketamine 
based on their retention times which showed that the S-ketamine was retained 
longer than the R/S-ketamine on the S-MIP column. The enantioseparation by 
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the S-MIP column therefore indicated the potential of chiral selectivity towards 
both ketamine enantiomers.  
This finding was in agreement with the study by Hart et al., who demonstrated 
that MIPs for benzodiazepines were able to discriminate between enantiomers of 
the imprinted molecules and also a wide range of enantiomers of structurally 
related molecules [200]. The NIP captured some ketamine due to non-selective 
binding but the peak areas were lower than with the MIPs, indicating that the 
NIP had lower affinity and selectivity towards the ketamine enantiomers. 
Both MIP columns (Figure 7.3 and Figure 7.4) gave broad peaks with extensive 
tailing for the ketamine enantiomers which indicated that imprinting had taken 
place and the analytes had high affinity of the columns. 
 
Figure 7-3  Separation of enantiomers on the S-ketamine MIP column using HPLC-UV  
a = acetone, b = R/S-ketamine and c =S-ketamine 
 
The imprinting factors of S-ketamine and R/S-ketamine on the R/S–MIP column 
were quite similar due to the close retention times of both ketamine 
enantiomers. Based on that, the R/S-ketamine MIP column did not show the 
enantioseparation characteristic for both ketamine enantiomers and the peaks of 
the R/S- and the S-ketamine overlapped as shown in Figure 7.4. 
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Figure 7-4 Separation on R/S-ketamine MIP column  
             
Almost half of the drugs used are chiral, including ketamine. It is well known 
that both pharmacological effects and toxicity are related in most of cases to 
one enantiomer [201]. There can be differences in the activities of the 
enantiomers in which the pharmacologically inactive enantiomer can show 
unwanted side effects; in some cases antagonistic and even toxic effects are 
observed [202]. Therefore the chiral selectivity shown in this preliminary study is 
really very important because an HPLC column of this type could be used in 
forensic toxicology to distinguish the active isomer from the less active one.   
 
The advantage of chiral phases based on MIPs is the high antibody-like selectivity 
as shown in this study.  The limitation of this type of columns is the restricted 
range of applicability, since one special phase shows chiral recognition only for 
the same molecule used as template or very closely related compounds. 
 
7.5 Conclusion 
Molecularly imprinted polymers (MIP) for R/S- and S-ketamine have been 
prepared. Chromatographic evaluation using HPLC-UV demonstrated that the 
materials had been imprinted. The MIPs were ready and suitable to use for 
extracting ketamine (MISPE) from biological samples prior to further analysis 
using LC-MS. In addition to that, the S-ketamine MIP had the ability to 
discriminate between the racemate and pure S-enantiomer of ketamine and 
shows promise for use in chiral analysis of ketamine. 
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8 OPTIMISATION OF MOLECULARLY IMPRINTED 
SOLID PHASE EXTRACTION (MISPE) OF 
KETAMINE AND APPLICATION TO HUMAN HAIR 
SAMPLES  
 
8.1 Introduction 
The main goal in sample preparation is to obtain a clean extract with a high 
recovery of analyte of interest.  There is a general requirement in forensic 
toxicology to increase the sensitivity of analytical methods in order to determine 
low concentrations of drugs in complex biological matrices such as urine, blood 
and hair which may contain endogenous components that can interfere with the 
quantification of the analytes [170]. Molecularly imprinted polymers have gained 
an important role in recent years as SPE sorbents for the pre-concentration and 
extraction of analytes of interest in biological samples [192,203,154].  
The aim of this study was to optimise and evaluate the use of MISPE columns 
prepared in-house for ketamine extraction as well as to evaluate the use of 
MISPE in forensic toxicology in future as an alternative to conventional 
extraction methods. The principal intended application was hair analysis. 
8.2 Introduction to Hair Analysis  
The first toxicology testing of hair was carried out by the Baumgartner group 30 
years ago, using radioimmunoassay for determining opiate abuse histories [204]. 
Since then, hair has been used as an alternative to body fluids such as blood, 
urine and tissues which are only able to provide short term information of drug 
exposure, within 1-5 days prior to sample collection [205].  There are a few 
advantages of using hair analysis such as non-invasive sample collection, 
reducing risk for sample adulteration, the ability to reveal chronic drug use and 
the application of sectional analysis to estimate the approximate time of drug 
exposure and, most importantly to gain long-term information on the magnitude 
of drug use. The limitations of hair sample analysis include limited sample 
weight and low drug concentrations.  
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The life span of a single hair varies from about 4 months to 4 years. Human hair 
grows at approximately 1 to 1.5 cm per month and the rate is dependent on 
factors including anatomical location, and the race, sex and age of the person 
[206].  
A single strand of hair consists of a root and a shaft. The hair bulb and follicle 
are part of the root, while the shaft consists of medulla, cortex and cuticle. 
After ingestion, drugs will circulate in the bloodstream including the blood 
vessels of the hair bulb. They can diffuse out of the blood vessels and become 
entrapped in the core of the hair shaft as it grows out from the hair follicle. 
Therefore, hair samples are suitable for determining drug abuse histories. 
Hair analysis cannot be used as the sole evidence in a court of law, but only to 
support other evidence of drug use, due to unsolved controversies such as 
passive contamination, mechanism of drug incorporation, effectiveness of wash 
procedures and bias of different cosmetic hair treatments, as proposed by the 
Society of Forensic Toxicologist (SOFT) in 1992 [15].  
There are a few published reports of ketamine hair testing as the individual drug 
or in combination with other drugs using GC-MS/MS [207,208]. The current study 
pioneered a radical approach by using MIP as sorbent for the solid phase 
extraction in tandem with LC-MS/MS analysis. This approach has never before 
been reported for the determination of ketamine and metabolites in the forensic 
toxicology field.    
8.3 LC-MS/MS Conditions 
LC analysis was carried out using (A) 3 mM aqueous ammonium formate plus 
0.001% formic acid and (B) acetonitrile as mobile phase in a gradient elution 
program as shown in Table 8-1.  Chromatographic separation was performed 
using a Synergi Hydro RP column (150 mm x 2.0 mm ID, 4 µm particle size) from 
Phenomenex, which was equipped with a guard column (4.0 mm x 2.0 mm, 4 
µm)  containing the same stationary phase. Ionization of analytes was performed 
using electrospray ionisation (ESI) in the positive ion mode and data was 
collected in the Selective Reaction Monitoring (SRM) mode and processed using 
Xcalibur Software version 1.3 also from Thermo Finnigan.  
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The LC-MS-MS method was based on a published method for the analysis of 
multiple drugs in hair, including amphetamines, benzodiazepines, cocaine and 
opiates [209]. Details of the LC-MS/MS conditions are explained in Chapter 5. In 
the present analysis the running time was shortened to 25 min and the flow rate 
was increased from 250 µl/min to 300 µl/min.  
Table 8-1 LC-MS/MS conditions  
Time (min) 3 mM ammonium formate + 
0.001% formic acid  
(A %) 
Acetonitrile   
(B %) 
0 75 25 
6 75 25 
15 20 80 
17 10 90 
18 10 90 
18.5 75 25 
25 75 25 
 
8.4 MISPE Method Development and Optimisation  
Method development, optimisation and evaluation of ketamine MISPE included 
the column packing procedure, template removal, choice of conditioning, 
washing and elution solvents, binding capacity studies and cross-reactivity to the 
metabolites and other drugs.   
8.4.1 MISPE Column Preparation  
To prepare the MISPE columns, 20 mg ± 0.5 of (±)-ketamine MIP and NIP were 
weighed into culture tubes.  Polyethylene frits with a pore size of 20 µm were 
inserted into empty 1 ml polypropylene SPE cartridges. The cartridges were 
connected to a vacuum manifold. The MIP and NIP in the culture tubes were 
slurried with 3.0 mL acetonitrile and the slurry was transferred to the empty SPE 
cartridges and sedimented with application of vacuum, in order to ensure the 
particles were uniformly packed into the cartridges [210]. The cartridges were 
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subjected to vacuum for 30 s before insertion of second frit on top of the 
sorbent beds. The cartridges were labelled for identification purposes. In total, 
27 MIP columns and 30 NIP columns were prepared. Figure 8-1 shows examples of 
a (±)-ketamine MIP column, NIP column and empty column. 
 
Figure 8-1 Examples of (±)-ketamine MIP, NIP column and empty columns. 
 
8.4.2 Template Removal 
This test was carried out because of a published study [211] which reported that 
there was an amount of template still remaining in the MIP even after extensive 
washing with acid and organic solvent using a Soxhlet extraction. The template 
remaining in the MIP was assessed by running 1 mL of acetonitrile with 5 % acetic 
acid (v/v)  through the prepared columns (n=3). The eluates were collected and 
evaporated under nitrogen and then reconstituted with the mobile phase prior to 
the LC-MS/MS analysis. A calibration curve of 0-200 ng spiked unextracted 
ketamine was constructed for the determination of remaining template. In this 
study, approximately 32 ng ketamine was eluted from 20 mg polymer; it was 
necessary to remove the retained ketamine before the polymer could be used in 
the MISPE protocol.  
In order to remove the template totally, the MIP cartridge was treated several 
times in series with different solvents as follows: 1 ml (90:10 v/v) methanol: 
acetic acid, 1 mL acetonitrile, 1 mL chloroform and 1 mL of 30 % acetic acid in 
acetonitrile. This approach to template removal has been successfully used in a 
previous study [212] but using different solvents for the treatment. This approach 
helped to release the template by promoting polymer swelling and disruption of 
template/polymer interactions.  After each treatment cycle, the 30 % acetic 
acid/acetonitrile fraction was collected, evaporated and reconstituted with the 
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LC-MS mobile phase prior to analysis. Between treatments, the MIP sorbent was 
allowed to dry.  
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Figure 8-2 Reduction of template bleeding over 15 washes 
 
The results showed that there is no more observable template bleeding from the 
polymer when treated more than 14 times with washing solution cycles (Figure 
8-2). Therefore, all the cartridges were treated with these solutions prior to 
being used in the extraction procedure. We experienced difficulty in removing 
the ketamine template, most probably due to a strong interaction between the 
ketamine template and the polymer, and also the template could be trapped 
within the polymer matrix in non-specific locations, like a clathrate complex, as 
suggested by the chromatographic evaluation of the MIP which gave an 
imprinting factor of 3.78 for (±)-ketamine on the (±)-ketamine column. 
8.4.3 Evaluating the Elution Solvent 
A stepwise gradient of 5 to 50 % acetic acid acetic acid in acetonitrile was used 
for washing the MIP columns (n=3) to select the optimised elution solvent for the 
extraction steps. Columns were spiked with 250 ng of ketamine standard and 
washed, beginning with the lowest to the highest concentrations of acetic acid 
in acetonitrile. The last trace of spiked ketamine was eluted with 30 % of acetic 
acid in acetonitrile (v/v), as shown in Figure 8-3. This percentage of acetic acid 
was therefore used as the elution solvent for the extraction. 
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Figure 8-3 Effect of eluting solvent composition on recover of ketamine from the MIP.  
 
8.4.4 Effects of conditioning and loading solvent on ketamine 
binding to MIP and NIP  
This test was performed to assess the effect of different loading solvents in the 
recognition step. For those cases where recognition is driven by hydrogen 
bonding, the interaction forces between the analyte and the polymer are 
diminished when increasingly polar solvents are applied. To determine the effect 
of solvent on the ketamine MIP, the imprinted and non-imprinted polymers were 
conditioned with several alternative solvents, namely 1 mL chloroform, 
dichloromethane, toluene or acetonitrile prior to loading 50 ng ketamine in 1 ml 
of the same solvent. Vacuum was not applied to give the solvent and the MIP 
time to equilibrate and the solvent dripped through the MIP cartridges under 
gravity flow.  
The cartridges were then washed with 0.5 ml of the solvent used in the loading 
step before eluting with 1.0 ml 30 % (v/v) acetic acid in acetonitrile. The 
fractions collected after the loading (FL), washing (FW) and elution (FE) steps 
were evaporated using a stream of nitrogen gas and reconstituted in 60 µl of the 
LC-MS/MS mobile phase, 20 µl of which was injected for analysis. The 
percentage of ketamine bound to the polymer was calculated using Equation 8-1, 
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which is based on the assumption that 100 % of the ketamine loaded was eluted 
at the end of the extraction. 
Equation 8-1 % bound = (peak area for FE/peak area of (FL + FW + FE)) x 100 
 
The percentages of ketamine which bound to the polymers using four different 
solvents in the conditioning and loading protocol are shown in Table 8-2. The 
percentages of ketamine bound to the MIP were much higher than to the NIP, 
demonstrating the imprinting of the polymer. This data may enable the optimal 
solvent for use in further experiments in this subsequent work to be identified.  
According to the theory of molecular imprinting, an MIP tends to exhibit optimal 
molecular recognition when in the presence of toluene, the best porogen to use 
during polymerization. However, the percentage of ketamine bound was higher 
when using chloroform, suggesting that stronger binding occurs in the more polar 
solvent. In other words, the solvent with the higher dipole moment (chloroform) 
is the more effective solvent for rebinding in this study.  
Table 8-2 Effect of solvent on ketamine binding to the MIP and NIP 
 % bound 
Solvent 
  Dipole 
Moment 
Debyes (D) 
MIP NIP 
Toluene 0.38 18 4 
Chloroform 1.08 66 1 
Dichloromethane 1.14 57 10 
Acetonitrile 3.44 35 3 
 
When ketamine was reintroduced to the ketamine MIP sorbent, the binding was 
best in chloroform, followed by dichloromethane, acetonitrile and toluene as 
shown in Figure 8-4.  It was noticed that some ketamine was lost in both the 
loading and washing steps with all solvents. This may be explained by slow 
kinetics in the interaction between the polymer and the analytes. These 
experiments (n=3) demonstrated that the cartridges worked when using organic 
solvents and gave rise to various recovery percentages depending on the 
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selection of solvent. Next, the cartridges were used for extraction of ketamine 
extraction from aqueous media.   
Ketamine breaktrough in extraction steps    
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Figure 8-4 Effects of solvent on ketamine MIP binding. 
 
From the results shown in Figure 8-4, it was also found that chloroform was 
suitable for use as the washing solvent to deliver cleaner extracts with the 
highest ketamine recovery during the extraction process. The breakthrough of 
ketamine in MIP and NIP using different solvents in extraction steps is shown in 
Figure 8-5. 
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Figure 8-5 Comparison of breakthrough of ketamine using MIP and NIP columns. 
 
8.4.5 Problem of Using Chloroform 
To test the method in aqueous samples, 0.1 to 100 ng of ketamine was spiked in 
1 mL of phosphate buffer 0.1 M pH 5.0. The cartridge was preconditioned with 3 
mL of acetonitrile followed by 1 mL of the phosphate buffer. The MIP column 
was conditioned with acetonitrile followed by phosphate buffer for activating 
the MIP column because the hair was pre-extracted in phosphate buffer before 
loaded into the MIP cartriges. In this aqueous sample, chloroform was not used 
even though the solvent indicated to be the best conditioning solvent in organic 
environment.  Each sample was loaded on a cartridge which was then washed 
with 1 mL chloroform. The analytes retained in the cartridge were eluted with 1 
mL 30 % (v/v) acetic acid in acetonitrile. 100 ng of internal standard was then 
added after the extraction.  
The results showed that there was no linear calibration of MIP extraction when 
using chloroform as the wash solvent. It was seen that there were two layers of 
solvent when chloroform was used in the washing step due to immiscibility of 
the buffer and chloroform. This may be explained by elution of trapped 
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template from the polymer following the sudden change of solvent from 
phosphate buffer (polar) to chloroform (non-polar) which altered the ratio of 
ketamine to internal standard and affected the linearity of the calibration curve.  
Subsequently chloroform was not used in the washing step but was replaced with 
an alternative, more polar, solvent such as pure acetonitrile or 1 % acetic acid in 
acetonitrile to avoid template bleeding due to polymer shock.  
8.4.6 Recovery of Ketamine using MIP and NIP, with 0.1M 
Phosphate Buffer pH 5 as the loading solvent 
In this experiment, 50 ng of ketamine was spiked in 1 mL of 0.1M phosphate 
buffer  pH 5.0 (n=3). MIP and NIP cartridges were preconditioned with 3 mL of 
acetonitrile followed by 1 mL of the phosphate buffer. Each sample was passed 
through a cartridge and then eluted with 1 mL 30 % (v/v) acetic acid in 
acetonitrile. The recoveries of ketamine from the MIP and NIP are shown in 
Figure 8-6. 
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Figure 8-6 Recovery of MIP and NIP without washing step 
 
Analytes present in samples are retained on both MIP and NIP under aqueous 
loading conditions due to non-specific hydrophobic interactions [155] which 
explains the data shown in Figure 8-6.  In this regard, a washing step of 0.5 ml 1 
% acetic acid in acetonitrile was added to the SPE protocol to “switch on” the 
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molecularly selective retention mechanism of the MIP. The results are shown in 
Figure 8-7.  
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Figure 8-7 Recoveries of MIP and NIP with washing step 
 
This experiment showed that the selectivity of an MIP for an analyte depends on 
the careful choice of the extraction procedures as demonstrated in other 
studies, for example by the Baggiani group [213] for the clean up of phenytoin 
from plasma samples. The washing step helped to produce a cleaner extract 
with an acceptable analyte recovery. The final optimised MISPE method is shown 
in Table 8-3. 
Table 8-3 Optimised MISPE protocol for extraction of ketamine from aqueous samples 
 
Extraction Steps 
 
 
Solvents 
 
Conditioning 
 
3.0 mL acetonitrile;  
1.0 mL 0.1M pH 5.0 phosphate buffer 
 
Loading 
 
ketamine in 1.0 mL 0.1M pH 5.0 phosphate 
buffer 
 
Washing 
 
0.5 mL of 1 % acetic acid in acetonitrile 
Eluting 
 
1.0 mL 30% acetic acid in acetonitrile 
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8.4.7 Cross-reactivity of Ketamine MIP to Morphine, PCP and 
Tiletamine 
It has been postulated that the selective molecular recognition within the 
molecularly imprinted cavity can be attributed not only to cooperative binding 
of pre-organized functional groups but also to the shape selectivity that is 
complementary to the template [214]. In this study morphine, PCP and tiletamine 
were selected to investigate the role of shape selectivity of the (±)-ketamine 
MIP. 50 ng morphine, PCP and tiletamine were subjected to the same extraction 
procedure as used for ketamine in triplicate. The molecular structures of 
morphine, PCP and tiletamine are shown in Figure 8-8.  
 
 
Figure 8-8 Molecular structures of morphine, PCP and tiletamine. 
 
The eluents were collected from the extraction and two unextracted samples 
containing the same amounts of morphine, PCP and tiletamine were blown down 
and reconstituted in the mobile phase prior to the LC-MS/MS analysis. The 
percentage of morphine, PCP and tiletamine bound to the ketamine MIP was 
calculated using Equation 8-2. 
Equation 8.2  % bound = (peak area of extracted drugs/ peak area of 
unextracted drugs) x 100 
 
 
By using the same extraction protocol for the other drugs as for ketamine, the 
cross-selectivities of the MIP for morphine, PCP and tiletamine were found to be 
less than 5 %. The finding indicated that the analytes with different shape and 
different functional groups from those of the template ((±)-ketamine) has lower 
affinity towards the MIP, hence the MIP has decreased selectivity towards these 
N
O
NHC2H5
S
     TiletaminePhencylidine(PCP)Morphine 
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analytes. This finding was in agreement with the study by Spivak et al., which 
demonstrated that large analytes showed less selectivity when introduced to an 
MIP synthesised with a template that was smaller, when steric exclusion will 
reduce binding to the imprinted sites[214]. On the other hand, analytes smaller 
than the template have reduced contact with the polymer matrix that makes up 
the binding cavities, which results in lower Van Der Waals or hydrophobic 
interactions and reduced selectivity.  
8.4.8 Binding Capacity of Ketamine MIP 
Experiments for the determination of the ketamine binding capacity of the 
ketamine MIP cartridge were performed using the optimised procedure, with 
0.1M phosphate buffer pH 5 as the solvent of choice. High concentrations of 
ketamine ranging from 500 to 3000 ng were dissolved in 1 mL 0.5M phosphate 
buffer pH 5 and extracted separately using different ketamine MIP cartridges 
(n=2). A mixture of 50 ng of each internal standard was added to the eluent 
after the extraction.  The eluent was evaporated to dryness with a nitrogen 
stream and the residue was reconstituted with the initial mobile phase prior to 
analysis by LC-MS/MS.  
A graph of peak area ratio of ketamine over the internal standard against the 
concentration of ketamine loaded was plotted as shown in Figure 8-9.  This 
indicated that the level of ketamine binding was essentially constant when the 
MIP was loaded with 2500 ng of ketamine.   
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Figure 8-9 Ketamine binding capacity 
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From this result, a cartridge of 20 mg ketamine MIP sorbent bound 2500 ng 
ketamine, so the binding capacity of the imprinted polymer was 125 ng of 
ketamine per mg MIP. There is no previous literature about the binding capacity 
of an anti-ketamine MIP available for comparison. However, a binding capacity 
of 0.125 µg/mg polymer is lower than the average binding capacity of other MIPs 
recorded in the literature, which is 1-5 µg per mg polymer. Examples include a 
chlorpromazine MIP [215] with an absorption capacity of 10 µg per mg polymer and 
a 17β-estradiol MIP [216] with an absorption capacity of 3.6 µg per mg polymer. 
However, the binding capacity obtained in the anti-ketamine MIP was sufficient 
for the analytical work in this study due to the lower concentrations of drugs in 
hair. 
8.5 Method Validation and Application to Hair Samples 
8.5.1 Human Hair Samples 
Human hair samples were provided by four females from a drug prevention 
centre in Malaysia.  Samples were collected by a collaborating research unit at 
University of Science, Malaysia. Hair samples (approximately of 75 µm in 
diameter) were cut close to the scalp at the posterior vertex area.  The hair 
samples were folded and put into aluminium foils prior to placement in paper 
envelopes. The hair samples were washed using hair shampoo, rinsed twice in 
water, sonicated for 10 minutes and dried.  After drying, the hair samples were 
decontaminated and sonicated in 10 ml dichloromethane for 10 minutes at room 
temperature. The samples were then dried in a hot air oven at 45 ºC and then 
cut into very small pieces of less then 1 mm.  
The ready cut samples were put into aluminium foils and envelopes and then 
mailed to Department of Forensic Medicine and Science, University of Glasgow. 
Upon receipt, the samples were stored in dark and dry conditions at room 
temperature. Samples Q, R, S, V and a mixed sample of Q, R, S and V are shown 
in Figure 8-10. 
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Figure 8-10 Hair Samples Q, R,S,V and a mixed sample of Q,R,S and V. 
 
8.5.2 Preparation of Hair Samples 
Blank hair samples were collected from volunteers in the laboratory.  All 
samples were wrapped in aluminium foil and stored in a cupboard at room 
temperature. Hair samples were washed with 0.1% aqueous sodium dodecyl 
sulphate (SDS) and sonicated for 10 minutes.  The hair samples were then rinsed 
and sonicated for 10 minutes, twice with deionised water and twice with 
dichloromethane, then left to dry in air.  The dried hair samples were then 
weighed and approximately 10 mg samples were transferred to vials for the hair 
pre-extraction process. 
In the hair pre-extraction process, 10 ± 0.1 mg samples were prepared by adding 
1.5 mL 0.1 M phosphate buffer pH 5.0. Standards and internal standards 
ketamine-d4 and norketamine–d4 were added to the vials prior to the 
incubation.  The vials were left to incubate for 18 hours at 45 ºC. The hair 
extracts were cooled and transferred to clean vials.  
8.5.3 Solid- Phase Extraction Using (±)-Ketamine MISPE Columns 
MISPE was carried out using the in-house prepared ketamine imprinted SPE 
columns with the optimised procedure. Each cartridge was preconditioned with 
3.0 mL acetonitrile followed by 0.1 M phosphate buffer pH 5.0. Each sample was 
passed through a cartridge and washed with 0.5 mL 1% acetic acid in acetonitrile 
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to remove interferences. The analytes retained in the cartridge were eluted 
with 1.0 mL 30% (v/v) acetic acid in acetonitrile.  
8.5.4 Linearity, Precision and Stability Studies 
Linearity was determined over the concentration range 0-100 ng per 10 mg 
spiked hair. 10 mg of blank decontaminated hair was spiked with 0, 2, 5, 10, 25, 
50 and 100 ng of ketamine and norketamine standards and 100 ng of the internal 
standard mixture of each analytes. The hair samples were limited in terms of 
availability and 10 mg was choosing as the sample weight to suit the real hair 
sample analysis. The samples were then pre-extracted, extracted with MISPE and 
analyzed by LC-MS/MS. The calibration curves were constructed by plotting the 
peak area ratios of standards over internal standards against analyte 
concentration and were subjected to linear regression analysis. 
The intra- and inter-day precision were determined by analysing the mixed 
samples, namely Pooled 1, Pooled 2 and Pooled 3, which were mixtures of the 
four individual hair samples. Because of the limited sample availability, only 
three samples were analysed in the same day (intra-day precision) and the 
experiment was carried out over three different days for inter-day precision 
values. Accuracies were not determined because the precision study did not 
have the target (true) concentration. The inter-day precision values were also 
used as a short stability study for the analytes in real human samples over a 
period of three weeks, as the pooled samples were analysed in three different 
weeks. The values were determined by comparing the results of analysis with 
those obtained when the calibration was done on the same day. 
8.5.5  Matrix Effect Analysis 
Six replicate extracts, each made with 10 mg of blank decontaminated hair, 
were spiked with 50 ng of both ketamine and norketamine (set a).  Another six 
replicates were prepared containing the same concentration of ketamine and 
norketamine in 1 ml loading solvent, 0.1M pH 5.0 phosphate buffer (set b) prior 
to MISPE. 100 ng of internal standard mixture was added to each replicate in the 
two sets after the extraction. The percentage matrix effect was calculated 
according to Equation 8-3, where ‘a’ and ‘b’ are the peak area ratios of the 
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analyte to internal standard in human hair extract and phosphate buffer, 
respectively. Values were calculated to determine analyte suppression or 
enhancement due to matrix interference. 
Percentage of matrix effect = a/b x 100%                                  Equation 8-3     
 
8.5.6 Limits of Detection (LOD) and Lower Limits of Quantification 
(LLOQ)  
The LOD and LLOQ were determined for each drug using spiked hair. 10 mg of 
blank decontaminated hair was spiked with 0.1, 0.2, 0.3, 0.4, 0.5, 0.75, 1, 2 and 
5 ng of ketamine and norketamine and 100 ng of the internal standard mixture 
of each ketamine and norketamine was added. The samples were then pre-
extracted, extracted with MISPE and analyzed by LC-MS/MS.  The LOD and LLOQ 
were calculated from the regression lines as the concentrations which gave 
signal-to-noise ratios of 3 and 10, respectively. 
8.5.7 Recovery Study of Ketamine and Norketamine 
(±)-Ketamine and (±)-norketamine were used to test the selectivity of the 
ketamine MIP.  50 ng samples of each drug were prepared in 1 mL 0.1 M 
phosphate buffer pH 5.0 (n=5). The samples were incubated and extracted to 
determine the recoveries of ketamine with the MIP. 100 ng of internal standard 
was then added after the extraction. The recovery was calculated by comparing 
peak area ratios obtained from extracted samples (quantitation ion/internal 
standard) to the peak area ratios of the same concentration of pure standards 
(quantitation ion/internal standard) in unextracted samples. The percent mean 
recovery and percent relative standard deviation (RSD) was calculated for each 
drug at each concentration. 
8.5.8  Hair Case Samples 
Four hair samples from Malaysia were tested in this study. Samples were cut and 
pre-washed by the collaborating research unit at the University of Science, 
Malaysia, as mentioned in Paragraph 8.5.1. 10 mg of blank decontaminated hair 
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was spiked with 0, 2, 5, 10, 25, 50 and 100 ng of ketamine and norketamine 
standards and 100 ng internal standards were added to each vial to generate a 
calibration curve. The samples were then incubated, extracted with MISPE and 
analyzed by LC-MS/MS according to the validated method.  
8.6 Validation Results and Discussion 
8.6.1 Linearity, Pecision and Stability Studies 
8.6.1.1 Linearity 
Ketamine and norketamine regression lines had R2 > 0.99 over the concentration 
range 0-10 ng/mg. From the calibration graph shown in Figure 8-11, it can be 
observed that the response of the method (peak area ratios) for norketamine 
were much lower than ketamine for the same spiked concentration. 
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Figure 8-11 Calibration for ketamine and norketamine from 0-100 ng/10 mg hair 
 
8.6.1.2 Intra-day and inter-day precision using authentic hair samples 
The intra- and inter-day precision study was performed using unknown analyte 
concentrations from pooled samples to reflect the imprecision of real hair 
samples during analysis. The analyses were carried out using three replicates for 
intra-day precision and the same experiment was repeated for 3 separate days 
over a 3-week period for inter-day precision. Replicates were limited to three 
due to limited availability of sample.  Ketamine and norketamine showed good 
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precision for both intra-day and inter-day, with low RSDs as depicted in           
Table 8-4.  
Table 8-4 Intra-day and inter-day precision study using authentic pooled hair samples 
Intra-day  
(n=3) 
Pooled samples 
Inter-day 
(n=3) x 3 different days 
Pooled samples 
Analyte 
Mean  SD 
R.S.D. 
(%) 
 
 
Mean   
 
   SD 
RSD (%) 
 
Ketamine 2.81 0.07 2.37 2.63 0.20 7.90 
Norketamine 0.88 0.07 0.9 0.87 0.01 7.5 
 
8.6.1.3 Stability 
A short stability study of ketamine and norketamine using the authentic pooled 
hair samples was carried over a period of three weeks. Samples (n=3) were 
washed and incubated and extracted following the optimised procedure. All 
samples were kept in the freezer (-20 ºC) for up to three weeks prior to the next 
MISPE extraction and analysis by LC-MS/MS. The results of analysis of the second 
and third batches were compared with those obtained on the first day of 
analysis. There was no significant decrease for norketamine during a storage 
period of three weeks, when norketamine decreased by 1.7 %. However, 
ketamine decreased by 14.3 %. The results are shown in Table 8-5. 
Table 8-5 Stability of ketamine and norketamine in freezer for three weeks   
Pooled samples kept in freezer ( n=3) 
 
Duration Ketamine concentration (ng/mg) Percentage remaining 
Week 1 2.81 100.00 % 
Week 2 2.70 96.4 % 
Week 3 2.35 85.7 % 
   
Duration Norketamine concentration (ng/mg) Percentage remaining 
Week 1 0.880 100.00 % 
Week 2 0.875 99.4 % 
Week 3 0.865 98.3 % 
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8.6.2 Matrix Effect Study  
Ion suppression is common in LC-MS analysis when analyzing trace levels of 
analyte(s) in complex matrixes such as hair samples. The matrix effect for 
ketamine showed minimal ion suppression of 6.8 % while norketamine showed a 
slight ion enhancement of 0.2 % for this particular set of samples. The matrix 
effect is often caused by the co-elution of matrix components with analyte(s) of 
interest and improved selectivity/sample clean-up during sample preparation is 
critical. Because the MIP used was targeted for ketamine, it was shown that the 
matrix effect was minimized when using MIP sorbents. In comparison, significant 
matrix effects were demonstrated in an unpublished study [217] using 
conventional SPE where the quantification ion of ketamine (m/z: 220) was 
suppressed by 47.3% and the quantification ion of norketamine (m/Z: 207) was 
enhanced by 62.2%.  
 Table 8-6 Matrix effect using ketamine MIP columns 
Analyte 
Spiked concentration 
(ng)  
 
Matrix Effect (n=6) 
(%) [RSD] 
 
Ketamine 50 - 6.8 [12.3] 
 
Norketamine 50 + 0.2 [13.2] 
 
8.6.3 LOD and LLOQ 
The LOD and LLOQ values for ketamine were 0.1 and 0.4 ng/mg hair, 
respectively.  The values were slightly higher for norketamine, with an LOD of 
0.1 ng/mg and LLOQ of 0.5 ng/mg hair as shown in the chromatograms shown in 
Figure 8-12.  
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Figure 8-12 Quantification of (a) ketamine at 0.2 ng/mg and (b) norketamine at 0.5 ng/mg 
hair 
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The washing step prior to elution of analytes from an SPE cartridge helps to 
eliminate other interferences and can result in a cleaner chromatogram. As a 
consequence, the washing step added during the MISPE method resulted in 
cleaner extracts. Because extraction selectivity is significantly improved, lower 
background is observed, allowing the method to achieve lower detection limits 
as shown in Table 8-7. 
Table 8-7 Analytical characteristics of LC–ESI-MS method for ketamine and norketamine 
Compound 
 
Linear range 
(ng  mg−1 
hair) 
 
Regression line 
equation 
 
Correlation 
coefficient 
(R2) 
 
 
LOD 
(ng/mg 
hair) 
LLOQ 
(ng/mg hair) 
 
Ketamine 0 - 10 
Y = 0122x + 
0.0297 
0.9953 
 
0.1 
 
0.37 
 
Norketamine 0 - 10 
Y = 0.0007x + 
0008 
0.9990 
 
0.1 
 
0.47 
 
 
By careful design of the polymerisation reaction and the resulting imprinting 
sites, the binding cavities can be engineered to offer multiple interaction points  
    
Figure 8-13 Created binding cavities for analytes rebinding  
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with the analyte(s) of interest. This leads to a stronger interaction between the 
sorbent and the analyte(s), and low limits of detection can be achieved. 
8.6.4 Recoveries of Ketamine and Norketamine 
The results showed that the MIP recovered a high percentage of ketamine and 
norketamine with acceptable RSD values. The results are tabulated in Table 8-8. 
Table 8-8    Recoveries of ketamine and norketamine from hair. 
Analyte 
Spiked 
concentration 
(ng 10 mg−1) 
MIP 
Recovery 
(%)  
      (  n=5 )    
 
RSD 
NIP 
Recovery 
(%)                
(  n=5 )    
 
RSD 
Ketamine 50.00 86.12 
 
9.34 
 
31.54 
 
18.94 
 
 
 
Norketamine 
 
50.00 
 
88.37 
 
5.04 
 
27.82 
 
22.67 
 
 
The high recovery of ketamine from the MIP arises from the excellent molecular 
recognition of the template molecule imparted by the imprinting process.  
Lower recoveries were obtained when the NIP was used as the extraction 
sorbent, as expected, together with high percent RSD values.  The lower RSD 
values may reflect the fact that the MIP is well-defined in respect to its binding 
compared to NIP. 
8.6.5 Hair Sample Analysis 
The four hair samples supplied from a drug abuse prevention centre in Malaysia 
were tested after the method was validated and ready for analysis of real 
samples. The hair samples were obtained from four females with a history of 
multiple drug use, including ketamine. The pre-cut and pre-washed hair samples 
were incubated extracted using MISPE and analyzed by LC-MS/MS according to 
the validated method. The results are shown in Table 8-9. In this study the 
application of the MISPE method successfully detected ketamine and 
norketamine for the chronic users; in future it may be useful for testing of single 
use applications such as date-rape cases. 
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Table 8-9 Hair sample weights, colours and concentrations of ketamine and norketamine  
Sample 
Number 
Weight MIP 
(mg) Hair Colour 
Ketamine 
concentration 
ng/mg  
Norketamine 
concentration 
ng/mg 
Q 19.96 Dark brown 4.4 present * 
R 19.85 Black 5.7 1.2 
S 20.02 Black 2.2 0.6 
V 10.01 Light brown 0.2 present * 
* equal to or higher than the detection limit but lower than the quantification limit 
It is well known that drug deposition in hair is related to its lipophilicity. The 
change from a secondary amine in ketamine to a primary amine in norketamine 
increases the polarity and decreases the lipophilicity of norketamine compared 
to ketamine, therefore the concentration of ketamine in hair was higher than 
that of norketamine in this study. This concentration may also reflect the 
relative concentration of ketamine and norketamine in blood which was in 
agreement with the finding of Xiang et al. [101]. The ratio of norketamine to 
ketamine in hair was not consistent. 
Ketamine is weakly basic (pKa = 7.5) and exists as a cation at physiological pH. 
As melanin is a polyanionic polymer, melanin and ketamine interact strongly and 
facilitate ketamine incorporation into hair. Since concentrations of melanin 
increase in the order of white < brown < black hair, concentrations of ketamine 
and norketamine also increase accordingly, as found by Xiang et al. [101]. The 
present study focused on the development and validation of MIP extraction and, 
due to the limited number of samples, the connection between hair colour and 
the concentration of ketamine was inconclusive.  
As seen in the chromatograms of (a) the blank extract and (c) the pool sample 
(Figure 8-14) obtained using the MISPE method, the MIPs led to clean extracts 
and achieved the aim of this study to provide a cleaner extraction with less 
interference, as shown in Figure 8-14. From the chromatogram of the pool 
sample, it seems that most of the interferences were removed during the 
washing step, leaving only ketamine, norketamine and the internal standards, 
ketamine-d4 and norketamine-d4 bound to the polymer. Furthermore, the blank 
analysis demonstrated no ketamine template bleeding. 
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(a) Blank hair sample 
 
(b) Internal standard ketamine-d4 (left) and norketamine-d4(right) 
 
  (C) pooled positive hair samples 
 
Figure 8-14 LC-MS-MS chromatograms for (a) blank, (b) internal standards and (c) pooled 
positive hair samples. 
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The MIP in this study was prepared on a small scale, (1 gram of template) and 
produced less than thirty columns. Therefore, the MIP columns were reused 
throughout the study. This demonstrated that the MIP columns were robust and 
could withstand extreme conditions of different solvents, temperature and pH 
and may be helpful in decreasing the cost of sample analysis.  
8.7 Conclusion 
In this study, an MIP extraction method for ketamine in hair samples has been 
developed and validated.  The extraction has been found to be selective and 
sensitive with less matrix effects than a comparable unpublished method using 
conventional SPE.  The method can also be applied to norketamine, the principal 
metabolite of ketamine, due to the group-selective binding nature of the MIP, 
but not to structurally dissimilar analytes such as PCP and tiletamine.  The 
concentrations of ketamine detected in hair samples from chonic ketamine 
abusers ranged from 0.2 to 5.7 ng/mg and norketamine from 0.6 to 1.2 ng/mg 
and two samples contained trace amounts of  norketamine (below the limit of 
quantitation).   
The MIP columns were found to be reusable, robust and able to withstand 
various treatments with different pH and solvents as used in this study. The 
combination of MISPE and LC-MS-MS method detected ketamine and norketamine 
in hair samples of chronic users. This method may be extended to the detection 
of single ketamine use such as in drug facilitated rape cases and so may be very 
useful for the investigation of drug-facilitated crime cases in forensic toxicology. 
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9 COMPARISON OF MISPE WITH CONVENTIONAL 
SPE FOR THE DETECTION OF KETAMINE IN 
HAIR SAMPLES 
 
9.1 Introduction and Aims 
SPE methods have been used and accepted for the extraction of ketamine from 
both urine [218] and plasma [123] samples prior to LC-MS/MS analysis, but have not 
been well established for the analysis of ketamine in hair using LC-MS/MS. As 
previously indicated, most work published on the analysis of ketamine and its 
metabolites were done by GC-MS. In the present study, an SPE procedure was 
evaluated and validated for comparison with anti-ketamine MIP extraction 
(MISPE) as described in Chapter 8. MISPE extraction coupled with LC-MS/MS 
showed good selectivity towards the template, ketamine, and the metabolite, 
norketamine.  
The aim of this study was to compare the ketamine hair results of four hair case 
samples from Malaysia obtained using a conventional SPE system [217] and the 
MISPE system developed previously and described in Chapter 8.  The study was 
intended to determine if MISPE showed any advantages or disadvantages over 
conventional SPE in terms of improved sensitivity, specificity and its potential in 
reducing matrix effects. 
 
9.2 Experimental 
9.2.1 Instrumentation 
LC-MS-MS analysis of ketamine was carried out using a Thermo Finnigan LCQ 
Deca XP (Thermo Finnigan, San Jose CA, USA) equipped with a Surveyor 
autosampler and MS pump system. Chromatographic separation was performed 
using Synergi Hydro RP (150 mm x 2.0 mm ID, 4 µm particle size) from 
Phenomenex and a 4.0 mm x 2.0 mm, 5 µm guard column (Phenomenex, 
Torrance CA, USA) with the same packing material as the column. Ionization of 
analytes was performed using electrospray ionisation (ESI) in the positive ion 
mode and data were collected in the Selective Reaction Monitoring (SRM) mode 
and processed using Xcalibur Software version 1.3 also from Thermo Finnigan.  
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9.2.2 Chemicals and Materials 
Methanol, acetonitrile, chloroform, ammonium hydroxide, phosphoric acid, 
formic acid, potassium dihydrogen phosphate, dipotassium hydrogen phosphate 
and ammonium formate were of analytical grade and purchased from BDH 
(Poole, UK).  Ammonium acetate was purchased from Sigma-Aldrich (Dorset, 
UK).   
Ketamine, ketamine-d4, norketamine and norketamine-d4 standards as solutions 
in methanol were obtained from LGC Promochem (Teddington, UK).  World Wide 
Monitoring Clean Screen® columns (ZSDAU 020) were purchased from United 
Chemical Technologies, Inc. (Pennsylvania, USA). 
 
9.2.3 Preparation of Solutions 
9.2.3.1 Mobile Phase 
A mobile phase consisting of 3 mM ammonium formate and 0.001% formic acid in 
water was prepared by adding 0.189 g ammonium formate and 10 µl of 
concentrated formic acid to a 1L volumetric flask and making up to 1L with 
deionised water. 
9.2.3.2 Preparation of pH 5.0 Phosphate Buffer  
1.70 g of sodium hydrogen phosphate and 12.14 g of sodium dihydrogen 
phosphate were weighed into a 1 L volumetric flask and made up to volume with 
deionised water.  The pH was adjusted to pH 5.0 using phosphoric acid. 
9.2.4 Hair Samples 
The four hair samples tested were from chronic users and were obtained with 
consent from a drug prevention centre in Malaysia.  The case samples were 
screened positive using ketamine Neogen ELISA.  Negative hair samples were 
from volunteers in the Glasgow University laboratory.  
9.2.5 Preparation of Hair Samples 
Blank hair samples were collected from volunteers in the laboratory. Hair 
samples were washed with 0.1% aqueous sodium dodecyl sulfate (SDS) and 
sonicated for 10 minutes.  The hair samples were then rinsed and sonicated for 
10 minutes, twice with deionised water and twice with dichloromethane, then 
left to dry in air at room temperature overnight.  Each sample was then split 
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between two separate vials for extraction by SPE and MISPE procedures.  Blank 
hair was also washed using the same procedure prior to spiking with ketamine 
and norketamine standards to produce the calibration curves.  
Spiked hair samples weighing 10 ± 0.1 mg were prepared by adding 1.5 mL 0.1 M 
phosphate buffer pH 5.0. Standards and internal standards ketamine-d4 and 
norketamine–d4 were added in the vials prior to the incubation.  The vials were 
left to incubate for 18 hours at 45 ºC. The hair extracts were cooled and 
transferred into clean vials.  
9.2.5.1 Conventional SPE Method 
The conventional SPE method selected for this study used a mixed-mode cationic 
exchange mechanism (Clean Screen® columns, ZSDAU 020). The sorbent is 
composed of silica substituted with C8 chains and benzenesulfonic acid residues.  
Ketamine and norketamine are retained on the column via both hydrophobic and 
ionic interactions. 
Clean Screen® (ZSDAU020) extraction cartridges were conditioned sequentially 
with 3 mL methanol, 3 mL deionised water and 1 mL phosphate buffer (0.1M, pH 
5.0). The vortexed samples were loaded in 2 mL phosphate buffer (0.1 M, pH 
5.0) and allowed to drip through without application of vacuum. The columns 
were then washed with 3 mL phosphate buffer (0.1 M, pH 5.0), 1 mL acetic acid 
(1.0 M) and dried for 5 minutes under full vacuum. The drugs were eluted using 2 
mL methanol/2 % aqueous ammonium hydroxide.  The eluant was dried under 
nitrogen at 40oC and the residue was reconstituted in 100 µL of initial 
composition mobile phase.  A 20 µL aliquot was used for LC-MS-MS analysis. 
 
9.2.5.2 Ketamine MIP Extraction Method 
MISPE was carried out using the in-house prepared anti-ketamine MIP columns 
with the optimised procedure described in Chapter 8. Each cartridge was 
preconditioned with 3.0 mL acetonitrile followed by 0.1 M phosphate buffer pH 
5.0. Each sample was passed through a cartridge and washed with 0.5 mL 1% 
acetic acid in acetonitrile to remove interferences. The analytes retained in the 
cartridge were eluted with 1.0 mL 30% (v/v) acetic acid in acetonitrile. The 
eluted samples were blown down to dryness under a stream of nitrogen at 40oC 
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and reconstituted in 100 µL of the mobile phase in its initial composition.  20 µL 
was injected for analysis. 
 
9.2.6 LC-MS/MS Conditions 
LC was carried out using a mobile phase containing 3 mM ammonium formate 
and acetonitrile at a flow rate of 0.3 mL min-1.  The elution program consisted of 
a linear gradient (75-25%) of 3 mM ammonium formate over 6 minutes.  The 
percentage of ammonium formate was then decreased to 20% between 6 to 15 
minutes.  It was held at 10% between 17.0 to 18.0 minutes before being 
increased to the initial condition (75%) between 18.5 to 25 minutes. All mass 
spectral data was acquired in electrospray positive ion mode.   
 
The capillary temperature, sheath and auxiliary gas flow rates and collision 
energies were optimized during tuning for each analyte as in Chapter 8.  The 
probe voltage used was 4.5 kV.  Internal standard data was collected in selected 
ion monitoring (SIM) mode and analytes were identified on the basis of their 
retention time and full MS-MS spectra.  The product ion ratios were monitored to 
gain further qualitative identification data. 
 
9.2.7 Results and Discussion 
Hair sample weights, colours and concentrations of ketamine and norketamine 
detected using the MISPE and SPE procedures are summarised in Table 9-1. The 
MISPE procedure successfully detected ketamine and norketamine in all four 
samples Q, R, S and V at concentrations ranging from 0.2-5.7 ng/mg and 0.1 
ng/mg to 1.2 ng/mg respectively. The SPE procedure detected ketamine in all 
four samples at concentrations ranging from 0.5–6.7 ng/mg but only detected 
norketamine at very low concentrations in samples Q and R and not at all in 
samples S and V.  
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Table 9-1 Results of analysis of hair for ketamine and norketamine using MISPE- and SPE- 
based procedures. 
MISPE 
Sample 
Number 
Weight of 
hair sample 
(mg) 
Hair Colour 
Ketamine 
concentration 
ng/mg  
Norketamine 
concentration 
ng/mg 
Q 19.96 Dark brown 4.4 present* 
R 19.85 Black 5.7 1.2 
S 20.02 Black 2.2 0.6 
V 10.01 Light brown 0.2 Present* 
SPE 
Sample 
Number 
Weight of 
hair sample 
(mg) 
Hair Colour 
Ketamine 
concentration 
ng/mg  
Norketamine 
concentration 
ng/mg 
Q 19.92 Dark brown 4.2 present* 
R 20.04 Black 6.7 Present* 
S 19.82 Black 1.6 Negative 
V 10.02 Light brown 0.5 Negative 
* Equal or higher than LOD but below the LLOQ 
When compared to the concentrations of ketamine and norketamine in the 
pooled samples (a mixed sample of Q, R, S and V) analysed previously (Chapter 
8, Table 8-2), the results obtained in this study using MISPE for ketamine and 
norketamine gave the closest match to those concentrations.  
Table 9-2  Mean concentrations of ketamine and norketamine in hair case samples 
measured individually by MISPE- and SPE-based procedures and in pooled hair case 
samples.   
 
Mean concentrations in 
4 hair samples using 
the MISPE method 
(ng/mg hair) 
 
 
 
Mean concentrations 
in 4 hair samples using 
the SPE method 
(ng/mg hair) 
 
 
 
Mean concentrations 
in a mixed sample of 
Q, R, Sand V hair 
samples (from inter-
day precision 
measurements 
reported in Chapter 8) 
(ng/mg hair) 
 
ketamine 
 
norketamine 
 
ketamine 
 
norketamine 
 
ketamine 
 
norketamine 
 
3.1 
 
0.5 
 
3.3 
 
0.03 
 
2.6 
 
0.8 
 
The results demonstrated the the method using conventional SPE was acceptable 
for detection of ketamine but was not sensitive enough for detection of 
Norlida Harun - 2010                                                                                                             Page 148 
norketamine. The summary of method validation results of the SPE method are 
shown in Table 9-3 [219]. 
Table 9-3 Summary of method validation results of the SPE method 
 
Parameters 
 
Ketamine  
 
 
Norketamine 
 
Linearity 
 
0-10 ng/mg 
 
0-10 ng/mg 
 
 
LOD 
 
0.2 ng/mg 
 
0.5 ng/mg 
 
 
LLOQ 
 
0.9 ng/mg 
 
1.8 ng/mg 
 
 
Recovery 
 
92.3% (%RSD=5.7)  
 
114.2% (%RSD=6.5) 
 
 
Precision 2.59 % (%RSD= 15.9) 
 
0.74% (%RSD= 22.4) 
 
 
Matrix Effects Ion m/z 220 suppressed 
by 47.3% 
 
Ion m/z 207 enhanced 
by 62.2% 
 
                                       
Hair Samples (ng/mg) 
 
Q 4.2 < LOD 
R 6.7 < LOD 
S 1.6 Negative 
V 0.5 Negative 
 
Even though higher recoveries were obtained in the SPE method compared to the 
MISPE method using spiked standards during method validation, the results for 
real hair samples (Table 9.1) show that extraction steps using MISPE successfully 
reduced (cleaned up) the matrix effects or magnified (pre-concentrated) the 
sample compared to SPE and resulted in better detection of norketamine in real 
hair samples. Better selectivity to ketamine and norketamine using the MIP 
extraction, as noted before, might be due to the excellent molecular recognition 
of the template molecule and the lower LODs and LLOQs. The matrix effects in 
both extraction methods are shown in Table 9-4. 
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Table 9-4 MISPE versus SPE matrix effects 
Analyte 
Spiked 
concentration 
(ng mL−1) 
 
MISPE Matrix 
Effect 
(%) [RSD] 
 
 
SPE Matrix 
Effect 
(%) [RSD] 
 
Ketamine 50 - 6.8 [12.3] -47.3 [ 9.4] 
    
Norketamine 50 + 0.2 [13.2] + 62.2[16.4] 
 
One more possible reason for lack of selectivity to norketamine by SPE was 
because two of the hair samples (S and V) were dyed. An analysis using scanning 
electron microscopy by Guthrie et. al [220] showed some deposition of dye and 
bleach in hair and these may have caused some interference with the detection 
of norketamine in the conventional SPE method. Cosmetic treatments such as 
dyeing reduce the binding of drugs in hair as these processes damage the hair 
structure, especially cuticle, which protects the inner part of the hair. 
Ketamine, the parent drug, is more lipophilic and less polar and is more strongly 
bound in hair than the metabolite, norketamine, which is more hydrophilic and 
more polar. Norketamine, having less affinity to the hair matrix than ketamine, 
would be more likely to be washed out of damaged hair than ketamine and this 
could result in very low concentrations of norketamine in dyed hair.  
 
Hair washings were not analysed in this study, so no conclusions can be drawn 
concerning possible interferences from the dyed hair samples. The results also 
demonstrated that MISPE was not affected by interferences from dyed hair 
samples, due to high selectivity of the imprinted material to ketamine and 
norketamine and also showed interferences were washed out during the 
extraction protocol.   
 
The MISPE method had lower LODs (0.1 ng/mg hair) for ketamine and 
norketamine compared to 0.2 ng/mg and 0.5 ng/mg hair for the SPE method 
which would have affected the detection of trace levels of norketamine using 
the SPE method and resulted in negative results for norketamine in samples S 
and V. 
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The recoveries of ketamine and norketamine were better using the SPE method, 
as shown in Table 9-5. However, the MISPE method detected norketamine in all 
four hair samples compared to the SPE method. This was due to lack of 
interference and better selectivity based on the excellent recognition of the 
template molecule of MIP material.  
This study was in agreement to an earlier study by Ariffin et al., on the 
comparison of benzodiazepine analysis in post mortem hair samples using MISPE 
and SPE, which also detected a higher number of diazepam positive case samples 
compared to the SPE procedure [132, 221] .   
Table 9-5 Extraction recoveries for ketamine and norketamine 
Analyte 
Spiked 
concentration 
(ng 10 mg−1) 
MISPE 
Recovery 
(%)  
      (  n=5 )    
 
RSD 
SPE 
Recovery 
(%)                
(  n=5 )    
 
RSD 
Ketamine 50.00 86.1 
 
9.34 
 
92.3 
 
5.7 
 
 
 
Norketamine 
 
50.00 
 
88.4 
 
5.04 
 
114.2 
 
6.5 
 
 
The average ketamine and norketamine concentrations detected in the pooled 
positive hair sample by both methods are shown in Table 9-6. The results 
obtained following MISPE demonstrated higher precision for both ketamine and 
norketamine than those obtained using SPE, which is also attributed to the low 
matrix effects obtained using MISPE. 
Table 9-6 Inter-batch-precision for MISPE and SPE 
 MISPE  
(n=3) x 3 different days  
Pooled samples 
 SPE  
(n=3) x 3 different days 
Pooled samples 
Analyte 
Mean 
R.S.D. (%) 
 
 
Mean 
 
R.S.D. (%) 
 
Ketamine 2.63 7.9 2.59 15.9 
Norketamine 0.87 0.8 0.74 22.4 
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9.3 Conclusion  
MISPE coupled with LC-MS/MS demonstrated good selectivity and sensitivity for 
ketamine and norketamine in hair. SPE coupled with LC-MS/MS showed higher 
selectivity to ketamine and norketamine than MISPE in spiked samples but 
application to ketamine user samples indicated that the MISPE procedure 
detected more norketamine in all the four samples. High matrix effects in the 
SPE method might have interfered with the LC-MS/MS analysis and may have 
interfered with norketamine detection in hair. Both methods detected ketamine 
at a relatively high concentration in all four hair samples.  
 
The results of this preliminary study strongly suggested that the ketamine MIP 
can be successfully applied for the detection of ketamine in chronic users. This 
successful application of MISPE to the detection and quantification ketamine and 
norketamine in hair from chronic users suggests that the method should be 
evaluated for its ability to detect ketamine and norketamine in hair after 
administration of a single dose of ketamine, such as in date-rape cases. 
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10 AMPHETAMINES 
 
10.1  Introduction 
Amphetamine, dextro-amphetamine and methamphetamine are collectively 
referred to as amphetamines, often referred to as amphetamine type stimulants 
(ATS). They are members of a large group of synthetic compounds which are 
similar to the natural substance phenylethylamine, in food such as cheeses and 
wines, and cathinone, an active ingredient in khat leaves that are chewed in 
East Africa and the Arab Peninsula for their psychostimulant properties. 
Naturally-occurring ATS are quickly degraded in the liver by monoamine oxidase, 
and are not considered to be drugs that are dangerous to health except 
cathinone which closely resembles the amphetamines and shares the same 
pharmacology [222]. 
Phenethylamine
Amphetamine Methamphetamine
Cathinone
MDMA
 
 
Figure 10-1  Natural products and synthetic amphetamines  
 
Conversely, the synthetic amphetamines such as amphetamine, 
methamphetamine and 3,4-methylenedioxy-N-methylamphetamine (MDMA), 
which differ from phenylethylamine because of the presence of a methyl group 
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in the side chain, cannot be degraded by monoamine oxidase and can enter the 
bloodstream and exert toxic side effects in the body.  
Amphetamines have some medicinal uses and the drugs have also been misused 
around the world throughout most of the 20th Century. Amphetamines are known 
as psychologically addictive drugs and users often become dependent on them.  
This is caused by the depression experienced when the drug effects wear off 
which leads a user taking larger doses frequently to maintain the stimulant 
“high” effects. 
In the United Kingdom, amphetamines are controlled under the Misuse of Drugs 
Act 1971 as Class B drugs for non-injectable forms and Class A drugs if 
injectable. They are included in the Regulations to the Act under Schedule 2, by 
which it is illegal to produce, supply or possess these drugs without a Home 
Office licence. Unlike Schedule 1 drugs such as cannabis, Schedule 2 drugs have 
recognised medical uses and can be prescribed by a medical practitioner in the 
United Kingdom. Also, amphetamines are prescription only drugs under the 
Medicines Act. Doctors can prescribe pharmaceuticals such as Dexamphetamine 
Sulphate for narcolepsy or attention deficit hyperactive disorder and this is legal 
if prescribed and used by the person to whom they were prescribed. 
10.2  Chemical and Physical Properties of Amphetamines 
Amphetamines occur as stereoisomers as the C2 carbon atom is chiral. The right-
handed/dexro-isomer/R(+)-amphetamine is biologically more active than the 
left-handed/ levo-isomer/S(-)-amphetamine. Chemical modification of the basic 
amphetamine structure leads to other compounds such as methamphetamine, 
phentermine, MDMA and hundreds of others which individually possess different 
pharmacological actions.  Many of these chemical derivatives are based on the 
introduction of substituents on the benzene ring and are known as ring-
substituted amphetamines. 
 
 
 
Norlida Harun - 2010                                                                                                             Page 154 
10.3  Pharmacokinetics 
 
10.3.1 Routes of Administration  
Amphetamines can be administered by a variety of routes and the rates of 
absorption are different between each route. Oral administrations, including 
prescription tablets, dissolve in the stomach and are mostly absorbed during 
passage through the small intestine. This results in gradual absorption and 
prolonged duration of action as most pharmacy formulations are designed as 
short-acting and some as time-release medicines. Injection of amphetamines 
into a vein gives rapid entry into the blood circulation, avoiding an absorption 
phase, with consequent rapid peak level in the blood and delivery to the brain. 
Intravenous administration can produce the intense psycho-stimulant effects 
wanted by the user but have well-known associated risks of infectious disease 
including HIV and hepatitis. The inhalation route of administration, such as 
smoking the free base form, can deliver the drug to the enormous surface area 
of the lungs and ensures rapid absorption and action. Administration by nasal 
insufflation (snorting) of the salt form also results in rapid absorption through 
the nasal mucosa. 
As mentioned above, the route of administration also affects the legal 
classification in the United Kingdom.  Amphetamines formulated as tablets are 
Class B under the Misuse of Drugs Act but if prepared for intravenous use they 
are Class A drugs. Perhaps the most commonly injected drug in the group is 
methamphetamine, which is the most significant abused drug in the Far East, for 
example in Japan, where it is traditionally prepared for intravenous 
administration [227]. 
10.3.2 Distribution 
All amphetamines are highly lipid soluble in their un-ionised state and readily 
cross the membrane barriers to enter the bloodstream. The plasma half-lives of 
all amphetamines are in the range 6-12 hours with the exception of 
methamphetamine, which is 12-24 hours. Amphetamines are concentrated in the 
kidney, lungs, cerebrospinal fluid and brain. The degree of protein binding and 
volume of distribution vary widely, but the average volume of distribution is 5 
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L/kg body weight, which indicates potential problems with respect to post 
mortem redistribution.   
 
10.3.3 Elimination 
Under normal conditions, about 30 % of amphetamine is excreted unchanged in 
the urine but this excretion is highly variable and is dependent on urinary pH. 
When the urinary pH is acidic (pH 5.5 to 6.0), elimination is predominantly by 
urinary excretion with approximately 60% of a dose of amphetamine being 
excreted unchanged by the kidney within 48 hours. In the situation when the 
urinary pH is alkaline (pH 7.5 to 8.0), elimination is predominantly by 
metabolism (deamination) and < 7 % is excreted unchanged in the urine, the 
half-life ranging from 16-31 hours. For chronic users, amphetamine 
concentrations in urine range from 1-90 mg/L and methamphetamine from 25-30 
mg/L.  
10.3.4 Metabolic Pathways of Amphetamines  
The amphetamines are metabolised primarily in the liver by three oxidation 
pathways involving cytochrome P450 including N-dealkylation, side-chain 
hydroxylation and aromatic ring hydroxylation, which are illustrated in Figure 
10-2[223]. Additional transformations occur for ring-substituted amphetamines 
which are described below. Methamphetamine undergoes N-demethylation to 
give amphetamine or aromatic hydroxylation to form p-
hydroxymethamphetamine (pOHMAMP, pholedrine) and is subsequently oxidised 
to benzoic acid and excreted as glucuronide or glycine (hippuric acid) conjugate. 
Minor metabolites include p-hydroxyamphetamine (pOHAMP), norephedrine 
(NOREPH) and p-hydroxynorephedrine (pOHNOREPH) which are 
pharmacologically active and may contribute to the pharmacological effects in 
chronic use.   
 
The most commonly-used ring substituted amphetamine, 3,4-
methylenedioxymethamphetamine (MDMA, Ecstasy) is metabolised by N-
dealkylation to 3,4-methylenedioxyamphetamine (MDA), and by O-demethylation 
to form the intermediates 3,4-dihydroxymethamphetamine (HHMA) and 3,4-
dihydroxyamphetamine (HHA). HHMA and HHA undergo O-methylation, forming 
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4-hydroxy-3-methoxymethamphetamine (HMMA) and 4-hydroxy-3-
methoxyamphetamine (HMA). 3,4-Methylenedioxyethylamphetamine (MDEA) 
undergoes N-deethylation to form MDA and, following cleavage of the 
methylenedioxy group, 3,4-dihydroxyethylamphetamine (HHEA) and 4-hydroxy-3-
methoxyethylamphetamine (HMEA). The hydroxylated metabolites may also 
undergo conjugation to form glucuronide and/or sulfate metabolites.  
 
Figure 10-2 Metabolic pathways of methamphetamine (MAMP), amphetamine (AMP), 3,4-
methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyethylamphetamine 
(MDEA). Abbreviations: AMP, Amphetamine; HHA, 3,4-dihydroxyamphetamine; HHEA, 3,4-
dihydroxyethylamphetamine; HHMA, 3,4-dihydroxymethamphetamine; HMA, 4-hydroxy-3-
methoxyamphetamine; HMEA, 4-hydroxy-3-methoxyethylamphetamine; HMMA, 4-hydroxy-3-
methoxymethamphetamine; MAMP, N-methylamphetamine; MDA, 3,4-
methylenedioxyamphetamine; NOREPH, norephedrine; pOHAMP, p-hydroxyamphetamine; 
pOHNOREPH, p-hydroxynorephedrine; pOHMAMP, p-hydroxymethamphetamine. 
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10.4  Pharmacodynamics   
10.4.1 Mode of Action 
Amphetamines are sympathomimetic drugs which stimulate both the central and 
peripheral nervous system. They may be direct agonists at norepinephrine 
(noradrenaline) receptors but may also increase the rate of release of 
norepinephrine, the neurotransmitter of postganglionic sympathetic nerve 
fibres. Increased central activity in the brain acts on the hypothalamus-pituitary-
adrenal axis which causes epinephrine to be released from the adrenal medulla 
into the circulation. Epinephrine stimulates the sympathetic part of the 
autonomic nervous system, which increases heart and respiration rates and 
alters the diameter of blood vessels so that oxygenated blood is preferentially 
supplied to the muscles and brain, such that mental alertness is increased. The 
digestive system is inhibited to leave more blood for muscle use and this 
decreases appetite.  
10.4.2 Effects of Amphetamines 
An amphetamine user may experience a temporary boost in self-confidence and 
feel far more energetic than usual, talkative and can perform increased physical 
activity, but may find it difficult to rest and sleep and will have little or no 
appetite.   
10.4.3 Side effects 
After a period of chronic use, an amphetamine user becomes exhausted 
physically and mentally due to extensive physical activities, loss of water and 
inability to sleep. As a result, users often feel fatigued and depressed for a few 
days after using amphetamines and may also feel irritable, anxious and restless. 
Other side effects include blurred vision and dizziness. Many women who use 
amphetamines find that their periods become irregular or even stop. High doses, 
especially if frequently repeated, can produce delirium, panic attacks, 
hallucinations and feelings of paranoia. Acute overdose of amphetamines 
produces seizures, hypertension, tachycardia, hyperthermia, psychosis, 
hallucinosis, stroke and may result in a fatality. 
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10.5  Medicinal Use of Amphetamines  
Amphetamine was first marketed in the 1930s under the trade name Benzedrine, 
an over-the-counter inhaler used to treat nasal congestion. Later, in the 1930s 
and 1940s, both dextroamphetamine (Dexedrine) and methamphetamine 
(Methedrine) were used by the armed forces as performance enhancers in World 
War II. Amphetamines were common in the 1950's and 1960's for treatment of 
mild depression and as anorexics for body slimming. Their current medical use is 
limited, with only Dexedrine (dexamphetamine sulphate) currently available for 
use in the treatment of narcolepsy - a rare disorder marked by episodes of 
uncontrollable sleep and methylphenidate (Ritalin) for the treatment of 
attention deficit hyperactivity disorder (ADHD) in children.  
10.6  Misuse of Amphetamines  
According to the World Drug Report 2006 published by UNODC [224], 25 million 
people used ATS in 2004, of which some 10 million people used ecstasy either 
recreational or regularly. More than 60 per cent of the world’s ATS users live in 
Asia while more than 50 per cent of the world’s ecstasy users live in Western 
Europe and North America. Annual prevalence of amphetamine use is highest in 
Oceania, followed by North America and East and South-East Asia.  
In Europe, which is home to an estimated 2.7 million users of ATS, amphetamine 
use is far more widespread than the use of methamphetamine which is limited to 
the Czech Republic and some Baltic States. There was a small fall in the 
reported use of amphetamine in UK from 1996 to 2000 after years of increases in 
the early 1990s. This is also reflected in the report by UNDOC which indicates 
that the markets for ATS seem to be stabilizing, reflecting improved 
international law enforcement cooperation and improvements in precursor 
control.  
10.7  Toxicological Data 
The toxic dose of an amphetamine derivative varies considerably due to 
individual variations and the development of tolerance. Fatal amphetamine 
cases have been reported following ingestion of doses as low as 1.3 mg/kg (91 
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milligrams for a person weighing 70 Kg), although tolerance has been                             
developed to accommodate doses of up to 1,000 mg at a time and up to 5 g in a 
day, with a blood levels from 2.0 to 3.0 mg/L. The recreational dose of MDMA or 
MDEA is of the order of 80-120 mg and produces blood levels in the range of 0.1–
0.25 mg/L. However, most cases of serious toxicity or fatality have involved 
blood levels ranging from 0.5 mg/L to 10 mg/L, up to 40 times higher than the 
usual recreational range, although some have had levels as low as 0.11– 0.55 
mg/L which are in the normal range or a little above it. This is an important 
point, because it demonstrates the degree to which the seriousness of the 
effects can be dependent on environmental factors other than the drug 
concentration [225]. 
10.8  Previous Work and Aims 
There are numerous publications on analytical procedures for the detection and 
identification of amphetamines in biological fluids including methods to detect 
amphetamines as a group in a variety of matrices, such as urine[226], plasma [227], 
brain and other tissues [228,229], sweat [230, 231,232], meconium [223], oral fluid [31,232] 
and skin [233]. Gas chromatography-mass spectrometry has dominated the 
methods for determination of amphetamines because of the volatile nature of 
the analytes, especially following the preparation of chemical derivatives. 
A few papers deal with the analysis of amphetamines using liquid 
chromatography-mass spectrometry [127,234-237]. One paper describes the analysis 
of amphetamines which were successfully extracted using a commercial 
molecularly imprinted polymer prior to LC-MS/MS analysis, which was the aim of 
this study [238] .     
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11 APPLICATION OF MISPE AND LC-MS/MS FOR 
THE DETERMINATION OF AMPHETAMINES IN 
WHOLE BLOOD 
11.1  Introduction 
The company MIP Technologies has developed proprietary products based on 
molecularly imprinted polymers to improve the extraction of analytes from 
complex matrices. The products are based on the selectivity of the MIPs which 
are capable of extracting a wide range of analytes or analyte classes.  
The products are based on selectivity which is introduced during MIP synthesis, 
in which a template molecule, which is either the target analyte or one designed 
to mimic the analyte, guides the formation of specific cavities that are sterically 
and chemically complementary to the target analyte(s), as described in detail in 
Chapter 6.  
Molecularly imprinted polymers have been used successfully to extract several 
analytes, such as clenbuterol, a drug prescribed as a decongestant and 
bronchodilator for breathing disorders [239], chloramphenicol, an antibiotic [240] 
and β-blockers, a class of drugs used for the management of cardiac 
arrhythmias, heart failure and hypertension [241]. Recently, MIPs have been used 
successfully for extracting zidovudine and stavudine, which are used to treat 
acquired immunodeficiency syndrome (AIDS), from plasma samples [242]. 
In this study, Amphetamines SupelMIPTM, a commercial molecularly imprinted 
solid-phase extraction product for amphetamine-type compounds was evaluated 
for the extraction of amphetamines from post-mortem blood. Extraction 
protocols using Amphetamines SupelMIPTM have previously been used to obtain 
high recoveries for amphetamines from urine [238].  
11.2  Experimental Section 
11.2.1 Instrumentation 
A Surveyor HPLC system linked to an LCQ™ Deca XP Plus ion trap mass 
spectrometer (Thermo Finnigan, San Jose, CA, USA) was used for analysis of 
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whole blood samples.  The equipment came with a data processing system, 
Xcalibur 1.3. HPLC was performed on a Synergi Hydro RP column (150 mm x 2.0 
mm i.d., 4 µm particle size, Phenomenex, Torrance CA, USA) fitted with a 5 µm 
guard column with the same packing material as the column. The guard column 
holder was from Phenomenex, Macclesfield, UK.  
11.2.2 Chemicals and Materials 
Amphetamine, methamphetamines, MDMA, MDA and MDEA and their deuterated 
internal standards, amphetamine-d11, methamphetamines-d14, MDMA-d6, MDA-
d5 and MDEA-d6 were obtained from LGC Promochem (Teddington, UK). 
Ammonium acetate and ammonium formate were purchased from Fluka (Buchs, 
Switzerland). Formic acid, methanol and acetonitrile were of HPLC grade and 
were from BDH (Poole, UK). Amphetamines SupelMIPTM columns (25 mg/3 mL, lot 
number SPMG060961) were purchased from Supelco (Bellafonte, PA).  Vials and 
caps for sample injection using an autosampler were obtained from Kinesis Ltd, 
(Greensbury Farm Bolnhurst, UK). 
11.2.3 Standard Solutions 
Stock solutions of all standards, at a concentration of 1.0 mg/mL, were diluted 
to obtain working solutions of 10 ng/µL, 1.0 ng/µL and 0.1 ng/µL. Stock solutions 
of internal standards, 100 ug/mL were also diluted to obtain working standards 
at a concentration of 1.0 ng/µL. These working solutions were used to construct 
calibration curves with six points at concentrations of 0, 25, 100, 250, 500 and 
1000 ng/mL for the 5 types of amphetamines. Stock and working solutions were 
kept refrigerated at 4 °C when not in use, with a nominal shelf life of 6 months.  
11.2.4  Blank Blood 
Time-expired packed red blood cells were obtained from the blood bank 
(Scottish Blood Transfusion Service, Gartnavel Hospital). These red blood cells 
were suspended in an equal volume of isotonic saline (0.1 M sodium chloride 
solution) before use. Ethical approval for use of the blood cells was obtained 
from the Scottish Blood Transfusion Service, Edinburgh. 
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11.2.5 Solutions 
11.2.5.1 Preparation of Mobile Phase 
An acidic mobile phase consisting of 3 mM ammonium formate and 0.001% formic 
acid in water was prepared by adding 0.189 g ammonium formate and 10 µl of 
concentrated formic acid to a 1L volumetric flask and making up to 1L with 
deionised water. 
11.2.5.2 Preparation of Ammonium Acetate Buffer (10 mM, pH 8.0) 
In a fume hood, 0.575 mL glacial acetic acid was measured into a 1000 mL 
volumetric flask containing 800 mL deionised water. Then 1.30 mL concentrated 
ammonium hydroxide was added. The pH was adjusted to 8.0±0.1 with 
ammonium hydroxide if the pH was less than 8.0 or acetic acid if the pH was 
greater than 8.0. The solution was then made up to 1.0 L with deionised water. 
11.2.5.3 Preparation of Other Solvents 
Aqueous acetonitrile (60:40 v/v) was prepared by adding 60.0 mL acetonitrile to 
40 mL deionised water. 1 % HAc (v/v) was prepared by adding 1.0 mL glacial 
acetic acid to 99 mL acetonitrile. 1 % formic acid in acetonitrile (v/v) was 
prepared by adding 1.0 mL concentrated formic acid to 99.0 mL MeCN.     
11.2.6 LC-MS-MS Conditions 
LC analysis was carried out using a mobile phase gradient programme combining 
3 mM ammonium formate buffer + 0.001% formic acid (pH ~3) and acetonitrile at 
a flow rate of 0.3 mL/min as shown in Table 11-1.  A 20 µl aliquot of sample was 
injected onto the Synergi Hydro RP LC column using partial loop mode. 
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Table 11-1 Gradient conditions  
Time (min) 3 mM ammonium formate + 
0.001% formic acid (A %) 
Acetonitrile (B %) Flow rate 
(µL.min-1) 
0 75 25 300 
6 75 25 300 
15 20 80 300 
17 10 90 300 
18 10 90 300 
18.5 75 25 300 
25 75 25 300 
 
Mass spectral data were acquired for both analytes and their deuterated internal 
standards in the electrospray (ESI) positive ion mode which produced protonated 
molecular ions, [M + H]+.   The electrospray probe voltage used was 4.5 kV.  The 
capillary temperature, sheath and auxiliary gas flow rates and collision energies 
were optimized during tuning for each analyte (Table 11-2).  
Internal standard data was collected by Selected Ion Monitoring (SIM) for 
identification of the parent ions and analyte data was collected in the mode 
over the mass range m/z 60-250. Selected reaction monitoring (SRM) was used 
where one parent ion and one product ion were identified because of the low 
molecular weight of these compounds [243]. The quantitation ion was the major 
product ion produced on precursor fragmentation. The ratios of quantitation ion 
to internal standard were calculated.  Therefore in this study for positive sample 
identification the ratio of quantitation ion to internal standard was used, the 
value either greater than or within ± 20 % of the ratio for the lowest calibration 
standard.   
The optimum tuning LC parameters, the precursor and the product ions for 
amphetamines was shown in Table 11-2. 
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Table 11-2 The optimum tuning LC parameters, the precursor and the product ions for 
amphetamines 
Compound 
Sheath 
Gas 
(AU) 
Auxiliary 
Gas(AU) 
Capillary 
temperature         
( ºC ) 
Collision 
Energy          
(%) 
 
Precursor 
Ion 
 
Product 
Ion 
 
Amphetamine 15 5 210 * 23 136 119 
Methamphetamine 15 5 210 28 150 119 
MDA 15 15 220 21 180 163 
MDMA 15 15 280 25 194 163 
MDEA 15 15 220 20 208 163 
* 210 ºC was used in the LC-MS method 
11.2.7 Extraction method 
11.2.7.1 Sample Pre-treatment 
Whole blood is a complex matrix containing many proteins which can 
subsequently cause matrix effects during the MIP extraction process. For this 
reason, a pre-treatment step was applied. Standards and internal standard were 
spiked into 1.0 mL aliquots of blood which was then diluted with 1.0 mL 
ammonium acetate buffer, pH 8.0, vortexed mixed and centrifuged at 3000 rpm 
for 10 minutes. The supernatant was transferred to a clean tube for the loading 
step in the extraction process.   
11.2.7.2 MISPE Protocol 
Amphetamines SupelMIPTM SPE cartridges were used to extract the 
amphetamines from blood. The SPE protocol was based on the manufacturer’s 
suggestion. It was assumed that the molecularly imprinted polymer material in 
the columns was made by monolith polymerisation as the particles varied in size, 
with an average particle size of 58.6 µm. The column was first conditioned with 
1.0 mL methanol, followed by 1.0 mL 10 mM ammonium acetate buffer, pH 8.0 
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without the application of a vacuum. Then the pre-treated blood samples were 
loaded on the SPE cartridges. The cartridges were then washed sequentially with 
2 x 1.0  ml DI water, taking care not to let the column dry out, 1.0 mL 60/40 v:v  
MeCN/DI water followed by a drying step of 5-10 minutes with full vacuum, and 
finally with 1.0 mL of 1 % HAc in MeCN. 2 x 1.0 mL 1 % formic acid in MeCN was 
used to elute the amphetamines with mild application of vacuum between each 
elution. The combined SPE eluant was evaporated to dryness under a stream of 
nitrogen gas without heating. Finally, the residues were reconstituted with 
100 µL initial mobile phase and vortex mixed.   
 
11.2.8 Method Validation 
11.2.8.1 Linearity, LOD and LLOQ 
Linearity was established for 5 amphetamines over the range 0-1000 ng/mL.  
Amphetamines were spiked into human whole blood to achieve concentrations of 
0, 25, 100, 250, 500, and 1000  ng/mL along with internal standards at 50 ng/mL 
(n=2) and these were then extracted by MISPE and analysed by LC-MS/MS.  
Calibration curves were prepared by plotting peak area ratios of 
standards/internal standard against the spiked analyte concentrations. These 
were subjected to linear regression analysis. Limit of Detection (LOD) values 
were calculated statistically using three times the standard error of the 
regression line and Lower Limit of Quantification (LLOQ) values were calculated 
statistically using ten times the standard error of the regression line [29, 244, 245].  
11.2.8.2 Matrix Effect Assessment 
This study was conducted to assess the effects on the LC-MS analysis of the 
extracts of interferences which are co-extracted along with the analytes from 
the blood matrix. Three replicates of 1 mL blank blood were spiked at three 
levels (50, 450 and 900 ng/mL) with amphetamine, methamphetamine, MDMA, 
MDA and MDEA. Another three replicates were prepared by spiking the same 
amounts of amphetamines in 2 mL of loading buffer rather than blood.  
All of the samples were vortexed, centrifuged and extracted using the MISPE 
procedure described earlier. 50 ng of each internal standard was added to each 
replicate after the extraction. The peak area ratios of the analytes to internal 
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standards in blood extracts were divided by those obtained from samples 
prepared using the loading buffer  to give the matrix effects as a percentage [33].  
11.2.8.3 Recovery studies 
Amphetamines were spiked at concentrations of 50, 450 and 900 ng/mL of each 
compound in 1 mL aliquots of blood (n=6), which were then processed using the 
MISPE procedure. Two unextracted standards of each concentration levels were 
also prepared and were kept in the fridge throughout the extraction. 50 ng of 
deuterated internal standards of each compound were then added after MISPE to 
each extracted and unextracted standard before blowing down under nitrogen. 
Percentage recoveries were determined by comparing peak area ratios of the 
extracted and unextracted standards.   
11.2.8.4 Intra- and Inter-day Precision 
The intra- and inter-day precisions were determined by analysing human whole 
blood samples spiked at concentrations of 50, 450 and 900 ng/mL with 
amphetamine standards six times in the same day and once a day during 3 
successive days. 
11.2.8.5 Application to Case Blood Samples 
Case blood samples were obtained from the Department of Forensic Medicine 
and Science, University of Glasgow and were analysed using the method protocol 
described earlier. The results obtained by LC-MS/MS method in this study were 
compared with those previously obtained during the initial investigation of the 
cases using the accredited Departmental GC-MS procedure (without reanalysis)  
.The time period between the samples being analysed for the first time and 
reanalysed using MISPE extraction and the developed LC-MS/MS method was six 
months to a year. 
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11.3  Results and Discussion 
11.3.1 Linearity and Determination of the LOD and LOQ 
Regression analysis of graphs of peak area ratios of amphetamines to internal 
standards versus concentration showed good linearity in the range of 0-1000 
ng/mL as shown in Figure 11-1.  
y = 0.0087x - 0.0524
R2 = 0.9972
y = 0.0042x + 0.097
R2 = 0.9911
y = 0.0042x - 0.0961
R2 = 0.9985
y = 0.0019x - 0.0332
R2 = 0.9942
y = 0.0004x + 0.0047
R2 = 0.997
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Figure 11-1 Calibration curves for the 5 amphetamines 
 
Correlation coefficients (R2) for the calibration curves were better than 0.99 in 
each case. Calculated LODs and LLOQs based on regression lines for the 5 
amphetamines are shown in Table 11-3. 
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Table 11-3  Calibration curve regression coefficient, linear range, LOD and LLOQ for five 
amphetamines in whole blood and comparison of LOD/LLOQ with a validated GC-MS 
method 
 
Amphetamine Coefficients 
Variations 
 
R2 
Linear 
range 
ng/mL 
LC-
MS/MS 
LOD  
ng/mL 
GC-MS 
LOD 
ng/mL 
LC-
MS/MS 
LLOQ  
ng/mL 
GC-MS 
LLOQ 
ng/mL 
 
Amphetamines 
 
0.9972 
 
0-1000 
 
0.4 
 
 
10 
 
1.3 
 
25 
 
Methamphetamine 
 
0.9985 
 
0-1000 
 
0.2 
 
 
10 
 
0.8 
 
25 
 
MDMA 
 
0.9911 
 
0-1000 
 
0.3 
 
 
1 
 
0.9 
 
5 
 
MDA 
 
0.9942 
 
0-1000 
 
0.4 
 
 
1 
 
1.4 
 
5 
 
MDEA 
 
 
0.9970 
 
0-1000 
 
0.6 
 
 
5 
 
1.9 
 
10 
 
 
MISPE has been found in previous studies to provide lower detection limits than 
conventional SPE due to increased selectivity which results in cleaner extracts 
and in this study the application of the method to the whole blood samples gave 
low  LODs ( <1.0 ng/mL) and LLOQs ( <2.0 ng/mL) for all five amphetamines 
investigated. This compares favourably with the routine GC-MS procedure, which 
has LODs and LOQs in the range 1.0 ng/mL and 25.0 ng/mL respectively. 
11.3.2 Matrix Effect Study 
The matrix effects observed during the analysis of 5 amphetamines at three 
concentrations are shown in Table 11-4. 
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Table 11-4 Matrix effects for 5 amphetamines 
Analyte 
Spiked concentration 
(ng mL−1) 
 
Matrix Effect 
                 (%) [RSD] 
50 - 4.9 [2.4] 
450 + 4.6 [6.6] Amphetamine 
900 - 4.0 [9.9] 
50 +10.3 [0.9] 
450 +7.3 [8.4] Methamphetamine 
900 +6.3 [11.1] 
50 +3.9 [6.7] 
450 +0.2 [5.0] MDMA 
900 +0.1 [2.6] 
50 +12.3 [0.6] 
450 +5.0 [9.3] MDA 
900 -7.2 [3.3] 
50 -5.0 [2.1] 
450 -5.9 [5.4] MDEA 
900 -5.0 [9.1] 
 
 
From the data given in Table 11-4, it can be seen that blood matrix components 
co-extracted by MISPE were found to cause acceptable levels of suppression and 
enhancement to the MS response during LC-MS analysis of the five 
amphetamines. Good MS compatibility and minimized matrix effects were 
obtained due to elimination of interfering substances by the wash steps included 
in the MISPE protocol. The cartridges were washed sequentially with 2 x 1.0 mL 
deionised water, 1.0 mL 60/40 v/v MeCN/DI water followed by a drying step of 
5-10 minutes with full vacuum, and with 1.0 mL of 1 % HAc in MeCN. The results 
demonstrated that there were no significant interfering peaks which co-eluted 
at the retention times of the analytes and internal standards, demonstrating 
again the improvement in selectivity brought by the MIP that allows the removal 
of these interferences. Subsequently, all standard solutions were prepared in 
whole blood to match the matrix of real case samples.  
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11.3.3 Recovery Study 
Recoveries of amphetamines from blood at different concentrations are 
presented in Table 11-5. Overall the highest recovery was obtained for 
methamphetamine, followed by MDMA, amphetamine, MDA and MDEA. 
Table 11-5 Recoveries of amphetamines from human whole blood  
 
50 ng/mL 450 ng/mL 900 ng/mL 
QA compound Mean 
recovery 
(%) 
(n=6) 
RSD of 
recovery 
(%) 
 
Mean 
recovery 
(%) 
(n=6) 
RSD of 
recovery 
(%) 
 
Mean 
recovery 
(%) 
(n=6) 
RSD of 
recovery 
(%) 
Amphetamines 40.9 8.1 38.3 7.8 40.2 4.5 
Methamphetamines 42.2 7.6 61.4 8.2 50.3 1.2 
MDA 38.0 13.4 37.9 9.0 38.5 9.8 
MDMA  47.5 8.5 50.3 9.5 50.1 4.8 
MDEA 32.4 10.6 33.7 8.2 31.4 9.6 
 
The recoveries were in the range 32.4 % to 61.4 % with RSDs of less than 11 %. 
These were significantly lower than the recoveries from urine found in a study 
performed by the manufacturer using the same MISPE columns and extraction 
protocol but different LC column for separation. The manufacturer’s recoveries 
were between 97 % and 113 % with % RSD of 1.41 to 9.84 for the same group of 
amphetamines analysed in urine [238]. The comparison GC-MS method did not 
provide recovery data for the validated method but data for drift assay showed 
no drift in analytes concentration.  
According to Martin et al., in order to get high efficiency results in the analysis 
of beta-blockers in plasma samples using MIP, it was necessary to perform a 
protein precipitation step ahead of the MISPE [246]. Therefore unsatisfactory 
recoveries in this study may be due to the incomplete protein precipitation step 
ahead of the MISPE protocol used for whole blood in this study. However, the 
method was suitable for routine application as the LODs and LOQs and precision 
(Section 11.3.4) were good. The average recoveries from blood were not 
significantly different for the 5 amphetamines at three levels according t values 
calculated using Student’s t-test (Table 11-6). 
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Table 11-6 T-test results  
Set of  samples Set A 
  
Set B  
 
Set C  
 
Concentration level 
 
50 ng/mL 
 
450 ng/mL 
 
900 ng/mL 
 
Amphetamine 40.9 38.3 40.2 
Methamphetamine 42.2 61.4 50.3 
MDA 38 37.9 38.5 
MDMA 47.5 50.3 50.1 
MDEA 32.7 33.7 31.4 
 
T test results 
 
Set A vs. Set B  Set A vs. Set C Set B vs. Set C 
T value 0.74 0.68 0.73 
P value   <0.05 <0.05 <0.05 
 
11.3.4 Intra- and Inter-day Precision 
The intra- and inter-day precisions were determined by analysing human whole 
blood samples spiked with amphetamines at concentrations of 50, 450 and 900 
ng/mL analytes, ten times in the same day and once a day during three 
successive days. 
Good precisions were obtained using the method described above. Relative 
standard deviations (RSDs) for intra- and inter-day precision were less than 10 % 
and are shown in Table 11-7.  
Table 11-7  Intra- and inter-day precisions for amphetamines in human blood samples  
  
Intra-day (n=6) Inter-day (n=6 x 3) 
Amphetamines Amount 
added 
(ng/mL) 
Amount 
detected  
(ng/mL) 
 
RSD (%) 
Amount 
detected 
 (ng/mL) 
 
RSD (%) 
50 52.9 5.8 52.6 6.2 
450 449.5 1.7 446.5 0.6 
Amphetamine 
900 896.5 1.1 897.8 0.2 
 
50 54.7 2.6 51.3 6.0 
450 452.2 1.9 448.9 0.7 
Methamphetamine 
900 895.6 0.8 900.5 0.6 
 
50 54.7 0.6 54.5 1.7 
450 446.2 1.7 446.6 1.9 
MDA 
900 895.4 0.4 897.3 0.5 
 
50 52.7 1.5 48.7 7.7 
450 447.4 1.1 446.8 0.9 
MDMA 
900 897.2 0.4 892.6 1.0 
 
50 50.4 5.3 50.8 5.1 
450 447.3 7.2 450.8 8.1 
MDEA 
900 903.4 8.5 896.9 1.1 
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The method showed good reproducibility as obtained in the intra- and inter-day 
precision results. The precision values for a comparative GC-MS method are 
tabulated in Table 11.8 for comparison. 
Table 11-8 The Intra- and inter-day precisions for amphetamines in human blood samples 
for GC-MS method 
  Intra-day (n=10) Inter-day (n=10 x 10 days) 
Amphetamines Amount 
added 
(ng/mL) 
Amount 
detected  
(ng/mL) 
 
RSD (%) 
Amount 
detected 
 (ng/mL) 
 
RSD (%) 
Amphetamine 125 128.9 1.6 127.9 6.2 
 
Methamphetamine 125 111.8 6.7 121.4 8.1 
 
MDA 125 138.6 2.2 124.8 9.7 
 
MDMA 125 125.5 2.6 116.5 8.2 
 
MDEA 125 132.7 2.3 123.30 7.0 
 
 
11.3.5 Case Samples 
Blood samples were obtained with permission from post mortem cases from 
Forensic Medicine and Science, University of Glasgow which had previously been 
analysed and reported and which were due for disposal. Analysis of case 
materials is permitted as long as the results of analysis are given to the 
pathologist and Procurator Fiscal to supplement the case investigation.   
The samples were selected from positive and negative cases for the 5 
amphetamines and the results were compared with the routine GC-MS method. It 
was not possible to obtain samples which were positive for each of the 5 
amphetamines. Most of the samples were positive only for amphetamine and one 
case was positive only for MDMA. Drug related deaths caused by amphetamines 
in Scotland are not many, as shown in the statistics, and there were only 13 drug 
related deaths involving ecstasy in 2006 [218].  
The results for real cases are shown in Table 11-9. In this study the application 
of commercial MISPE successfully detected amphetamines in the positive 
samples but the concentrations found were lower than those obtained using the 
accredited routine GC-MS method. This is unlikely to be due to the low 
recoveries of amphetamines of this method, which were between 30-65 % for the 
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5 amphetamines at all levels, as this is corrected by the use of internal 
standards. It is possible that analyte losses occurred during storage between the 
times of the original analysis and the present study. Even though amphetamines 
are very stable compounds, studies of the stability of amphetamines have shown 
that MDA, MDMA and MDEA have some degradation when stored at 4º C for more 
than 13 weeks especially at low concentrations [21]. 
On the other hand, the method detected low levels of analytes in the samples 
such as for MDMA and has proven the method has low LODs and LLOQs for the 5 
amphetamines. Of two negative samples from GC-MS one also came out negative 
for all five analytes in the MIPSE-LC-MS/MS analysis but the other showed the 
presence of MDMA which was found negative in the original analysis. 
Table 11-9 Comparison of GC/MS and LC/MS results 
 GC-MS  LC-MS/MS  
Sample 
Number 
 
Analyte 
Concentration 
(ng/mL) 
Analyte 
Concentration 
(ng/mL) 
        
1 Amphetamine 380 
Amphetamine; 
MDMA 
116 
6.5 
       
2 
Negative for all 5 
amphetamines  
 
Negative for all 5 
amphetamines  
 
       
3 
Negative for all 5 
amphetamines  
 MDMA 9.9 
       
4 Amphetamine  860 Amphetamine 529 
       
5 Amphetamine  870 Amphetamine 335 
       
6 MDMA 1800 MDMA 1548 
       
7 Amphetamine  890 Amphetamine 636 
 
It was also noted that most of the cases were from poly-drug users and not from 
users of amphetamines alone (Table 11-10). Apart from amphetamines, the 
common drugs present in the samples were benzodiazepines, cocaine and 
metabolites, morphine and metabolites, cannabis and alcohol. Poly-drug use was 
also common in England as discussed by Williams and Parker in their published 
paper [247] . 
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Table 11-10  Other drugs present in the post mortem blood samples 
Sample 
 Number 
 
Other drugs detected (mg/L) 
 
1 
Diazepam, temazepam, lamotrigine, desmethyldiazepam, oxazepam, 
benzoylecgonine, alcohol  
   
2 
negative for all drugs  
 
   
3 
negative for all drugs  
 
   
4 
Carboxyhaemoglobin (19 %), alcohol 
 
   
5 
Codeine and metabolites, cannabis and metabolites, benzodiazepines 
 
   
6 
Alcohol, lignocaine, diazepam, lorazepam, phenytoin 
 
   
7 
Benzodiazepines, morphine and metabolites, mirtazapine, alcohol 
 
 
11.4 Conclusion 
A commercial cartridge was evaluated for use in a method for the quantitation 
of five amphetamines in human blood based on MISPE and LC-MS/MS analysis. 
The method demonstrated good linearity, LOD, LOQ, accuracy and precision and 
low matrix effects. However the recoveries obtained were lower than expected 
for the five amphetamines and the method requires further optimisation for 
routine use in forensic toxicology if lower detection limits of drugs in whole 
blood are required. The recoveries for the five amphetamines were lower than 
in the comparison GC-MS method but the LODs and LLOQs were found to be 
better and suitable for detection of low levels amphetamines in post mortem 
blood.  This may be a result of the incomplete sample pre-treatment  ahead of 
the MISPE protocol used for whole blood in this study, and may be affected by 
the gap between the original analyses and samples being reanalysed in this study 
(within six months to a year) during which some degradation of the analytes may 
have occurred in the whole blood samples.  
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12 GENERAL CONCLUSIONS AND FURTHER 
WORK 
 
12.1 General Conclusions 
In response to the challenge in the field of forensic toxicology to improve 
methods of identification and quantification of analytes, particularly in terms of 
selectivity and sensitivity, the work in this thesis investigated the use of a novel 
technique in sample preparation, molecularly imprinted solid phase extraction 
(MISPE). The present work also investigated the use of LC-MS/MS analysis which 
has recently become available in routine forensic toxicology for the 
identification and quantification of drugs in biological specimens. The model 
compound used was ketamine, for which an anti-ketamine MIP was synthesised 
in-house, and amphetamine, for which a commercial MIP was used. During the 
period of this research, the majority of published work regarding the analysis of 
ketamine and amphetamine was still based on GC-MS.   
In the present work, LC-MS/MS analysis following ketamine MIP extraction was 
found to be selective and sensitive and to give clean extracts with fewer matrix 
effects than a comparable method based on conventional SPE. The anti-
ketamine MIP had cross-reacted with norketamine, the main metabolite of 
ketamine due to the group-selective binding nature of the MIP.  The MIP columns 
were found to be reusable, robust and able to withstand treatment with a range 
of different pH values and solvents. In addition, preliminary results indicated 
that chiral selectivity may also be obtained using an anti-S-ketamine MIP. 
The combination of MISPE and LC-MS-MS detected ketamine and norketamine in 
a higher proportion of hair samples of chronic users compared to a conventional 
SPE method. For this reason, the MISPE method should be extended for more 
challenging analysis of detecting single ketamine use, such as in drug facilitated 
rape cases, which would be very useful for the investigation of these cases in 
forensic toxicology. 
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The commercially-available product, Amphetamines SupelMIPTM, was evaluated 
for use in MISPE and LC-MS/MS analysis for quantitation of five types of 
amphetamines in human post mortem blood. The method demonstrated good 
linearity, LOD, LLOQ, accuracy, precision and matrix effects but the recoveries 
obtained were lower than expected for the five amphetamines and therefore 
required further optimisation to trigger the selectivity of the MIP before being 
recommended for use in forensic toxicology, which requires high recoveries in 
order to permit the detection of drugs at low concentrations in whole blood.  
The main problem arising from the in-house synthesised MIPs was due to 
bleeding of entrapped template.  A vigorous and time-consuming procedure was 
carried out to extract the template completely from the polymer.  In the 
ketamine MIP, the template strongly interacted with the monomer and was only 
removed after washing more than 14 times with an appropriate extraction 
solvent.  However, for Amphetamines SupelMIPTM, this problem was solved by 
the careful bleeding test by the manufacturer.   
The present work also included the development and validation of an ELISA 
screening method and an LC-MS/MS confirmation method for the identification 
and quantitation of ketamine and its major metabolite norketamine in urine 
samples. The Neogen® ELISA kit was found to be sensitive, specific and precise 
for ketamine screening at a cut-off concentration of 25 ng/mL coupled with an 
LC-MS/MS cut-off of 2 ng/mL. The ELISA procedure demonstrated 100 % cross-
reactivity to ketamine and minimal cross-reactivity to its main metabolite 
norketamine. The LC-MS/MS confirmation method demonstrated excellent 
linearity, LOD, LLOQ, accuracy and precision, with acceptable matrix 
interference effects. The screening efficiency of ELISA and the LC-MS/MS 
confirmation method was evaluated with 34 urine specimens from ketamine 
users collected from persons attending pubs and nightclubs in Malaysia. The 
combination of tests demonstrated excellent efficiency, sensitivity and 
specificity and could be reliably used for screening and confirmation of ketamine 
in urine specimens. The data for ELISA and LC-MS/MS analysis of both urine and 
hair samples found that ketamine and norketamine are present in all specimens 
and highlighted that ketamine is being abused in Malaysia.  
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12.2  Further Work 
In the study described in Chapter 6, three liquid chromatography columns, 5.00 
cm x 4.6 mm, with a frit size of 0.2 µm were packed with S-ketamine MIP, R/S 
ketamine MIP and NIP. The amount of packing in each column was approximately 
0.5 gram polymer. These columns have been pre-evaluated using HPLC-UV and 
LC-MS/MS. The preliminary data obtained on HPLC-UV analysis using ketamine 
standards demonstrated the columns can potentially used for LC-MS/MS analysis 
for direct injection of ketamine and norketamine samples. 
Further work should be carried out to investigate whether these columns made 
in-house based on the MIP materials can successfully be used for the detection 
of ketamine and norketamine in sample matrices such as urine, pre-extracted 
blood and hair for direct injections to LC-MS/MS, which has not been tried 
before. If this was shown to be feasible, it would contribute significantly to 
forensic toxicology in terms of reducing the analysis time and increasing the 
selectivity and sensitivity of the method.  
To enable this, the columns should be optimised in terms of the column length 
and diameter, the MIP particle size, column efficiency, column reproducibility, 
range of pressure applied, and range of pH and solvent to be compatible or 
better than the commercial polymer based LC columns, especially for LC-MS/MS 
applications [100]. No studies have yet been published on MIP-based LC-MS/MS 
columns, even though many preliminary data have been published using HPLC-UV 
[248, 249]. 
Also, further work should include studies on the other major metabolite of 
ketamine, dehydronorketamine, which is now commercially available as a 
standard, to complete the whole study on ketamine and its main metabolites.  
Further work should also be carried out on the chiral selectivity shown by the 
MIP columns in this preliminary study.  This is very important because half of the 
drugs in use are chiral, including ketamine, and an HPLC column of this type 
could be used in forensic toxicology to distinguish the active isomer from the 
less active one [201].   
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ABSTRACT 
An ELISA and a LC-MS/MS confirmation method were developed and validated for the 
identification and quantitation of ketamine and its major metabolite norketamine in urine 
samples. The Neogen® ketamine microplate ELISA was optimized with respect to sample and 
enzyme conjugate volumes and also the sample pre-incubation time before addition of the 
enzyme conjugate. The ELISA kit was validated to include an assessment of the dose-response 
curve, intra- and inter-day precision, limit of detection (LOD) and cross-reactivity.  The 
sensitivity and specificity were calculated by comparison to the results from the validated LC-
MS/MS confirmation method. An LC-MS/MS method was developed and validated with respect to 
LOD, LLOQ, linearity, recovery, intra- and inter-day precision and matrix effects. The ELISA 
dose-response curve was a typical S-shaped binding curve, with a linear portion of the graph 
observed between 25-500 ng/mL for ketamine. The cross-reactivity of 200 ng/mL norketamine to 
ketamine was 2.1 % and no cross-reactivity detected with 13 common drugs tested at 10,000 
ng/mL. The ELISA LOD was calculated to be 5 ng/mL. Both intra- (n=10) and inter-day precisions 
(n=50) were below 5.0 % at 25 ng/mL. The LOD for ketamine and norketamine was calculated 
statistically to be 0.6 ng/mL.  The LLOQ values were also calculated statistically and were 1.9 
ng/mL and 2.1 ng/mL for ketamine and norketamine. The test linearity was 0-1200 ng/mL with 
correlation coefficient (R2) > 0.99 for both analytes. Recoveries at 50 ng/mL, 500 ng/mL and 
1000 ng/mL range from 97.9 % to 113.3 %.  Intra- and inter-day precision between extracts for 
n=5 and n=25 respectively for ketamine and norketamine were excellent (< 10 %). Matrix effects 
analysis showed an average ion suppression of 5.7 % for ketamine and an average ion 
enhancement of 13.0 % for norketamine for urine samples collected from six individuals. A 
comparison of ELISA and LC-MS/MS results demonstrated a sensitivity, specificity and efficiency 
of 100 %.  These results indicated that a cut-off value of 25 ng/mL ketamine in the ELISA screen 
is particularly suitable and reliable for urine testing in a forensic toxicology setting. 
Furthermore, both ketamine and norketamine were detected in all 34 urine samples collected 
from individuals socializing in pubs by the Royal Malaysian Police. Ketamine concentrations 
detected by LC-MS/MS ranged from 22 -31,670 ng/mL and norketamine concentrations ranged 
from 25 - 10,990 ng/mL. The concentration of ketamine and norketamine detected in the 
samples are most likely indicative of ketamine abuse. 
Keywords: Ketamine, Norketamine, ELISA, LC-MS/MS, Urine  
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Introduction: Ketamine is an anesthetic drug used clinically for both humans and animals. A 
recent increase in ketamine abuse, especially in Far East countries such as Taiwan, Singapore 
and Malaysia, has led to the development of a growing number of detection methods. Ketamine 
and its enantiomers have short distribution and elimination half-lives therefore require rapid, 
sensitive and reliable detection methods. This study optimised and evaluated the suitability of 
the commercially available Neogen ELISA ketamine kit for use in forensic toxicology.   
Materials and Methods: Ketamine ELISA kits were purchased from Neogen Corporation, 
Lexington, USA.  ELISA steps were automated using a Miniprep 75 automated pipettor and the 
microplates were read at 450 nm with a Sunrise EIA reader from Tecan. Twelve different sets of 
conditions with respect to sample and enzyme conjugate volumes and incubation times were 
applied for optimising the method. This was followed by method validation procedures including 
dose-response curve, intra and inter-day precision, limit of detection, sensitivity, specificity, 
and cross-reactivity studies. Finally the optimised and evaluated method was tested with human 
urine samples.   
Results and Discussion: The optimised method used 20 µl of sample in each microplate well.  No 
pre-incubation time was required and 180 µl conjugate were added immediately.  The plates 
were then incubated for 45 minutes in the dark, washed with 300 µl diluted phosphate buffer 
and 150 µl K-Blue substrate was added. The reaction was stopped with 1 N aqueous hydrochloric 
acid and the plates were read at 450 nm. The test linearity was from 10 ng/ml to 1000 ng/ml 
and the cross-reactivity for norketamine at 200 ng/ml ketamine was 2.1%. The test showed zero 
cross-reactivity to amphetamine, methamphetamine, MDA, MDMA, MDEA, cocaine, 
benzoylecgonine, diazepam, morphine, 6-MAM, methadone, PCP and tiletamine at 10,000 ng/ml. 
The LOD obtained was 5 ng/ml.  Precision was better than 10%, with intraday precision (n=10) 
2.47% and inter-day precision ( n=50) 4.79%  at a concentration of  25 ng/ml.  Forty-four urine 
samples were analysed using the method: 10 control samples from laboratory personnel screened 
negative and 33 samples from Malaysian Royal Police cases screened positive and one negative at 
a cut-off of 25 ng/ml. The positive samples had previously been confirmed by GC-MS in the Drug 
Laboratory, Kuala Lumpur General Hospital, Malaysia. The sensitivity for the test was 97% and 
the specificity was 100%.        
Conclusion: A simple, rapid and efficient ELISA test for ketamine has been optimised and 
validated.  Automated procedures required less then 3 hours for 96-well samples. The test was 
very specific to the parent compound and showed minimal cross-reactivity to the metabolite 
norketamine. The precision was good, with a wide linear range dose-response curve. The kit 
detected ketamine at a range of concentrations in 44 urine samples. It can determine trace 
concentrations of ketamine and is fit for the purpose of forensic toxicology screening.  
 
Key Words: Ketamine, ELISA, Forensic Toxicology 
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ABSTRACT 
Background: A recent increase in the misuse of ketamine as a recreational drug in South East 
Asian countries such as Taiwan, Singapore and Malaysia has necessitated the development of 
analytical methods for this drug. In this study, two different techniques were developed for 
screening and confirmation. Method: The commercially available Neogen ELISA kit for ketamine 
was selected and optimised with respect to sample and enzyme conjugate volumes and the pre-
incubation time. Method validation parameters investigated for ELISA were dose-response curve, 
intra and inter-day precision, LOD, sensitivity, specificity, and cross-reactivity studies. For 
confirmation, an LC-MS-MS method was developed and validated with respect to LOD, LLOQ, 
linearity, recovery, precisions and matrix effects. All samples were hydrolysed at 60◦C for 3h 
using β-glucoronidase from Helix pomatia. Ketamine and norketamine were extracted by solid 
phase extraction using World Wide Monitoring Clean Screen® columns. LC-ESI-MS-MS analysis was 
carried out using a Thermo Finnigan LCQ Deca XP instrument and chromatographic separation 
was performed using a Synergi Hydro RP column. Both methods were applied to 34 human urine 
case samples provided by the Narcotics Department of the Royal Malaysian Police. Results: The 
ELISA test was linear from 25-500 ng/mL. The cross-reactivity for the main metabolite, 
norketamine at 200 ng/mL ketamine was 2.1% and no cross-reactivity was detected with thirteen 
other common drugs at a concentration of 10,000 ng/mL. The LOD obtained was 5 ng/mL and the 
precision was <10%, with intraday precision (n=10) 2.47 % and inter-day precision (n=10 x 5 days) 
4.79 % at a cut off concentration of 25 ng/ml. For the LC-MS-MS method, the LODs for ketamine 
and norketamine were 0.56 and 0.63 ng/mL and the LLOQs were 1.88 and 2.10 ng/mL 
respectively. The test demonstrated wide linearity over the range of 0-1200 ng/mL with r2 better 
than 0.99 for both ketamine and norketamine.  The recoveries were acceptable for both analytes 
at low (50 ng/mL), medium (500 ng/mL) and high (1000 ng/mL) concentrations and ranged from 
97.9% to 113.3%. The method demonstrated good intra and inter-day precision (< 10 %). Matrix 
effects analysis for ketamine showed ion suppression of <10 % while norketamine showed ion 
enhancement   of <20 %. Conclusion: A simple, rapid and efficient ELISA screening test for 
ketamine has been optimised and validated.  A complementary sensitive and precise LC-ESI-
MS/MS method for confirmation has also been developed and validated. Using the cut off value 
of 25 ng/mL, the Neogen ELISA demonstrated a very good correlation with the LC-MS-MS method 
with a sensitivity and specificity of 100%. The LC-MS-MS method detected various concentrations 
of ketamine and norketamine in 34 human urine samples. Both methods are reliable for routine 
screening and confirmatory analysis of samples used in workplace drug testing and in forensic 
toxicology.   
Keywords: Ketamine; ELISA; LC-MS-MS, Urine  
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Introduction: A Molecularly imprinted polymer (MIP) is a synthetic polymer 
bearing on its surface the molecular imprint of a specific target molecule (the 
template). The polymer has a permanent memory of the template and is capable 
of selectively rebinding it. To date, the application of MIPs has been dominated 
by solid phase extraction [1]. The present paper describes the synthesis of MIPs, 
optimisation of molecularly imprinted solid phase extraction (MISPE) and its 
application to real hair samples for the determination of drugs prior to LC-MS-MS 
analysis. 
Synthesis: MIPs were prepared by bulk polymerization using ketamine, diazepam 
and flunitrazepam as templates, using methacrylic acid (MAA) as monomer, 
ethylene glycol dimethacrylate (EGDMA) as crosslinker and toluene and 
chloroform as porogens. The templates were extracted from the MIPs with 
methanol/ acetic acid (9/1, v/v) for 24 h. The monoliths were ground to the 
desired particle size of 25 to 38 µm and 20 mg of MIP was packed into each SPE 
cartridges. 
Method: MISPE optimisation included template removal, choice of conditioning, 
washing and elution solvents, studies of binding capacity and cross-reactivity to 
metabolites and other drugs, and equilibration of the columns with the aqueous 
environment. After MISPE optimisation, LC-MS/MS methods were validated for 
each analyte, including measurement of the limit of detection (LOD), lower limit 
of quantification (LLOQ), linearity, recovery, intra- and inter-assay precision and 
matrix effects. These methods were applied to hair samples from individuals 
who had been shown positive for benzodiazepines in post-mortem blood by ELISA 
and from chronic ketamine users in Malaysia. 
Results: Drugs successfully extracted with this application included ketamine 
and norketamine, diazepam, lorazepam, chlordiazepoxide, temazepam, 
flunitrazepam, nordiazepam, nitrazepam [2,3]. The ketamine and norketamine 
levels in chronic ketamine users were quite high, ranged from 0.2-5.7 ng/mg and 
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0.6 to 1.2 ng/mg. Low levels of benzodiazepines in post mortem hair samples 
were detected by both diazepam and flunitrazepam as the MIPs templates 
ranged from 0.02 ng/mg to 1.0 ng/mg. 
Conclusion: These studies demonstrated that, in terms of sensitivity, selectivity, 
lack of interferences and robustness, MISPE can be recommended for accurate 
and precise determination of drugs in forensic toxicology. 
 
Key words: MIPs, SPE, ketamine, benzodiazepines, hair, LC-MS/MS  
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Summary Text: Molecularly imprinted polymers (MIP) are highly cross-linked 
polymers synthesised in the presence of template molecules. Post-synthesis, the 
template is removed, leaving behind imprinted binding sites (cavities) that have 
a permanent memory of the template and that are capable of rebinding with the 
template molecule, or structurally similar molecules, in a strong and selective 
manner. Ketamine is a licenced anaesthetic that is misused as a recreational 
drug. In this study MISPE and LC-MS/MS were successfully applied to the 
detection and quantification of ketamine and its metabolite, norketamine, in 
human hair. The method showed good sensitivity, selectivity, lack of 
interferences and robustness. MISPE can be recommended for accurate and 
precise determination of drugs in forensic toxicology 
Introduction: Molecularly imprinted solid-phase extraction (MISPE) for the 
detection of ketamine, an anaesthetic drug which is widely misused as a 
recreational club drug, in hair has not been reported previously. This study 
assessed MISPE as an alternative to conventional solid phase extraction for trace 
detection of drugs in forensic toxicology using ketamine as a model substance.                                              
Synthesis: MIPs were prepared by bulk polymerization using (±)- ketamine and 
(+)-S-ketamine as templates, methacrylic acid (MAA) as monomer, ethylene 
glycol dimethacrylate (EGDMA) as crosslinker and toluene as porogen. Ketamine 
hydrochloride was first converted to the free base ketamine. Template was 
extracted from product MIPs with methanol/ acetic acid (9/1, v/v) for 24 h. The 
monoliths were ground to the desired particle size of 25 - 38 µm.  Preliminary 
evaluation with HPLC-UV in comparison with a non-imprinted polymer (NIP) 
indicated that both (±)- ketamine and (+)-S-ketamine had been imprinted. 20 mg 
of MIP was then packed into each SPE cartridge for the study.  
Method: Optimisation of MISPE included template removal, selection of solvents 
use in the extraction and studies of binding capacity and cross-reactivity to 
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metabolites and other drugs. After MISPE optimisation, LC-MS/MS methods were 
validated for each analyte, including measurement of the limit of detection 
(LOD), lower limit of quantification (LLOQ), linearity, recovery, intra- and inter-
assay precision and matrix effects. These methods were applied to hair samples 
from chronic ketamine users in Malaysia. 
Results: Template was removed by sequential treatment with acetonitrile, 
chlororm and 30 % methanol in acetic acid. Recovery of ketamine was 87 % for 
(±)-ketamine using the MIP compared to 32 % using the NIP. The binding capacity 
was 0.125 µg/mg polymer, which was sufficient for the analytical application.  
LODs for ketamine and norketamine were 0.10 and 0.14 ng/mg hair and LLOQs 
were 0.37 and 0.47 ng/mg hair, respectively. The method was linear from 0-10 
ng/ mg hair with linear correlation coefficients (R2) better than 0.99 for both 
ketamine and norketamine.  The recoveries from adulterated hair samples were 
86 % for ketamine and 88 % for norketamine at concentrations of 50 ng/mg, The 
method demonstrated good intra- and inter-day precision of <5% based on 
analysis of pooled hair samples for both analytes. Minimal matrix effects were 
observed during LC-MS/MS analysis of ketamine (ion suppression, -6.8 %) and 
norketamine (ion enhancement + 0.2 %). Ketamine and norketamine 
concentrations in the samples analysed were relatively high, ranging from 0.2-
5.7 ng/mg and 0.6 to 1.2 ng/mg, indicating that the samples were from chronic 
ketamine users.  
Conclusion: This study demonstrated that MISPE combined with LC-MS/MS can 
provide a sensitive, selective, robust and clean method of analysis which can be 
recommended for accurate and precise determination of drugs in forensic 
toxicology.  
Key words: MIPs, MISPE, ketamine, hair, LC-MS/MS 
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Title: Molecularly imprinted solid phase extraction 
(MISPE) and liquid chromatography - tandem mass 
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Background: This preliminary study was a comparison of validated MISPE and 
conversional SPE methods coupled to LC-MS/MS analysis in hair samples from 
living subjects. An anti-ketamine imprinted polymer was synthesized and used as 
MISPE sorbent; the polymer was capable of rebinding ketamine or structurally 
similar molecules, in a strong and selective manner.  
Samples: Blank hair samples for method development and validation were from 
volunteers in the laboratory. The method application was tested on real hair 
samples collected from four chronic females’ ketamine users at a drug 
prevention centre in Malaysia.    
Method: Hair samples were decontaminated with 0.1% aqueous sodium dodecyl 
sulfate (SDS), deionised water and dichloromethane, then air dried.  10 ± 0.1 mg 
samples plus 50 ng ketamine and norketamine internal standards were incubated 
for 18 hours at 45 ºC in 1.5 mL 0.1 M phosphate buffer pH 5.0 and subsequently 
extracted by SPE and MISPE followed by LC-MS/MS analysis. Clean Screen® 
(ZSDAU020) cartridges were used for SPE and compared with the MISPE.  
Results: MISPE and SPE coupled with LC-MS/MS methods were linear from 0-10 
ng/ mg hair with R2 better than 0.99 for both ketamine and norketamine. For 
MISPE, the LODs for ketamine and norketamine were 0.10 ng/mg hair and LLOQs 
were 0.4 and 0.5 ng/mg hair while for SPE, LODs were 0.5 ng/mg for ketamine 
and norketamine and LLOQs were 0.9 and 1.8 ng/mg. The recoveries were above 
85% for both analytes and methods. The average ketamine and norketamine 
intra- and inter-batch imprecision were <5% for the pooled hair sample on both 
methods. MISPE showed low matrix effects in hair during LC-MS/MS analysis; 
ketamine (ion suppression, -6.8 %) and norketamine (ion enhancement + 0.2 %) 
whereas very significant values was demonstrated in SPE method for the two 
analytes. MISPE successfully detected ketamine and norketamine in all the four 
samples. The ketamine and norketamine levels ranging from 0.2-5.7 ng/mg and 
norketamine from <0.5 ng/mg to 1.2 ng/mg. SPE detected ketamine ranging 
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from 0.5 – 6.7 ng/mg but norketamine were not detected in 2 out of the four 
samples and less than LLOQ in the other 2 samples.  
Conclusion: The MISPE coupled with LC-MS/MS demonstrated good selectivity 
and sensitivity for ketamine and norketamine in hair. SPE coupled with LC-
MS/MS showed higher selectivity to ketamine than MISPE but less sensitivity for 
norketamine. High matrix effect for SPE method might interfere with the LC-
MS/MS analysis and caused less sensitivity for norketamine detection in hair.  
Key words: MIPs, SPE, ketamine, norketamine, hair, LC-MS/MS  
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Abstract 
 
An anti-ketamine molecularly imprinted polymer (MIP) was synthesized and used 
as the sorbent in a solid-phase extraction protocol to isolate ketamine and 
norketamine from human hair extracts prior to LC-MS/MS analysis. Under 
optimised conditions, the MIP  was capable of selectively rebinding ketamine, a 
licensed anaesthetic that is widely misused as a recreational drug, with apparent 
binding capacity of 0.13 µg ketamine per mg polymer. The limit of detection 
(LOD) and lower limit of quantification (LLOQ) for both ketamine and 
norketamine were 0.1 ng/mg hair and 0.2 ng/mg hair, respectively, when 10 mg 
hair was analysed. The method was linear from 0.1-10 ng/mg hair, with 
correlation coefficients (R2) better than 0.99 for both ketamine and 
norketamine.  Recoveries from hair samples spiked with ketamine and 
norketamine at a concentration of 50 ng/mg were 86% and 88% respectively. The 
method showed good intra- and inter-day precision (<5%) for both analytes. 
Minimal matrix effects were observed during LC-MS/MS analysis of ketamine (ion 
suppression -6.8%) and norketamine (ion enhancement +0.2%). Results for 
forensic case samples demonstrated that the method successfully detected 
ketamine and norketamine concentrations in hair samples with analyte 
concentrations ranging from 0.2-5.7 ng/mg and 0.1 to 1.2 ng/mg, respectively.  
Keywords: MIPs, SPE, ketamine, norketamine, hair, LC-MS/MS 
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Background: A commercial molecularly imprinting based column (Amphetamines 
SupelMIP TM) from Supelco was used in extraction prior to LC-MS/MS analysis for 
detection of five types of amphetamines in post mortem whole blood. The 
columns were previously evaluated by Supelco for use of amphetamines 
detection in urine and demonstrated high recoveries. Seven case blood samples 
were obtained from Forensic Medicine and Science, University of Glasgow. The 
LC-MS/MS method underwent method validation procedures and the results were 
compared with the previously obtained results of the routine GC-MS procedures. 
Method:  Pre-treatment: Internal standard was spiked into 1.0 ml aliquots of 
bloods which were diluted with 1.0 ml 10 mM ammonium acetate buffer pH 8.0, 
vortexed mixed and centrifuged at 3000 rpm for 10 minutes. Extraction: The 
column was conditioned with 1.0 ml methanol, followed by 1.0 ml 10 mM 
ammonium acetate buffer, pH 8.0 without application of a vacuum. The pre-
treated sample was loaded on the SPE cartridges then cartridges were washed 
sequentially with 2 x 1.0  ml DI water, not to let the column dry out, 1.0 mL 
60/40 v/v  MeCN/DI water followed by a drying step of 5-10 minutes with full 
vacuum, and finally with 1.0 mL of 1 % HOAc in MeCN. 2 x 1.0 mL 1 % formic acid 
in MeCN was used to elute the amphetamines with mild application of vacuum 
between each elution. The SPE eluant was evaporated to dryness under a stream 
of nitrogen gas without heating. The residues were reconstituted with 100 µL 
initial mobile phase and vortex mixed prior to LC-MS/MS analysis.   
Results: MISPE LC-MS/MS methods were linear from 0-1000 ng/ml blood with R2 
better than 0.99 for the five amphetamines. The LODs were 0.2 – 0.6 ng/ml and 
the LLOQ were from 0.8 -1.9 ng/ml for all 5 amphetamines. Matrix effects were 
within ± 10 for 3 levels (50, 450 and 900 ng/ml) for the 5 amphetamines. The 
recoveries were between 32.4 to 61.4 with RSD less than 11 % compared to 97 to 
113 with RSD of 1.4 to 9.8 for the same group analysed in urine. The intra and 
inter-day precision RSD were less than 10 %. The method detected the same 
class of amphetamines in all samples but the concentrations were lower than 
comparison GC-MS method but detected low levels of amphetamines compared 
to comparison GC-MS.    
Conclusion: The method demonstrated good linearity and precision with low 
matrix effects. The LOD and LLOQ were better than the comparison GC-MS 
method and suitable for detection of low levels of amphetamines in post mortem 
blood. The case samples results were lower than the result obtained by the 
routine GC-MS may be resulted from incomplete protein precipitation step ahead 
of extraction and also may be affected by gap of reanalysed (6 months to one 
year) which some degradation may occurred in the whole blood especially for 
MDMA and MDEA. 
Key words: MISPE, amphetamines, whole blood, LC-MS/MS  
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